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PART 1   INTRODUCTORY PART 
 
Infection or infectious process is the interaction of a pathogenic microorganism and a 
microorganism under the influence of environment. If, as a result, the equilibrium of the 
organism's interaction with its environment is disturbed an infectious disease ensues mani-
fested by clinical symptoms. 
An infectious disease is a form of infectious process. The specific feature of an in-
fectious (epidemic) disease is its contagiosity, i.e. transmissibility from one body to 
another. 
The General Character of an Infectious Disease. A characteristic of acute infec-
tious diseases is their cyclic course, which is distinctly divided into the following indi-
vidual stages: the incubation period, or stage of latency, the prodromal stage (premoni-
tory symptoms), the stage of development, the stage of subsidence, and the period of 
convalescence. 
The incubation period begins from the moment of infection and ends with the ap-
pearance of the first signs of the disease. Every disease has an incubation period of 
definite length. 
During incubation the causative agent multiplies producing toxic products in the 
process. In addition a reconstruction of the organism takes place as it reacts to the ac-
tion of the extreme irritant. 
A prodromal or premonitory period is not observed in all infectious diseases. It is 
characterized by the appearance of the first indefinite signs of illness (mild chill, low 
fever, malaise, headache, etc.). It does not usually last long (one to three days). 
The stage of development of a disease has its own complex of symptoms appear-
ing and developing in a definite sequence, and then gradually declining in the stage of 
subsidence. The general symptoms of all the acute infectious diseases are fever, the de-
velopment of inflammatory processes, and a more or less pronounced toxemia. 
Fever occurs when various infectious and noninfectious processes interact with the host's 
defense mechanism. In most children fever is either due to an identifiable microbiologic agent 
or subsides after a short time. Fever in children may be categorized as (1) fever of short dura-
tion with localizing signs for which the diagnosis can be established by clinical history and 
physical examination, with or without laboratory tests; (2) fever without localizing signs, for 
which the history and physical examinations do not suggest a diagnosis but laboratory tests 
may establish an etiology; and (3) fever of unknown origin (FUO). 
Bacteraemia and virusaemia are very important in the pathogene-sis and develop-
ment of clinical signs of some infectious diseases. An important sign of an infectious 
disease is a more or less marked intoxication. Toxicoses caused by endotoxins, the 
products of decomposition of bacteria, tissues, products of disordered metabolism, are 
not specific. 
Many infectious diseases are attended by neurotoxicosis which is characterized by affections 
of the central nervous system. Hyperther-mic, meningeal, and convulsive syndromes, oedema of 
the brain, during which the danger of brain protrusion into the great foramen arises, are very 
important. The Waterhouse-Friderichsen syndrome, which is characterized by a violent onset, 
 3
hyperthermia, marked adynamia, loss of consciousness, frequent vomiting, fall of arterial pres-
sure to a circulatory collapse, is especially dangerous. 
Acute intestinal infections, and sometimes other infectious processes in children to 2 years of 
age, may be attended by toxicosis with dehydration due to loss of the body water caused by 
frequent stools and vomiting. Metabolic acidosis develops due to the loss of the electrolyte (as a 
result of the upset water-ionic balance, haemo-dynamics, and the disordered acid-base equilib-
rium). The degree and character of dehydration may be different. Isotonic, water-deficit 
and salt-deficit dehydrations are differentiated. 
With convalescence there is more or less rapid elimination of all symptoms of the 
disease, but complete restoration of the organism's normal functional condition is often a 
lengthy process. Adynamia, rapid mental fatiguability, and lability of the cardiovascular 
system are common. 
Not infrequently exacerbation is observed in the stage of subsidence of the clinical mani-
festations of an infectious disease, and relapse or recurrence of almost the whole symptom 
complex in the period of recovery. 
Superinfection – there is a new infection, mostly by another type of the same causative agent (dysen-
tery, scarlet fever). 
Mixed infections, in which the infectious process is complicated by involvement of 
two and more causative agents, occur frequently. Various associations of causative "gents 
are possible: mixed bacterial, bacterial-fungal, viral-bacterial, and viral infections are differ-
entiated. 
Clinical Forms and Complications. Infectious diseases have a great variety of 
clinical forms. The-manifestations and severity of a disease depend both on the properties 
(virulence) of the causative agent and on individual peculiarities of the organism's reactivity, 
which are determined by age, type of higher nervous activity, physical state, previous ill-
nesses, etc. 
Hypertoxic forms of infectious disease (diphtheria, scarlet fever,. dysentery, etc.) are ap-
parently associated with previous sensitization of the child's organism. 
Atypical forms are of great practical interest, and are often difficult to diagnose. They in-
clude so-called formes frustes with rudimentary symptoms (viz. angina scarlatinosa, whoop-
ing-cough without paroxysms, the catarrhal form of diphtheria, etc.) which are especially 
common when carrier state is encountered. They therefore play a great role in the epidemiol-
ogy of infectious diseases. 
Complications are pathological processes closely linked genetically with the main disease 
and developing during the course of the latter or during convalescence. Their incidence de-
pends on the severity of the disease (its clinical form), peculiarities of the organism's reactivity 
(particularly of age reactivity), the conditions of the patient's environment, and on nursing and 
treatment. 
Features of infection and immunity in children 
Physiological immaturity is the cause of imperfect protective reaction of the newborns. 
Atypical inflammatory processes, inability to form the cell barrier round the infection focus, 
i.e. to localize it and to preclude its propagation, are found in infants.  
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The non-specific mechanism of protection against viruses, interferonogenesis, also de-
pends on maturity of the body and its age. Production of interferon is minimal in infants under 
one year of age, or they are interferon-negative. This is encourage to develop deferent viruses 
diseases. 
The source or the natural reservoir of an infection is an infected human animal (the sick 
and carriers). Not only patients with clinically manifest forms of the disease are dangerous as 
regards infection but also those suffering from atypical forms frustes. 
The mechanism of infection is specific for each infectious disease and depends on local-
ization of the causative agent in the human (of animal) organism, i.e. or the source of infec-
tion. This localization determines the route of discharge of the microbe into the environment. 
 In diseases in which the causative agents are discharged from the organism mainly in the 
secretions of the mucous membranes of the nose, throat, pharynx, and upper respiratory tract 
infection is direct, by the aerial-droplet route (respiratory infections – measles, german mea-
sles, influenza, whooping-cough, diphtheria, scarlet fever, chickenpox, mumps). 
The causative agent can also be spread by direct contact of a healthy person with a source 
of infection. The transmission of infection via infected objects, i.e. by indirect contact (through 
dishes, toys, towels, handkerchiefs, patient clothes. 
The alimentary method of transmission of infection (by food) is characteris-
tic of intestinal infections. Foodstuffs can become infected by a sick person or a 
carrier during transportation, sale, or cooking. Water-borne infection can occur 
through drinking infected water, accompanying extensive epidemics with an 
explosive onset and course. 
Transmission of the causative agents by living vectors (the transmissive route) is charac-
teristic of many infection diseases (flies, blood-sucking arthropod parasites, mosquitoes, ticks). 
The problem of congenital infectious diseases is transplacental transmission of the 
causative agent from a sick mother to the foetus. 
A most important factor in the epidemic process is the susceptibility of a popula-
tion. This is usually defined by the so-called index of contagion, of more correctly, the 
index of susceptibility. 
Diagnosis. Precise and early diagnosis of acute infections in children is of great practical 
significance not only because it largely determines the efficacy of the treatment, but also be-
cause it is indispensable for the most important anti-epidemic measure early isolation of the 
source of infection. 
The various laboratory tests and other auxiliary methods of examination are of vi-
tal importance. The most reliable are methods of detecting the infective agent in the 
patient's organism. 
Laboratory diagnosis of bacterial infections 
Gram stain. The examination of a Gram stain should be carried out on all fluids to be 
cultured. In addition to giving rapid results, the Gram stain may be useful in interpreting the 
subsequent cultural data because it allows identification of cellular exudate and the predomi-
nant organisms.  
Special cultures. Most medically important bacteria can be cultivated on blood agar, 
chocolate agar, and eosin methylene blue or MacConkey agar. New media preparations en-
 5
hance the recovery of anaerobic organisms. For collection of anaerobic cultures, material 
should be rapidly transported to the laboratory in a capped syringe, or special swabs supplied 
in oxygen-free tubes should be used. 
Blood culture. Culturing the blood is one of the most fruitful procedures in the diagnosis 
of bacterial disease. It should be done carefully before administration of antibiotics, using 
iodine-alcohol for skin disinfection. A number of different blood culture techniques are now 
available, most of which use 50- to 100-mL bottles containing broth nutritious for bacteria 
into which not more than 5–10 mL of blood are introduced. Some blood culture bottles also 
contain an oxygen-free carbon dioxide–enriched atmosphere that allows the recovery of an-
aerobes. Repeating blood cultures may be necessary to determine (1) whether treatment has 
been successful particularly in high-risk patients who have infections that are difficult to treat 
and (2) whether the isolate is a contaminant when the organism reported is usually nonpatho-
genic. Whether an organism isolated from blood is a pathogen or a contaminant should be 
carefully considered, since "nonpathogens" such as coagulase-negative staphylococci may 
cause disease. 
Examination of cerebrospinal fluid. Fluid obtained by lumbar puncture or ventricular 
tap should be collected in sterile, capped containers and transported quickly to the laboratory, 
where centrifugation is done to concentrate organisms. Gram stains of cerebrospinal fluid 
(CSF) sediment are helpful; the presence of organisms distinguishes bacterial from viral dis-
ease, but stains should not be relied on for the identification of a specific organism. It is better 
to use broad-spectrum initial therapy in life-threatening disease and to wait for the culture 
report before ordering specific treatment. Counterimmunoelectrophoresis and agglutination of 
antibody-coated latex beads are additional rapid, accurate methods for diagnosis. Specific 
antisera can be used to detect antigens of Haemophilus influenzae type b, Neisseria meningi-
tidis, Staphylococcus pneumonia, group B streptococci, and Escherichia coli K1. 
Urine culture. Urine for culture and colony count can be obtained in midstream (clean-
catch), by catheterization, or by suprapubic puncture. The last method is the most reliable; 
urine so obtained should normally be sterile. Urine collected by catheter is likely to reflect 
infection if there are 103 organisms/mL or more. Clean-catch urine, if obtained after adequate 
cleansing, can be considered abnormal if 105 or more organisms/mL are present, and possibly 
abnormal if between 104 and 105 organisms/mL are counted. Clean-catch urine specimens 
from girls who have inadequately washed, and specimens allowed to sit at room temperature 
for some time before being transported to the laboratory, may result in unreliable cultures. 
Culture of feces. Rectal swabs or stool specimens are cultured either to identify common 
bacterial pathogens such as Salmonella and Shigella or to determine the predominant flora of 
the intestine in a patient with weakened host defenses whose endogenous flora may become 
pathogenic. Since feces contain mostly anaerobic bacteria, routine cultures identify only the 
predominant aerobic organisms among the billions of bacteria contained in each gram of 
feces. 
A number of organisms have recently been added to the list of bacterial pathogens 
found in feces, including Helicobacter pylori, Yersinia enterocolitica, Clostridium difficile, 
Aeromonas spp., Plesiomonas spp., Vibrio spp., and E. coli 0157:H7. DNA probes, anti-
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gen detection methods, and toxin detection have all been applied to the rapid diagnosis of 
enteric pathogens. 
Exudates and transudates. Abscesses, pleural fluids, joint fluids, urethral exudates, and 
other miscellaneous exudates and transudates can be cultured directly on agar. In addition to 
cultures and stains, glucose and cell count determinations should be done on all transudates 
for the same reasons they are done on CSF. 
Nasopharyngeal, throat, and skin swabs. A dry rayon, Dacron, or calcium alginate 
swab is most efficient for collecting specimens from the skin and mucous membranes. 
Since drying rapidly destroys some pathogenic bacteria, swab specimens should be placed 
promptly in a transport medium. Interpretation of results of cultures from skin and mucous 
membranes is difficult because microbial flora are normally recovered from these areas. 
Some organisms are considered pathogenic wherever found, such as Corynebacterium 
diphtheriae, Bordetella pertussis, and Neisseria gonorrhoeae; others, such as Streptococcus 
pyogenes, N. meningitidis, H. influenzae, or staphylococci, may be pathogenic or non-
pathogenic, depending on circumstances. Still others, such as Streptococcus viridans, are 
rarely considered pathogenic. In respiratory tract disease there is little correlation between 
flora of the upper airway and that of the lower airway. Because sputum cultures are seldom 
reliable in children, bronchoalveolar lavage, tracheal aspirates, and lung punctures are 
sometimes necessary for accurate diagnosis. If bacteria such as C. diphtheriae or Bordetella 
sp. (which grow poorly in ordinary media) are suspected, the laboratory should be in-
formed prior to receipt of the specimen. 
Antibody-based techniques. Fluorescent antibody (FA) techniques have increased 
the diagnostic scope of direct microscopy. Specific antisera are now available commer-
cially for several common pathogens. In these sera the antibody molecules have been 
conjugated with a fluorescein dye. The specific dye-labeled serum is added to the smear 
containing the suspected organism, and the slide is microscopically examined for fluo-
rescence under ultraviolet light. Indirect FA methods are also applicable in the absence 
of conjugated antibodies. FA is used principally for identifying B. pertussis, Legionella 
pneumophila, and N. gonorrhoeae. 
Antibiotic sensitivity tests. Most laboratories routinely test bacterial isolates for sen-
sitivity to various antibiotics. The most prevalent technique of antibiotic testing is the 
agar disk diffusion method, in which a standardized inoculum of the organism is seeded 
onto a plate. Filter paper disks, each impregnated with an antibiotic, are placed on the 
agar surface, and after 18–24 hr of incubation, the zone of inhibition of bacterial growth 
around each disk is measured. Standard zone diameters indicating sensitivity or resis-
tance have been defined according to previous test results correlating zone sizes with 
sensitivity determined by inhibition of bacteria inoculated into dilutions of antibiotics in 
culture broth. 
Dna probes. The greatest revolution in microbiologic diagnosis to date has occurred 
through the use of DNA probes. Among those bacteria for which commercial probes are now 
available, Mycoplasma pneumoniae, M. tuberculosis, Mycobacterium avium–intracellulare, and 
enteric organisms figure prominently. 
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Laboratory diagnosis of viruses. If viral disease is a diagnostic possibility, specimens 
should be obtained for viral culture and rapid viral detection. Serologic tests are much less useful 
for viral diagnosis but obtaining an acute phase sample is sometimes indicated for later compari-
son with convalescent antibody titers. 
Rapid viral detection. Fluorescent-antibody techniques or other methods that use 
antibodies to detect viral antigens in clinical specimens provide rapid identification of 
viruses. For example, smears of mucosal cells stained by immunologic reagents can 
identify the antigens of respiratory viruses, such as respiratory syncytial virus or influ-
enza, for which there is a polyclonal or monoclonal antiserum. Rotaviruses, which 
cause infantile gastroenteritis, and hepatitis B surface antigen can be detected by en-
zyme-linked immuno-sorbent assay (ELISA) using specific antisera. 
Cytologic examination aids in diagnosis when inclusion bodies or syncytia are found 
but these methods are not sensitive enough to be relied upon for the diagnosis of life-
threatening infections, such as neonatal herpes. All rapid detection assays should be done in 
parallel with and confirmed by viral culture. 
Isolation. Viruses require living cells for propagation; the cells used most often are hu-
man or animal cell tissue cultures. Because some viruses are difficult to isolate and many 
require a variety of culture systems for their isolation, the clinician should describe the clinical 
signs, for example, pneumonia or skin lesions, when the specimen is sent to the laboratory. 
Specimens should be delivered to the laboratory promptly. 
Viral genome and virion detection. New methods for viral diagnosis rely upon the use 
of probes constructed of sequences complementary to the genome sequences of DNA or 
RNA viruses. Polymerase chain reaction (PCR) detects viral gene sequences using comple-
mentary nucleotides as primers to amplify a conserved region of the genome. These methods 
are technically complex and difficult to standardize, but reliable commercial assays are avail-
able to detect some viruses. False-positive results are common, particularly with PCR meth-
ods. While electron microscopy (EM) provides a tool for direct visualization of virions within 
infected cells, its use in clinical diagnosis has been replaced for the most part by viral antigen 
or genome detection methods. Its usefulness is also limited because different viruses in the 
same family, such as herpes simplex, cytomegalovirus, and other herpesviruses, are indistin-
guishable by EM morphology. 
Serologic tests. Correct diagnosis requires at least two blood specimens: the first 
should be obtained during the early acute phase of the disease "acute serum", and the sec-
ond "convalescent serum" 14–21 days later. If the second is taken earlier than 14 days after 
the first, it is advisable to take a third blood specimen 4–6 wk after the onset, since the rise 
of antibodies may be delayed, especially in infants. If it is not possible to send blood to the 
laboratory promptly, serum may be removed for preservation by freezing. Whole blood 
should never be frozen. To establish the etiologic diagnosis, it is necessary to demonstrate a 
fourfold rise in titer of antibody to an agent in the convalescent as opposed to the acute 
phase serum, when all specimens are tested together. IgM antibody titers should never be 
relied upon as the only diagnostic test for a serious viral infection. IgG antibody assays are 
often useful for establishing immune status because viral pathogens usually induce hu-
moral immunity that persists for years after primary infection. 
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Methods of Detecting Antibody. Antibody can be detected by a variety of specific se-
rologic methods; some are more appropriate than others for specific viruses. Complement-
fixation (CF) antigens are available for a great range of viruses, and CF antibodies have the 
advantage of correlating with recent infection but are less useful for showing past infection. 
Hemagglutination-inhibition (HI) antibodies correlate fairly well with neutralizing antibodies. 
Fortunately, many viruses such as the myxoviruses, rubella, and some enteroviruses can aggluti-
nate erythrocytes. Antibodies can be detected by the indirect fluorescence technique. ELISA and 
latex agglutination tests are now used most often to detect antibodies to viral antigens. These 
depend on the attachment of viral antigens to plastic wells or latex beads. 
Physical examination. Sweating in a febrile child should be noted. The continuing absence 
of sweat in the presence of an elevated or changing body temperature suggests dehydration from 
vomiting, diarrhea, or central or nephrogenic diabetes insipidus. It also should suggest anhidrotic 
ectodermal dysplasia, familial dysautonomia, or exposure to atropine. 
Red, weeping eyes may be a sign of connective tissue disease, particularly polyarteritis 
nodosa. Palpebral conjunctivitis in the febrile patient may be a clue to measles, coxsackievirus 
infection, tuberculosis, infectious mononucleosis, lymphogranuloma venereum, cat-scratch 
disease, or Newcastle disease virus infection. In contrast, bulbar conjunctivitis in a child with 
FUO suggests Kawasaki syndrome or leptospirosis. Petechial conjunctival hemorrhages suggest 
endocarditis. Uveitis suggests sarcoidosis, juvenile rheumatoid arthritis, systemic lupus erythe-
matosus, Kawasaki syndrome and vasculitis. Chorioretinitis suggests cytomegalovirus, 
toxoplasmosis, and syphilis. Proptosis suggests orbital tumor, thyrotoxicosis, metastasis (neuro-
blastoma), orbital infection, Wegener granulomatosis, or pseudotumor. A careful ophthalmic 
examination is important in most patients with FUO. 
The ophthalmoscope should also be used to examine for nailfold capillary abnormalities that are 
associated with connective tissue diseases such as dermatomyositis and systemic scleroderma. Emer-
sion oil or lubricating jelly is placed on the skin adjacent to the nailbed, and the capillary pattern is ob-
served with the ophthalmoscope set on +40. 
Fever of unknown origin is sometimes due to hypothalamic dysfunction. A clue to this 
disorder is failure of pupillary constriction due to absence of the sphincter constrictor muscle 
of the eye. This muscle develops embryologically when hypothalamic structure and function 
also are undergoing differentiation. 
Lack of tears or an absent corneal reflex may suggest fever resulting from familial dy-
sautonomia. A smooth tongue may reflect absence of fungiform papillae and also suggest this 
diagnosis. Tenderness to tapping over the sinuses and teeth should be sought, and the si-
nuses should be transilluminated. Oral candidiasis may be a clue to various disorders of the 
immune system. 
Fever blisters are common findings at patients with pneumococcal, streptococcal, ma-
larial, and rickettsial infection. They also are common in children with meningococcal 
meningitis (which usually does not present as FUO) but rarely are seen in children with 
meningococcemia. Fever blisters also are rarely seen with salmonella or staphylococcal 
infections. 
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Repetitive chills and temperature spikes are common in children with septicemia (re-
gardless of etiology), particularly when associated with renal disease, liver or biliary dis-
ease, endocarditis, malaria, brucellosis, rat-bite fever, or loculated collections of pus. 
Hyperemia of the pharynx, with or without exudate, may suggest infectious mononu-
cleosis, cytomegalovirus infection, toxoplasmosis, salmonellosis, tularemia, Kawasaki 
syndrome, or leptospirosis. 
The muscles and bones should be palpated carefully. Point tenderness over a bone may 
suggest occult osteomyelitis or bone marrow invasion from neoplastic disease. Tenderness 
over the trapezius muscle may be a clue to subdiaphragmatic abscess. Generalized muscle 
tenderness suggests dermatomyositis, trichinosis, polyarteritis, Kawasaki syndrome, or 
mycoplasma or arboviral infection. 
Rectal examination may reveal pararectal adenopathy or tenderness, which suggests a 
deep pelvic abscess, iliac adenitis, or pelvic osteomyelitis. A guaiac test should be obtained on 
any stool found on the examining finger; occult blood loss may suggest granulomatous colitis or 
ulcerative colitis as the cause of  FUO. 
The general activity of the patient and the presence or absence of rashes should be 
noted. Hyperactive deep tendon reflexes may suggest thyrotoxicosis as the cause of  FUO. 
Laboratory studies. Diagnostic tests most likely to provide a prompt definitive diag-
nosis should be used. Ordering a large number of tests in every child with FUO according 
to a predetermined sequence may waste time and money. Alternatively, prolonged hospi-
talization for sequential tests may be more costly. The tempo of diagnostic evaluation 
should be adjusted to the tempo of the illness; haste may be imperative in a critically ill 
patient, but if the illness is more chronic, the evaluation can proceed more slowly and de-
liberately, and, usually, in the ambulatory setting. 
A complete blood cell count with a differential cell count and a urinalysis should be 
part of the initial laboratory evaluation. An absolute neutrophil count <5,000 mm3 is evi-
dence against nonfulminant bacterial infection other than typhoid. Conversely, patients 
with >10,000 polymorphonuclear leukocytes or >500 nonsegmented polymorphonuclear 
leukocytes/mm3 have a high chance of having a severe bacterial infection. Direct examina-
tion of the blood smear treated with Giemsa or Wright stain may reveal malaria, trypano-
somiasis, babesiosis, or relapsing fever. 
An elevated erythrocyte sedimentation rate (ESR >30 mm/hr, Westergren method) in-
dicates inflammation and the need for further evaluation for infectious, autoimmune, or 
malignant diseases. A low ESR does not eliminate the possibility of infection or juvenile 
rheumatoid arthritis, but an ESR of >100 mm/hr suggests tuberculosis, Kawasaki syn-
drome, malignancy, or autoimmune disease. 
Blood cultures should be obtained aerobically. Anaerobic blood cultures have an 
extremely low yield and should only be obtained if there are specific reasons to sus-
pect an anaerobic infection. Repeated blood cultures may be required to diagnose endo-
carditis, osteomyelitis, or deep-seated abscesses producing bacteremia. Polymicrobial bac-
teremia suggests factitious self-induced infection or gastrointestinal pathology. The isolation 
of leptospires, Francisella, or Yersinia may require selective media or specific conditions not 
routinely employed. Urine culture should be obtained routinely. 
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Tuberculin skin testing should be performed carefully with polysorbate 80 (Tween) stabi-
lized purified protein derivative (PPD) that has been kept appropriately refrigerated. Other 
appropriate antigens should be placed to test for anergy. 
Roentgenographic examination of the chest, sinuses, mastoids, or gastrointestinal tract may be 
suggested by specific historical or physical findings. Roentgenographic evaluation of the gastroin-
testinal tract for inflammatory bowel disease may be helpful in evaluating selected children with 
FUO and no other localizing signs or symptoms. 
Examination of the bone marrow may reveal leukemia; metastatic neoplasm; my-
cobacterial, fungal, or parasitic diseases; and histiocytosis, hemophagocytosis, or stor-
age diseases. If a bone marrow aspirate is performed cultures for bacteria, Mycobacte-
rium, and fungi should be obtained. 
Serologic tests may aid in the diagnosis of infectious mononucleosis, cytomega-
loviral disease, toxoplasmosis, salmonellosis, tularemia, brucellosis, leptospirosis, and, 
on some occasions, juvenile rheumatoid arthritis. As serologic tests for more diseases 
become available through commercial laboratories, it is important to ascertain the 
sensitivity and specificity of each test before relying on these results to make a diagno-
sis. Serologic tests for Lyme disease are notoriously unreliable. 
Radioactive scans may be helpful in detecting osteomyelitis and abdominal ab-
scesses. Gallium citrate localizes in inflammatory tissues (leukocytes) associated with 
tumors or abscesses. 99mTc phosphate is useful for detecting osteomyelitis before 
plain roentgenograms demonstrate bone lesions. Indium-III granulocytes or iodinated 
IgG may be useful in detecting localized pyogenic processes. Echocardiograms may 
suggest the presence of vegetation on the leaflets of heart valves, as in subacute bacte-
rial endocarditis. Ultrasonography may identify intra-abdominal abscesses of the liver, 
subphrenic space, pelvis, or spleen. 
Total body computed tomography (CT) or magnetic resonance imaging (MRI) 
scanning permits the detection of neoplasms and collections of purulent material without 
the use of surgical exploration or radioisotopes. CT scanning is helpful in identifying 
lesions of the head, neck, chest, retroperitoneal spaces, liver, spleen, intra-abdominal and 
intrathoracic lymph nodes, kidneys, pelvis, and mediastinum. CT or ultrasound-guided 
aspiration or biopsy of suspicious lesions has reduced the need for exploratory laparo-
tomy or thoracotomy. Although scanning procedures can be very helpful in confirming a 
suspected diagnosis, they rarely lead to an unsuspected one. 
Biopsy is occasionally helpful in establishing a diagnosis of FUO. Bronchoscopy, 
laparoscopy, mediastinoscopy, and gastrointestinal endoscopy may provide direct visu-
alization and biopsy material when organ-specific manifestations are present. 
Treatment. Treatment of patients suffering from an infectious disease should be 
aetiopathogenic, complex, systemic, individualized, and as early as possible. 
Regimen, nursing, and diet. The most important element in the treatment of infectious pa-
tients is correct organization of the regimen. Children are especially sensitive patients. The 
growing body with its characteristic reactivity requires special care on the part of the medical 
personnel during performance by them of medical, diagnostic, and prophylactic measures. 
Psychic perception of the child is quite different from that of an adult. 
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Much attention should be paid to giving an adequate amount of fluid; this is particularly 
important in toxaemia and exsiccosis. Children should be fed at definite intervals, depending 
on their age, and meal times should be strictly observed. 
Causal treatment 
Various methods are employed in order to eliminate or render harmless the organism caus-
ing or maintaining the infectious process, and to detoxicate bacterial toxins (chemotherapy, im-
munotherapy, and phagotherapy). 
1. Chemotherapy (anti-malarial drugs, derivatives of arsenic and antimony, sulphona-
mides, antibiotics, etc.) is the treatment of an infectious disease by chemical agents acting on 
the causative agent. 
2.Immunotherapy is divided on 2 groups -active (vaccinotherapy, anatoxynotherapy) and 
passive (serotherapy, immunoglobulin). 
3. Phagotherapy is another method of acting on the causative agent of a disease. Bacterio-
phages are strictly specific, acting only on definite species of microbe, causing complete lysis. 
Specific bacteriophages are indicated in dysentery and salmonellosis.  
4. Therapy with biological preparations is close to the latter two methods. The prepara-
tions are obtained from microbes of normal intestinal microflora that are antagonists to some 
pathogenic microbes. These preparations are bifidumbacterin, bificol, lactobacteria, etc.; giv-
ing these preparations to treat dysbacteriosis caused by various diseases favours the restora-
tion of normal biocenosis. 
Non-specific pathogenetic therapy 
Apart from aetiological therapy, of great importance in infectious diseases is 
pathogenetic therapy, i.e. action on the mechanisms determining the development of 
pathological processes, and developing the organism's protective, compensatory, and 
restorative reactions. 
The methods of pathogenetic therapy include many elements with aetiotropic ac-
tion. Strict separation of aetiologic and pathogenetic therapy is impossible. 
The various methods of pathogenetic therapy employed in infectious diseases may 
provisionally be grouped as follows, according to their principal action: 
(a) non-specific methods of eliminating toxaemia (blood and plasma transfusion (polyglu-
cin), intravenous injection of hypertensive glucose solution, increased fluid intake, use of cortico-
steroids, saturation with vitamins); 
(b) action on the pathologically changed reactivity of the organism through stimu-
lation, desensitization (hormone therapy, use of anti-histamine drugs, general ultra-
violet irradiation, etc.); 
(c) restoration of disturbed physiological functions and their regulation (normaliza-
tion of metabolism, for example, of water-mineral metabolism in toxic dysentery; 
restoration of disturbed cardiovascular activity, restoration of normal lung ventilation, 
etc.); 
(d) depression of excessive and pathologically altered reactions (inflammation, 
hyperthermia, cough in croup and whooping-cough, intestinal spasm in dysentery, 
etc.); 
 12 
(e) replacement therapy (blood transfusion in anaemia, enzyme therapy in dysen-
tery, vitamins in hypovitaminoses, corticosteroids in disturbed funct'on of suprarenals, 
etc.). 
Prophylaxis 
General prophylactic measures are of the utmost importance, but to be continuous (even 
during periods that are favourable epidemicwise). Preventive measures desirable in an epi-
demic focus are as follows: 
1.  Isolation of the source of infection. 
2. To send the urgent massage to sanepidemic station 
3. Quarantine of contact children. 
4. Immunization of contact children (active of passive). 
5. Disinfections (concurrent and terminal). 
6. Follow-up of the epidemic focus. 
When a case of nosocomial infection is discovered, the patient should be immedi-
ately isolated, and the ward ventilated, and when the infection is caused by a stable agent, 
disinfected. With aerial-droplet infections (except German measles) the whole department or an 
individual ward is quarantined, depending on the infection, the type of patients, and the condi-
tions in the ward. Children who have not had the infection previously are no longer admitted, 
and the discharge of contacts is delayed. The question of what group of patients to quarantine, 
and on the need for this measure in such infections as chickenpox, mumps, whooping-cough, 
and influenza, is decided individually in each case, depending on the specific conditions; but it is 
desirable to consult an epidemiologist. An important item in control of nosocomial measles 
infection is properly organized serum prophylaxis among unimmunized contacts, thanks to 
which this very dangerous nosocomial infection is now relatively harmless in well-organized 
hospitals, and mortality has been reduced to zero. Each individual case of nosocomial infection 
needs to be analysed and recorded in a special journal of hospital infections. 
To avoid the danger of spread of infection from a hospital, or to reduce it to the 
minimum, it is necessary to observe strictly the rules for dismissal of infectious pa-
tients. Officially recommended terms for isolation of contagious patients should be 
strictly adhered to. Before discharge convalescents are given a bath or shower, and 
dressed in disinfected clothes. When a convalescing child is dismissed from the hospi-
tal, the parents are given an epicrisis where contacts (or absence of contacts) with in-
fectious patients are indicated. The rules for caring for convalescents and the prophy-
lactic measures needed at home, are explained to the relatives taking a child away 
from hospital. 
Sanitary, prophylactic, and anti-epidemic measures need to be skillfully combined 
with the treatment and the therapeutic regimen. It is of great importance in combating 
nosocomial infections to maintain the moral of patients and the general non-specific 
resistance of their organisms at a high level. 
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PART 2     VIRAL HEPATITIS 
 
S.P. Botkin regarded epidemic virus hepatitis as an independent infection. Viral 
hepatitis is a major health problem in developing and developed countries. 
Causative agents. Recent advances in the field of molecular biology have aided iden-
tification and understanding of the pathogenesis of the five viruses that are now known 
to cause hepatitis as their primary disease manifestation. These hepatotropic viruses are 
designated hepatitis A, B, C, D, and E. 
The five hepatitis viruses are a heterogenous group of viruses that cause similar acute 
clinical illness. Hepatitis A, C, D, and E are RNA viruses representing four different families, 
and hepatitis B is a DNA virus. 
The viruses of hepatitis are stable to the environmental factors (temperature in par-
ticular). 
 
Hepatitis A 
Etiology. HAV is a 27-nm diameter, RNA-containing virus that is a member of the Picornavi-
rus family. It was isolated originally from stools of infected patients. Laboratory strains of HAV 
have been propagated in tissue culture.  
Epidemiology. Hav infections occur throughout the world but are most common 
in developing countries, where the prevalence rate approaches 100 % in children by 
the age of 5 yr. Hepatitis A causes only acute hepatitis. The illness is much more likely 
to be symptomatic in adults; most infections in children younger than 5 yr are asymp-
tomatic or have mild, nonspecific manifestations. The transmission of HAV is almost 
always by person-to-person contact. Spread is predominantly by the fecal-oral route; 
percutaneous transmission is a rare occurrence and maternal-neonatal transmission is 
not recognized as an epidemiologic entity. Fecal excretion of the virus occurs late in 
the incubation period, reaches its peak just before the onset of symptoms, and is 
minimal in the week after the onset of jaundice. The mean incubation period for HAV 
is about 4 wk. 
Pathology and pathogenesis. The acute response of the liver to HAV is similar to 
that of the other four hepatitis viruses. The entire liver is involved with necrosis, most 
marked in the centrilobular areas, and increased cellularity, which is predominant in 
the portal areas. The lobular architecture remains intact, although balloon degeneration 
and necrosis of parenchymal cells occur initially. When the course of the disease is 
protracted, regeneration, sclerosis, dystrophic-necrotic processesare found. Injury in 
acute hepatitis is caused by several mechanisms. The initial injury in hepatitis A is 
thought to be cytopathic. Regardless of the mechanism of initial injury to the liver, 
damage from the five hepatitis viruses is evident in three main ways. The first is a 
reflection of injury to the hepatocytes, which release alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) into the bloodstream. The affection of hepato-
cytes and deranged permeability of cell membranes account for the increased activity 
in the blood of the enzyme aminotransferase. The ALT is more specific to the liver 
than the AST, which also can be elevated after injury to erythrocytes, skeletal muscle, 
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or myocardial cells. Protein, fat, carbohydrate, pigment, and water-salt metabolism are 
affected. There is hypoproteinaemia, accumulation of metabolites, and a considerable 
increase in blood bilirubin content. The liver loses its capacity to produce and store 
glycogen. There is a deficiency of vitamins A, B1, and B2; disturbance of vitamin K 
assimilation leads to reduction of prothrombin level and as a result to haemorrhagic 
phenomena. The height of aminotransferaseelevation does not correlate with the ex-
tent of hepatocellular necrosis and has little prognostic value. In some cases, a falling 
aminotransferase level may predict a poor outcome if the decline occurs in conjunc-
tion with a rising bilirubin and prolonged prothrombin time (PT). This combination of 
findings indicates that massive hepatic injury has occurred, resulting in few function-
ing hepatocytes. Viral hepatitis is also associated with cholestatic jaundice, in which 
both direct and indirect bilirubin levels are elevated. Jaundice results from obstruction 
of biliary flow and damage to hepatocytes. Elevations of serum alkaline phosphatase, 
5-nucleotidase, g-glutamy-l-transpeptidase, and urobilinogen all can reflect injury to 
the biliary system. Increased PT reflects abnormal protein synthesis by hepatocytes. 
Because of the short half-life of these proteins, the PT is a sensitive indicator of dam-
age to the liver. Serum albumin is another liver-manufactured serum protein, but its 
longer half-life limits its relevance for monitoring acute liver injury. Cholestasis re-
sults in a decreased intestinal bile acid pool and decreased absorption of fat-soluble 
vitamins. 
Clinical picture 
The incubation period of epidemic hepatitis A is between 15 and 50 days. The course of epi-
demic hepatitis has a cyclic character and consists of three stages, the preicteric, icteric, and con-
valescent. The preicteric stage, lasting from three to ten days, is met in most patients. Its most 
constant symptoms are dyspeptic, namely: anorexia, nausea, vomiting, abdominal pain, and 
sometimes diarrhoea or, on the contrary, constipation. 
There is prostration, moderate or slight elevation of temperature, and headache, but the 
temperature often remains normal. Catarrh of the respiratory tract, i.e. rhinitis, cough, pain all 
over the body, and headache are met less often. In some cases the leading symptom is rheu-
matoid pain in the joints and neuralgia (more common in adults than in children). A certain 
enlargement and slight tenderness of the liver are already noted at the preicteric stage, and 
sometimes (mostly in nursing babies) there is also enlargement of the spleen. Blood bilirubin 
content rises by the end of this period; there is also increased activity of the enzymes - aldolase 
and transaminase. Bile pigments appear in the urine, often rendering it dark yellow; the stool 
becomes pale. The ESR is usually normal or decreased. 
As a rule, the icteric stage is accompanied with a fall of temperature and im-
provement in the patient's condition. Jaundice develops gradually; initially the sclera and 
the soft palate are involved, and then the skin. The severity of the jaundice does not always 
conform to that of the disease. Hepatitis with a mild form of jaundice, or even without it, 
may sometimes end in cirrhosis, or change to toxic dystrophy of the liver. The jaundice is 
sometimes accompanied with slight pruritus of the skin, and epistaxis and a haemorrhagic 
rash are occasionally displayed. When the hepatitis runs a benign course the neuropsychic 
phenomena are usually mild, only adynamia, listlessness, and sometimes sleepiness and 
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irritability, being noted. Cardiovascular findings are bradycardia and enfeebled and impure 
cardiac sounds; but bradycardia is not met, as a rule, in nursing babies. The dyspeptic 
symptoms noted during the preicteric stage often become intensified: there is sharp loss of 
appetite, some patients have diarrhoea, and others constipation. The stool is usually pale 
(achylous). 
The liver is enlarged, hard, and moderately tender. Spontaneously arising pain in the 
hepatic region is common. The spleen is enlarged in one-fifth to one-third of patients. The 
affection of the liver is accompanied with its disturbed function detectable by examination 
of the blood and urine and by special functional tests. There is a marked increase in blood 
bilirubin content especially conjugate bilirubin. Bilirubinaemia increases significantly in 
severe cases mainly due to indirect bilirubin (free bilirubin). The onset of jaundice is 
marked by decreased diuresis. 
The urine becomes dark yellow or brownish-yellow in colour. Bilirubin and sometimes 
a little protein and individual erythrocytes are found in it. At the height of the disease, when 
no bile at all enters the intestine, urobilin disappears, but it reappears at the beginning of 
convalescence. Urobilinuria ceases after restoration of hepatic function. 
The deranged liver function (which corresponds to the gravity of the disease) involves 
(in addition to the pigment disorders) a decrease in the total protein content of the blood 
serum, dysproteinaemia, which develops mainly due to the increased gamma globulin 
content. Dysproteinaemia is also confirmed by positive sedimentation tests (thymol and 
sublimate tests) characterizing the stability and dispersion of the serai proteins. The coagu-
lating factors (prothrombin and proconvertin) are decreased. The activity of the blood se-
rum enzyme aldolase and aminotransferase increases. The increased activity of sorbit-
dehydrogenase and fructosomonophosphate aldolase is especially important. These en-
zymes are regarded as organospecific of the liver. Fat and carbohydrate metabolism is also 
upset. 
Blood findings. Erythrocyte count and haemoglobin content are often reduced 
particularly when the process is protracted. In the initial period leucocyte count usually 
remains within the range normal for the given age, but in the icteric stage slight leuco-
penia and relative lymphocytosis are often noted. The ESR remains normal or de-
creases. 
The icteric stage is divided into phases of progress, maximum development and 
abatement of icterus. Jaundice persists for ten to twenty days, on the average, but is 
sometimes as short as seven, or as long as 40 and more. As a rule, subsidence is 
slower than progress. As blood bilirubin falls and the other symptoms of the disease 
disappear, there is increased diuresis and improvement of the patient's general condi-
tion. 
Gradual restorations of hepatic function and decrease in the size of the liver pro-
ceed during the convalescent stage, which is sometimes protracted. There may be 
exacerbations and relapses. The residual phenomena (enlargement of the liver and 
mild icterus) may last for several months. The younger a child, however, the more 
rapid is convalescence. 
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This description of the clinic of virus hepatitis equally holds for its inoculation 
variant (hepatitis B). The latter only has the following special characteristics: shorter 
duration of the preicteric period and more frequent absence of this period; more pro-
nounced intoxication; gradual intensification of jaundice, its longer duration and more 
pronounced bilirubinaemia; relatively low indices of the thymol test and relatively low 
increase in IgM; more frequent enlargement of the spleen and a more severe course in 
general. Compared with hepatitis A, hepatitis B is more characterized by its pro-
tractedness and chronic forms. But it should be noted that this, to a certain extent, 
might be due to the special reactivity of infants less than 1 year of age in whom the 
inoculation hepatitis mostly occurs. The more severe course of inoculation hepatitis 
can probably be partially associated with the initial development of the infection 
against the background of another severe disease, for which some manipulations were 
carried out (e.g. blood transfusion). 
Epidemic hepatitis has various clinical forms. Acute, protracted, and chronic hepa-
titis is distinguished. Hepatitis is considered protracted if it lasts for over three months 
and chronic if it continues over six months. The latter term is however only conven-
tional and chronic hepatitis may (especially in severe cases) develop at earlier terms. 
At the same time, the process of recovery may continue for a few months, which may 
be due to the so-called post-hepatic astheno-dyspeptic syndrome with functional dis-
orders. Acute hepatitis is divided by severity into mild, moderately severe, severe, and 
grave; the last-named follows the course of toxic dystrophy of the liver. Hepatitis 
without clinical jaundice is distinguished as an atypical form; this form presents con-
siderable diagnostic difficulties. 
The form without clinical jaundice is much more common, but is not always recog-
nized. Many clinicists regard hepatitis occurring without jaundice and bilirubinaemia (as 
established at the laboratory) as the nonicteric hepatitis. It has the symptoms of the pre-icteric 
stage of hepatitis. Of-particular importance for diagnosis are pain in the hepatic region, swelling or 
slight tenderness of the liver, increased activity of aldolase and transaminase, positive thymol turbid-
ity test, and increase of urobilin content in the urine. Although this form is mild, it sometimes leads 
to toxic dystrophy of the liver or to cirrhosis. 
The grave form (toxic dystrophy of the liver) may begin as common hepatitis. The change to ma-
lignancy usually occurs during the first seven or ten days of the icteric stage. Adynamia progresses 
rapidly; anorexia, persistent vomiting and specific mouth smell is noted. Bilirubinaemia increases 
significantly at the expense of indirect bilirubin; residual nitrogen increases, and the alkali reserve of the 
blood decreases sharply (acidosis). There is a picture of very grave toxaemia with fulminant neuropsy-
chic symptoms (including maniac excitation, motor agitation, and delirium followed by a lapse into a 
comatose state). Most patients display a rapidly progressive contraction of the liver, a haemorrhagic 
tendency, arterial hypotension, and tachycardia. The disease is often fatal, but active treatment may 
bring recovery. 
Epidemic hepatitis may become chronic (this being particularly facilitated by repeated exacer-
bations and relapses), and last for months or even years. The outcome is either recovery, usually with 
residual phenomena, or cirrhosis of the liver. Virus hepatitis is often aggravated by affection of the bile 
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ducts (mostly their dyskinesia). The late periods of the disease may be marked by cholecystitis and 
cholangitis, which develop as a result of secondary bacterial infection. 
Diagnosis. Great difficulties are encountered in recognizing the disease during the 
preicteric stage or in cases without clinical jaundice. Examination of the blood for 
bilirubin, and of urine for bile pigments and urobilin, and the epidemiological anam-
nesis are of diagnostic value in these cases. For early diagnosis of hepatitis, particu-
larly of the form without apparent jaundice, of great aid is the determination of the 
activity of the following enzymes: aldolase, aspartate amino-transferase and alanin 
aminotransferase. The content of the latter two substances increases several times in 
virus hepatitis. Protein sedimentation tests (with thymol and sublimate) are also used. 
Anti-HAV is detected at the onset of symptoms of acute hepatitis A and persists 
for life. The acute infection is diagnosed by the presence of IgM anti-HAV, which can 
be detected for 3–12 mo; thereafter, IgG anti-HAV is found. The virus is excreted in 
stools from 2 wk before to 1 wk after the onset of illness. The PT should always be 
measured in a child with hepatitis to help assess the extent of liver injury; prolongation 
is a serious sign mandating hospitalization. 
 
Hepatitis B 
Etiology. HBV is a 42-nm diameter member of the hepadnavirus family, a noncy-
topathogenic, hepatotropic group of DNA viruses. The surface of the virus includes 
two particles designated hepatitis B surface antigen (HbsAg) The inner portion of the 
virion contains hepatitis B core antigen (HBcAg) and a nonstructural antigen called 
hepatitis B e antigen (HBeAg). Replication of HBV occurs predominantly in the liver 
but also occurs in lymphocytes, spleen, kidney, and pancreas. 
Epidemiology. The most important risk factor for acquisition of hepatitis B infec-
tion in children is perinatal exposure to an HBsAg-positive mother. The risk of trans-
mission is greatest if the mother also is HBeAg positive; 70-90 % of their infants be-
comes chronically infected if untreated. In most cases, antigenemia appears later, sug-
gesting that transmission occurred at the time of delivery; virus contained in amniotic 
fluid or in maternal feces or blood may be the source. Although most infants born to 
infected mothers become antigenemic from 2–5 mo of age, some infants of HBsAg-
positive mothers are not affected until later ages. 
HBsAg has been demonstrated inconsistently in milk of infected mothers. Breast-
feeding of unimmunized infants by infected mothers does not appear to confer a 
greater risk of hepatitis on offspring than does artificial feeding despite the possibility 
that cracked nipples may result in the ingestion of contaminated maternal blood by the 
nursing infant. 
HBV is present in high concentrations in blood, serum, and serous exudates and in mod-
erate concentrations in saliva, vaginal fluid, and semen. For these reasons, efficient transmis-
sion occurs through blood exposure and sexual contact. The incubation period ranges from 
45–160 days, with a mean of about 100 days. 
Pathogenesis. Hepatitis B, unlike the other hepatitis viruses, is a noncytopathic virus 
that causes injury by immune-mediated mechanisms. The first step in the process of acute 
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hepatitis is infection of hepatocytes by HBV, resulting in the appearance of viral antigens 
on the cell surface. These antigens, in combination with class I major histocompatibility 
(MHC) proteins, make the cell a target for cytotoxic T-cell lysis. 
Clinical manifestations. Many cases of HBV infection are asymptomatic. The usual 
acute, symptomatic episode is similar to HAV and hepatitis C virus (HCV) infections but 
may be more severe and is more likely to include involvement of skin and joints. The first 
clinical evidence of HBV infection is elevation of ALT, which begins to rise just before the 
development of lethargy, anorexia, and malaise, about 6–7 wk after exposure. The illness 
may be preceded in a few children by a serum sickness–like prodrome including arthralgia 
or skin lesions, including urticarial, purpuric, macular, or maculopapular rashes. Papular 
acrodermatitis, the Gianotti-Crosti syndrome, also may occur. Jaundice, which is present in 
about 25 % of infected individuals, usually begins about 8 wk after exposure and lasts for 
about 4 wk. Splenomegaly and lymphadenopathy are common. Chronic hepatitis occurs, 
and the chronic active form can result in cirrhosis and hepatocellular carcinoma. 
Virus hepatitis in infants under 1 year of age has special characteristics. They can 
probably be partially associated with the fact that the disease in infants is mostly 
evoked by virus B. The course of virus hepatitis in infants under 1 is more severe than 
in older children; toxic dystrophy of the liver occurs more frequently in them. The 
preicteric period in infants is short and is often overlooked. Jaundice, on the contrary, 
is longer (30-40 days) and is attended by pronounced hyperbilirubinaemia and a 
marked enlargement of the liver. Secondary bacterial (staphylococcal) infection often 
supervenes in these infants to account for the intermittent course of the disease. 
Diagnosis. The serologic pattern for HBV is more complex than for HAV and dif-
ference depending on whether the disease is acute, subclinical, or chronic. HBsAg is 
the first serologic marker of infection to appear and is found in almost all infected 
persons; its rise coincides closely with the onset of symptoms and disappeared soon. 
In chronic carriers HbsAg may persist longer than 6 months or even indefinitely.  
Same time HbsAg may be present in healthy carrier. HBeAg is often present during 
the acute phase and indicates a highly infectious state. HbcAg never presents in blood, 
it can be found only in hepatocytes by biopsy. 
Antibody to hepatitis B surface antigen (Anti-HBs) is diagnostic of previous HBV in-
fection or immunization conferring immunity against HBV. Only anti-HBsAg is present in 
persons immunized with hepatitis B vaccine, whereas anti-HBsAg and anti-HBcAg are 
detected in persons with resolved infection. 
Because HBsAg levels fall before the end of symptoms, IgM antibody to hepatitis 
B core antigen (IgM anti-HBcAg) also is required because it rises early after infection 
and persists for many months before being replaced by IgG anti-HBcAg, which per-
sists for years. Presence of IgM anti-HBcAg more than 6 months is considered evi-
dence of ongoing HBV replication. IgM anti-HBcAg usually is not present in perinatal 
HBV infections. 
Antibody to the “e”-antigen (anti-HbeAg) appears with the reduction of acute in-
fection. Its presence in chronic carries is associated with relatively low infectivity and 
a good prognosis. 
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Complications. Acute fulminant hepatitis occurs more frequently with HBV than 
with the other hepatitis viruses, and the risk of fulminant hepatitis is further increased 
when there is coinfection or superinfection with HDV. Mortality from fulminant hepa-
titis is greater than 30 %. HBV infections also can result in chronic hepatitis, which 
can lead to cirrhosis and primary hepatocellular carcinoma. Interferon alpha-2b is 
available for treatment of chronic hepatitis B in person’s 18 years of age or older with 
compensated liver disease. 
Prevention. Universal immunization of infants with hepatitis B vaccine is 
now recommended. Two recombinant DNA vaccines are available in the United 
States; both have proven to be highly immunogenic in children. The AAP rec-
ommends that infants born to HBsAg-negative women receive the first dose of 
vaccine at birth, the second at 1–2 mo of age, and the third between 6 and 18 
mo of age. Infants born to HBsAg-positive women should receive vaccine at birth, 1 
mo, and 6 mo of age. The first dose should be accompanied by administration of 0.5 
mL of hepatitis B immunoglobulin (HBIG) as soon after delivery as possible because 
the effectiveness decreases rapidly with increased time after birth. 
 
Hepatitis C 
Etiology. HCV is a single-strand RNA virus that has been classified as a separate genus 
within the Flaviviridae family. HCV is an enveloped virus, 50–60 nm in size that is transmitted 
mainly by blood or blood products, intravenous drug use, and sexual contact. Chronic liver dis-
ease is common in infected individuals. 
Epidemiology. The most important risk factors for HCV transmission are the use 
of intravenous drugs (40 %), transfusions (10 %), and occupational and sexual expo-
sure (10 %). The incubation period is range7–9 wk  (2–24 wk). 
Pathogenesis. HCV appears to cause injury primarily by cytopathic mechanisms, 
but immune-mediated injury also may occur. The cytopathic component appears to be 
mild, because the acute form is typically the least severe of all hepatitis virus infec-
tions; HCV rarely is fulminant. 
Clinical manifestations. The clinical picture of the acute infection is usually similar 
to that of the other hepatitis viruses. HCV is the most likely hepatitis virus to cause 
chronic infection; about two thirds of post-transfusion infections and about one third of 
sporadic, community-acquired cases will become chronic. Although chronic elevations 
of aminotransferase levels are common, chronic HCV will progress to cirrhosis in only 
about half of the patients, or about 25 % of all those initially infected.  
Diagnosis. The clinically available serologic assays for HCV are based on develop-
ment of antibodies to HCV antigens because no detectable antigens have been found in 
blood. The assays are used mainly for detection of chronic hepatitis C because they re-
main negative for at least 1–3 mo after the clinical onset of illness. Assays for viral RNA 
(polymerase chain reaction [PCR]) are costly. 
Complications. The risk of fulminant hepatitis is low with HCV, but the risk for 
chronic hepatitis is the highest among the hepatitis viruses. The usual chronic course is mild 
even when cirrhosis develops. 
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Prevention. There is no vaccine available, and none may be developed because 
animal studies suggest that HCV infection does not lead to protective immunity; the 
same individual can be infected multiple times with the same virus. 
 
Hepatitis D 
Etiology. Hepatitis D virus (HDV), the smallest known animal virus, is considered 
defective because it cannot produce infection without a concurrent HBV infection. 
Epidemiology. HDV infection cannot occur without HBV as a helper virus. 
Hepatitis D infections are uncommon in children but must be considered when fulmi-
nant hepatitis occurs. The incubation period for HDV superinfection is about 2–8 wk; 
with coinfection, the incubation period is similar to that of HBV infection. 
Pathophysiology. In contrast to HBV, HDV causes injury directly by cytopathic 
mechanisms. Many of the most severe cases of hepatitis B appear to be due to combined 
infection with HBV and HDV. 
Clinical manifestations. The symptoms of hepatitis D infection are similar to but 
usually more severe than those of the other hepatitis viruses. The clinical outcome for 
HDV infection depends on the mechanism of infection. In coinfection, acute hepatitis, 
which is much more severe than for HBV alone, is common, but the risk for chronic 
hepatitis is low. In superinfections, acute illness is rare, whereas chronic hepatitis is 
common. However, the risk of fulminant hepatitis is highest in superinfection. Hepati-
tis D should be considered in any child who experiences acute hepatic failure. 
Diagnosis. Detecting IgM antibody to HDV makes the diagnosis; the antibodies to 
HDV develop about 2–4 wk after coinfection and about 10 wk after superinfection. 
Complications. HDV must be considered in all cases of fulminant hepatitis. 
Prevention. There is no vaccine for hepatitis D. However, because HDV cannot 
occur without hepatitis B infection, HBV prevention eliminates HDV. HBIG and 
hepatitis B vaccines are used for the same indications as hepatitis B.  
 
Hepatitis E 
Etiology. Hepatitis E virus (HEV) has not been isolated but has been cloned using molecular 
techniques. This RNA virus is similar to the caliciviruses. Infection is associated with shedding of 
27- to 34-nm particles in the stool. 
Epidemiology. Infection is transmitted enterically, the highest prevalence has been reported in 
the Indian subcontinent, the Middle East, and Southeast Asia. The mean incubation period is about 
40 days (range, 15–60 days). 
Pathogenesis. HEV appears to act as a cytopathic virus. 
Clinical manifestations. The clinical illness in hepatitis E is similar to that of 
hepatitis A, the other enterically transmitted virus, but it is often more severe. Both 
viruses produce only acute disease; chronic illness does not occur. In addition to caus-
ing more severe illness than HAV, hepatitis E affects older patients, with a peak inci-
dence between 15 and 34 yr. Another important clinical difference is that HEV has a 
high fatality rate in pregnant women. 
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Diagnosis. IgM antibody to viral antigen becomes positive after about 1 wk of ill-
ness. 
Complications. HEV is associated with a high prevalence of death in pregnant 
women. 
Prevention. No vaccines are available. 
Diagnosis. Puncture biopsy should only be resorted to in separate doubted cases to diagnose 
chronic hepatitis. It should be remembered that the method is not sufficiently accurate since healthy 
tissue may be taken during the biopsy. 
Data of epidemiological anamnesis may be useful for establishment of the diagno-
sis. The diagnosis can only be confirmed by determining antigens and antibodies to 
its. 
Acute respiratory infections and other diseases characterized by fever during their ini-
tial period should be excluded in differential diagnosis. Enlarged liver, dark colour of the 
urine and colourless faeces, and especially increased activity of aminotransferase are very 
important for correct diagnosis. Haemolytic and obstructive jaundice may also interfere 
with correct diagnosis in the icteric period. Haemolytic jaundice is characterized by the 
absence of bilirubin in the urine, the faeces are not colourless but on the contrary are col-
oured more intensely. Free bilirubin content of blood increases. Obstructive jaundice, 
which is caused by obstruction of the bile ducts by stones, parasites, etc., is characterized by 
the absence of biochemical indices of liver affection; the indices of aminotransferase activ-
ity are normal. For differential diagnosis of leptospiral jaundice see the corresponding sec-
tion. 
Prognosis. The overwhelming majority of patients recover. There may be a transi-
tion to a chronic form (in 5 per cent of cases on average) with subsequent cirrhosis of 
the liver. It is more common in hepatitis B. The death rate is now low (fractions of 1 
per cent) but is higher in nursing babies and in hepatitis B. 
Treatment. Hepatitis patients must be hospitalized. Physical and mental quiet is 
of utmost importance. Bed rest is prescribed for the whole course of epidemic hepati-
tis; the patient is only allowed to leave his bed during the recovery period. 
Close attention has to be given to diet, which must be planned with due considera-
tion of the disturbed function of the liver, the extent of the toxaemia, and the patient's 
appetite. It should be mainly carbohydrates with adequate amount of animal protein. 
Limited intake of proteins and even complete eradication of proteins from the diet is 
only indicated in grave intoxication when a precomatose state develops. The menu 
should include milk products (cottage cheese, sour milk, yoghourt), vegetables, fruit, 
stewed fruit, sweet jellies, sugar, jam, honey. A minimum of fat and salt, and no ex-
tracts, hot spices, cocoa, or chocolate should be given. Adequate fluid (tea, fruit juices, 
alkaline mineral water, etc.) must be ensured. 
The patient's food should be enriched with vitamins. In addition it should be sup-
plemented by synthetic vitamin preparations, like ascorbic acid (100 to 300 mg daily), 
nicotinic acid (30 to 50 mg), and vitamins E1 and A.  Vitamin K (vikasol) is indicated 
for three to five days (0.005 to 0.01 g, depending on age, three times a day) when there 
are haemorrhagic symptoms. 
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In mild hepatitis bed rest and diet supplemented by these vitamins suffice for the 
majority. 
When the course of hepatitis is grave special measures are sometimes required to 
control the toxaemia. To this end a special diet, consisting only of fruit, sugar, jam, 
yoghourt, and abundant fluids, is recommended for one or two days. Cleansing or 
syphon enemas are prescribed to rid the bowel of accumulated toxic products. Intra-
venous drip infusions of 5 per cent glucose solution (300-500 ml and over) or Ringer's 
solution with ascorbic acid are recommended. 
Transfusion of plasma substitutes and albumin solution is employed for detoxica-
tion, stimulation of hepatic function, and desensitization. 
Steroid hormones (prednisolone, 2 mg/kg daily for seven to ten days) which pos-
sess an antiphlogistic, detoxifying, and desensitizing effect, are valuable, and are in-
cluded in the general therapeutic complex in severe forms of hepatitis. Definite indica-
tions for their prescription in increased doses (up to 5 ml/kg intramuscularly or intra-
venously) are a precomatose condition, and subacute or acute dystrophy of the liver. 
Plasma transfusion and hormone therapy are also employed when the disease has 
a protracted course. Physiotherapy (UHF, paraffin and ozokerite therapy) is also pre-
scribed in these cases. Antibiotic therapy (ampicillin, chloramphenicol, etc.) is pre-
scribed. 
Children who have had an attack of epidemic hepatitis should be kept under medi-
cal observation for six months and longer (up to 2 years) after discharge from hospital. 
They should be forbidden excessive physical strain and put on a light, digestible diet. 
No prophylactic vaccinations and no antihelminthic agents (apart from oxygen) 
should be prescribed during that period. Sanatorium treatment is recommended for 
children with long-term residual phenomena. 
 
PART 3  INFECTIOUS DISEASES OF ELEMENTARY TRACT (Shig-
ellosis, Sallmonellosis, Escherichiosis) 
30 to 40 percent of diarrheal episodes are caused by viruses, of which rotavirus is 
the best example. About 50 percent are due to bacterial infections of the gut. The pres-
ence of bacteria in the stools by itself is not a proof of these being causative agents. 
Bacteria cause diarrhea by two mechanisms: 1) through the action of toxins and 2) 
direct invasion of the intestinal mucosa. 
Shigellosis 
Four species of Shigella are responsible for illness: S. dysenteriae (serogroup A), 
S. flexneri (serogroup B), S. boydii (serogroup C), and S. sonnei (serogroup D). There 
are 12 serotypes in group A, 6 serotypes and 13 subserotypes in group B, 18 serotypes 
in group C, and 1 serotype in group D. 
Pathophysiology. The shigellae have the ability to invade colonic epithelial cells. 
This characteristic is encoded on a large (120–140 MD) plasmid that is responsible for 
synthesis of a group of polypeptides involved in cell invasion and killing. Shigellae that 
lose the virulence plasmid no longer act as pathogens. Escherichia coli that naturally or 
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artificially harbor this plasmid behave like shigellae. Shigatoxin, a potent protein synthesis–
inhibiting exotoxin, is produced in significant amounts only by S. dysenteriae serotype 1 
and certain E. coli (enterohemorrhagic E. coli or shiga-like toxin–producing E. coli). 
Shigellae require very low inocula to cause illness. Ingestion of as few as 10 S. dysente-
riae serotype 1 organisms can cause dysentery in some susceptible individuals. This is in con-
trast to organisms such as Vibrio cholerae, which require ingestion of 108–1010 organisms to 
cause illness. The inoculum effect explains the ease of person-to-person transmission of shig-
ellae in contrast to V. cholerae. Secretory IgA and serum antibodies develop within days to 
weeks after infection with Shigella.  
Pathology. The colon is the target organ for shigellae. The changes are most in-
tense in the distal colon, although pancolitis may occur. Grossly, localized or diffuse 
mucosal edema, ulcerations, friable mucosa, bleeding, and exudate may be seen. The 
following forms of intestinal affection are distinguished in dysentery: catarrhal, fol-
licular, croupous, and diphtheritic. 
Epidemiology. Infection with shigellae occurs most often during the warm 
months in temperate climates and during the rainy season in tropical climates. The sexes 
are affected equally. Although infection can occur at any age, it is most common in the 2nd 
and 3rd yr of life. Infection in the first 6 mo is rare. Breast milk, which in endemic areas 
contains antibodies to both virulence plasmid-coded antigens and lipopolysaccharides, may 
explain the age-related incidence. 
In industrialized societies, S. Sonnei is the most common cause of bacillary dysentery, 
with S. Flexneri second in frequency; in preindustrial societies, S. Flexneri is most com-
mon with S. Sonnei second in frequency. S. Dysenteriae serotype 1 tends to occur in mas-
sive epidemics, although it is also endemic in Asia. 
Contaminated food (often a salad or other item requiring extensive handling of the in-
gredients) and water are important vectors. However, person-to-person transmission is 
probably the major mechanism of infection in most areas of the world. 
Clinical manifestations. The most convenient and widespread classification of the 
clinical forms of dysentery is Kaltupin classification. There are typical and atypical forms 
of dysentery. Typical dysentery is divided into mild, moderately severe, and severe 
forms, the last-named may show prevalence either of local or of general phenomena 
(toxic form). 
After ingestion of shigellae there is an incubation period of several days before 
symptoms ensue. Characteristically, severe abdominal pain, high fever, emesis, ano-
rexia, generalized toxicity, urgency, and painful defecation occur. Physical examina-
tion at this point may show abdominal distention and tenderness, hyperactive bowel 
sounds, and a tender rectum on digital examination. 
The diarrhea may be watery and of large volume initially, evolving into frequent 
small-volume, bloody mucoid stools; however, some children never progress to the 
stage of bloody diarrhea, whereas in others the first stools are bloody. 
In mild cases the frequency of defaecation is three to eight times a day; the stool 
remains faecal in character, but assumes a greenish hue; pathological admixtures are 
not copious. In more severe cases bowel movements are very frequent (15 to 20 times 
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a day and more times). The stools are scanty, lose their faecal character, consist almost 
entirely of thick, almost transparent mucus, and are practically odorless. Later the mu-
cus with pus and blood. 
A leading place in the clinical picture of dysentery is taken by symptoms reflecting 
a spastic condition in the large intestine, namely, abdominal pain (spasmodic in char-
acter and precedes and accompanies each bowel movement, localized more frequently 
in the left iliac region), tenesmus, spastic contraction of the sigmoid colon. As severe 
dysentery progresses, paresis or paralysis replaces spasm of the sphincter, with result in 
gaping of the anus. 
Neurologic findings are among the most common extraintestinal manifestations of ba-
cillary dysentery, occurring in as many as 40 % of hospitalized infected children. Convul-
sions, headache, lethargy, confusion, nuchal rigidity, or hallucinations may be present be-
fore or after the onset of diarrhea. 
Untreated diarrhea may last 1–2 wk; only about 10 % of patients have diarrhea 
persisting for more than 10 days. Chronic diarrhea is uncommon except in malnour-
ished infants. 
The colitic syndrome is relatively mild in infants, and is usually not fully ex-
pressed. The stool often retains its faecal character but becomes liquid and greenish in 
colour. Mucus is almost always present, but blood flecks occur much less frequently. 
The stool may be dyspeptic in character. In most cases there is no tenesmus, but the 
baby shrieks and becomes red in the face during defaecation. Gaping of the anus is 
quite rare; much more frequently anal responsiveness is observed. The abdomen is 
inflated. Significant dehydration related to the fluid and electrolyte losses in both feces 
and emesis can occur at young children.  
The most common complication of shigellosis is dehydration with its attendant 
risks of renal failure and death. Other major complications, particularly in very young, 
malnourished children, include sepsis and disseminated intravascular coagulation. 
Complications caused by secondary infection are common in dysentery, particularly in 
infants (disbacteriosis, bronchopneumonia, stomatitis, gingivitis, nephritis, dystrophy, 
avitaminosis and anaemia).  
Differential diagnosis. The dysentery closely resembles many other intestinal diseases. 
Mild dysentery in infants under 1 should be differentiated from simple dyspepsia. It develops 
from overfeeding or from other negligence; its course is marked by apyrexia; stools are liquid, 
green, with insignificant admixtures of mucus (4-6 defaecations a day). Adherence to normal 
feeding rules will normally give a rapid positive effect. 
An erroneous diagnosis of dysentery in infants with intestinal invagination can 
lead to grave results. Invagination begins abruptly at a normal temperature, and the 
baby becomes very restless. There is tenesmus; stool consists of mucus and blood 
alone without faecal matter; no gases are evacuated. Usually the abdomen is soft, and 
a sausage-like tumour is palpable. Invagination can sometimes be revealed by digital 
examination of the rectum. Roentgenography of the abdominal cavity can help diag-
nosis. 
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Salmonella infections 
Salmonella infections occur worldwide. Acute gastroenteritis, the most frequent 
presentation, is usually self-limited, although bacteremia and focal extraintestinal in-
fections may develop, especially in immunocompromised patients. Enteric fever, a 
severe systemic disease typically caused by Salmonella typhi, is found mainly in de-
veloping countries, but it is seen elsewhere because of international travel. 
Etiology. Salmonella is a genus that belongs to the family Enterobacteriaceae and 
contains three species: S. typhi, S. choleraesuis, and S. enteritidis. The former two 
species have one serotype each, but S. enteritidis contains more than 1800 distinct 
serotypes.  
Salmonellae are motile, nonsporulating, nonencapsulated, gram-negative rods. 
Most strains ferment glucose, mannose, and mannitol to produce acid and gas, but 
they do not ferment lactose or sucrose. S. typhi does not produce gas. They are resis-
tant to many physical agents. Like other members of the Enterobacteriaceae, Salmo-
nella possesses somatic O antigens and flagellar H antigens. The O antigens are the 
heat-stable lipopolysaccharide components of cell wall; the H antigens are heat-labile 
proteins. The Kauffmann-White scheme commonly used to classify salmonellae sero-
types is based on O and H antigens. Another antigen is a virulence (Vi) capsular poly-
saccharide present on S. typhi and rarely found on strains of S. paratyphi C. 
 
Nontyphoidal Salmonellosis 
Epidemiology. The major reservoir of nontyphoidal salmonellae is infected ani-
mals, which constitute the principal source of human disease. Infected animals are 
often asymptomatic. Salmonella organisms have been isolated from many animals, 
including poultry (i.e., chickens, turkeys, and ducks), sheep, cows, pigs, pets, and 
birds. Animal-to-animal transmission may occur. Animal feeds containing fishmeal or 
bone meal contaminated with Salmonella are an important source of infection for 
animals. Moreover, subtherapeutic concentrations of antibiotics are often added to 
animal feed. Such practices promote the emergence of antibiotic-resistant bacteria, 
including Salmonella, in the gut flora of the animals. Data suggest that animal antibi-
otic exposure may be responsible for antibiotic-resistant Salmonella infections in man. 
Poultry and poultry products (mainly eggs), raw or powdered milk and dairy 
products caused about half of the common-source outbreaks. Because of the high in-
fecting dose, person-to-person transmission by direct fecal-oral spread is unusual but 
can occur, especially in young children who are not yet toilet-trained and do not main-
tain proper hygiene.  
Nosocomial infections have been related to contaminated medical instruments 
(particularly endoscopes) and diagnostic or pharmacologic preparations, particularly 
those of animal origin (e.g., pancreatic extracts, pituitary extracts, bile salts, pepsin, 
gelatin, vitamins, and carmine dye).  
During the period of Salmonella excretion, the individual may infect others, di-
rectly by the fecal-oral route or indirectly by contaminating foods. If one household 
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member becomes infected, the probability that another will also become infected is 
about 60 %. 
Pathology. Enterocolitis is the typical disorder caused by nontyphoidal Salmo-
nella infection. Salmonella organisms are capable of penetrating the intestinal mucosa. 
Intestinal inflammation, with polymorphonuclear leukocytes and macrophages, usu-
ally involves the lamina propria. Hyperplasia of the reticuloendothelial system is seen 
also within the liver and spleen. If bacteremia develops, it may lead to localized infec-
tion and suppuration of almost any organ. 
Pathogenesis. Ingested Salmonella organisms reach the stomach, where acidity is the 
first protective barrier. The acidity inhibits multiplication of the salmonellae, and when gastric 
pH reaches 2.0, most organisms are rapidly killed. Neonates and young infants have hy-
pochlorhydria and rapid gastric emptying, which contribute to their increased vulnerability to 
symptomatic salmonellosis. Because the transit time through the stomach is faster for drinks 
than for foods, a lower inoculum may cause disease in waterborne infection. 
Heat-labile, cholera-like enterotoxin is produced by many Salmonella isolates. This toxin 
and the prostaglandins that are produced locally increase cyclic adenosine monophosphate 
levels within intestinal crypts, causing a net efflux of electrolytes and water into the intestinal 
lumen. Bacteremia, however, is theoretically possible with any Salmonella strain, espe-
cially in individuals with reduced host defenses. 
Clinical manifestations. Acute Gastroenteritis. This is the most common clinical 
presentation. After an incubation period of 6–72 hr (mean, 24 hr), there is an abrupt 
onset of nausea, vomiting, and abdominal pain primarily in the periumbilical area and 
right lower quadrant, followed by mild to severe watery diarrhea and sometimes by 
dysenteric diarrhea, containing blood and mucus. Moderate fever of (38.5–39 C) af-
fects about 70 % of patients. Some children develop severe disease with high fever, 
headache, drowsiness, confusion, meningismus, seizures, and abdominal distention. 
Abdominal examination reveals some tenderness. The stool, which is usually not 
bloody, typically contains a moderate number of polymorphonuclear leukocytes and 
occult blood. Mild leukocytosis may be detected. Symptoms subside within 2–7 days 
in healthy children; fatalities are rare. 
Neonates, young infants, and children with primary or secondary immune defi-
ciency may have symptoms persisting for several weeks. At patients with AIDS, the 
infection may become widespread and overwhelming, causing multisystem involve-
ment, septic shock, and death.  
Bacteremia. Salmonella bacteremia is associated with fever, chills, and often with 
a toxic appearance. Children with certain underlying conditions who have Salmonella 
gastroenteritis are at increased risk of bacteremia, which may lead to extraintestinal 
infection. 
Asymptomatic Infection. After clinical recovery from Salmonella gastroenteritis, 
asymptomatic fecal excretion of salmonellae occurs for several weeks. A chronic car-
rier state is defined as asymptomatic excretion of Salmonella organisms for more than 
1 yr.  
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Differential diagnosis. Salmonella gastroenteritis should be differentiated from 
other bacterial, viral, and parasitic causes of diarrhea. Etiologic diagnosis on the basis 
of the clinical picture is not possible. In children with gastroenteritis, cultures of stools 
have higher yields than rectal swabs. Epidemiologic data may be helpful.  
Prognosis. Complete recovery is the rule in healthy children who develop Salmo-
nella gastroenteritis. Young infants and immunocompromised patients often have 
systemic involvement, a prolonged course, and complications. The prognosis is poor 
for children with Salmonella meningitis (~50 % mortality rate) or endocarditis. 
 
Escherichia coli 
Etiology and pathogenesis. Five classes of E. coli are recognized as agents associated with pe-
diatric gastroenteritis.  
Enterotoxigenic E. coli (ETEC). These E. coli serogroups produce a heat-labile en-
terotoxin (LT) and/or a heat-stable enterotoxin (ST). LT related to cholera toxin pro-
duced by Vibrio cholerae, stimulates adenylate cyclase, resulting in increased cyclic 
AMP. Due to colonization factor antigens (CFAs) E. coli adhere to intestinal epithe-
lium, the ETEC release ST or LT.  
Enteroinvasive E. coli (EIEC). These E. coli serogroups behave like shigellae in 
their capacity to invade gut epithelium and produce a dysentery-like illness because 
these E. coli possess a large virulence plasmid closely related to the Shigella plasmid. 
Invasion of epithelium causes cell death and a brisk inflammatory response (clinically 
recognizable as colitis). 
Enteropathogenic E. coli (EPEC). These diarrheagenic E. coli belong to sero-
groups that have been associated with outbreaks of infantile gastroenteritis but do not 
produce conventional enterotoxins or invade epithelial cells. The EPEC adhere to the 
intestinal mucosa in a distinctive way. The lesion consists of loss of microvilli with 
adherence of bacteria to the epithelial cells, which form a cup or pedestal in which the 
bacteria can be seen. Attachment results in increased intracellular calcium concentra-
tion and dense polymerization of actin at the site of attachment. 
Enterohemorrhagic E. coli (EHEC). These E. coli serogroups produce one or more 
toxins that kill mammalian cells. Two major toxins are produced by EHEC. One is 
essentially identical to shigatoxin, the protein synthesis–inhibiting exotoxin of Shigella 
dysenteriae serotype 1. The second is more distantly related to shigatoxin. The first 
toxin is called SLT-I (VT-1) and the second SLT-II (VT-2). These toxins kill cells by 
protein synthesis inhibition and cell death.  
Enteroaggregative E. coli (EAggEC). These E. coli serogroups have the ability to adhere to 
HEp-2 cells in tissue culture. They are also referred to as autoagglutinating and enteroadherent-
aggregative E. coli. It is likely that this group will be further subdivided, and some of these organ-
isms will be shown to be nonpathogens. 
Epidemiology. In the developing world, the various diarrheagenic serogroups of 
E. coli cause frequent infections in the first few years of life. They occur with in-
creased frequency during the warm months in temperate climates and during rainy 
season months in tropical climates. Most E. coli strains (except EHEC and perhaps 
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some EPEC) require a large inoculum of organisms to induce disease; person-to-
person spread is atypical, but foodborne or waterborne illness is common. 
Clinical manifestations 
As might be expected from the different mechanisms of disease production, the 
clinical features of E. coli–associated diarrhea vary from group to group. 
ETEC are a major cause of dehydrating infantile diarrhea in the developing world. 
The typical signs and symptoms include explosive watery diarrhea, abdominal pain, 
nausea, vomiting, and little or no fever. Resolution usually occurs in a matter of days. 
EIEC cause an illness that is indistinguishable from classic bacillary dysentery. Fever, 
systemic toxicity, crampy abdominal pain, tenesmus, and urgency with water or bloody 
diarrhea are characteristic. 
EPEC usually are isolated from infants and children in the first few years of life 
who have a nonbloody diarrhea with mucus; fever may occur. Unlike ETEC, EIEC, or 
EHEC, these organisms often cause a prolonged diarrheal disease. 
EHEC may cause an illness characterized by abdominal pain with diarrhea that is 
initially watery but within a few days becomes grossly bloody (hemorrhagic colitis). 
Although this pattern resembles that of shigellosis or EIEC disease, it differs in that 
fever is an uncommon manifestation. The major risk with EHEC is that approximately 
10 % of symptomatic infections are complicated by development of hemolytic-uremic 
syndrome. 
EAggEC cause significant fluid losses with dehydration, but vomiting and grossly 
bloody stools are relatively infrequent. These organisms, like the EPEC, are often asso-
ciated with prolonged diarrhea. 
Complications 
The major complications are those related to dehydration and electrolyte loss. In-
fection with EHEC is frequently associated with the hemolytic-uremic syndrome. 
Diagnosis 
Positive bacteriological study of the faeces is of decisive importance. The best bacterio-
logical results are obtained when the culture medium is inoculated with fresh faeces directly at 
the patient's bedside and before the beginning of treatment with antibiotics and sulphona-
mides, and when tests are repeated several times. Culture of both stool and rectal swab speci-
mens optimizes the chance of diagnosing intestinal infection. 
Indirect haemagglutination test, which is carried out with the blood serum of the patient, 
deserves special attention. The reaction becomes positive during the first week of the disease 
and it is highly sensitive. 
Coprology, i.e. microscopic study of faeces for pathological admixtures (mucus, leuco-
cytes, and erythrocytes), is widely employed as an auxiliary method.  
In children who appear to be toxic, blood cultures should be obtained; this is particularly 
important in very young or malnourished infants because of their increased risk of bacteremia. 
Treatment 
As with gastroenteritis of other causes, the first concern about a child with suspected shig-
ellosis should be for fluid and electrolyte correction and maintenance. In general, this therapy 
should include oral replacement and maintenance with rehydrating solutions such as those 
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specified by the World Health Organization. Early refeeding with breast milk or dilute for-
mula should be encouraged as soon as dehydration is corrected. Prolonged withholding of 
feeding frequently leads to chronic diarrhea and malnutrition. 
Drugs that retard intestinal motility should not be used because of the risk of prolonging 
the illness. 
In severe form nursing babies are given boiled water, salt solutions, tea. An adequate 
amount of fluid, namely 150 ml per kg of body weight, should be given. When vomiting is 
frequent, fluid must be given in small portions by spoon (one to two teaspoonfuls every five 
or ten minutes) or dripped from a pipette. Water diet is followed by fractional feeding with 
expressed breast milk (10-50 ml ten times per 24 hours, with fluid added up to the volume 
required for the given age. 
 
APPROXMATE AMOUNT OF ORS SOLUTION TO GIVE IN THE FIRST 4 
HOURS: 
Age Less then 
4 months 
4-11 
months 
12-23 
months 
2-4 years 5-14 
years 
15 years or 
older 
Weight: Less than 
5kg 
5-7.9 kg 8-10.9 kg 11-15.9 
kg 
16-29.9 
kg 
30 kg or 
more 
in ml 200-400 400-600 600-400 800-1200 1200-
2200 
2200-4000 
 
Antibiotics and chemotherapeutic agents. The next concern is a decision about the 
use of antibiotics. Some authorities recommend withholding antibacterial therapy 
because of the self-limited nature of the infection, the cost of drugs, and the risk of emer-
gence of resistant organisms. The risk of continued excretion and subsequent infection of 
family contacts further argues against the strategy of withholding antibiotics. 
Since viruses or toxigenic bacteria cause a large majority of cases of diarrhea and there 
is little evidence of inflammation of gut mucosa, it is neither necessary nor desirable to use 
antibacterial substance. Antimicrobial should be used only for infectious agents such as 
shigella, cholera vibrio, Entamoeba histolytic and giardia. They may be prescribed for very 
small and sick newborns infected with enteropathogenic strains of E. coli. They may have a 
role in some cases of diarrhea persisting for more than 3-4 weeks. 
Resistance to nalidixic acid is uncommon. Treatment regimens involve a 5-day course. 
For strains known to be susceptible to ampicillin, this drug is given at 100 mg/kg/24 hr di-
vided into four doses each day, cefixime (8 mg/kg/24 hr in two divided doses given orally for 
5 days), ceftriaxone (50 mg/kg/24 hr as a single daily dose given parenterally for 2–5 days), or 
nalidixic acid (55 mg/kg/24 hr in four divided doses for 5 days) can be given. Oral first- and 
second-generation cephalosporins are inadequate as alternative drugs. 
Complex of urgent measures should be taken to control intoxication. The appropriate 
treatment should be given in the presence of neurotoxicosis and the corresponding syn-
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dromes (hyperthermic, convulsive, etc.). In the presence of exsiccosis, measures should be 
taken to control it with due consideration of the degree and character of dehydration. 
Treatment with a bacteriophage in tablets coated with an acid-proof material is indi-
cated. Biological preparations such as coli-bacterin, bifidumbacterin, lactobacterin, linex 
and other preparations should be used to prevent and to treat dysbacteriosis. 
At patients with gastroenteritis, antimicrobial agents do not shorten the clinical 
course, nor do they eliminate fecal excretion of Salmonella. By suppressing normal in-
testinal flora, antimicrobial agents may prolong the excretion of Salmonella and increase 
the risk of creating the chronic carrier-state. They should be used in young infants and 
other children who are at increased risk of a disseminated disease and in those with a 
severe or protracted course. In children with severe disease, initial treatment with a third-
generation cephalosporin is recommended until antibiotic susceptibility is known.  
Symptomatic treatment. If a child vomits during oral rehydration therapy, it 
is best to stop ORT for ten minutes and then restart ORT by spoon. One or more 
doses of metoclopramide 0.1 to 0.2 mg/kg or phenothiazine (0.5 mg/kg) may be 
given in cases of severe vomiting, but should preferably be avoided since these 
can cause oculogyric spasms. Convulsions associated with diarrhea may be due 
to hypo - or hypematremia, meningitis, encephalitis, hypocalcemia following 
bicarbonate herapy for acidosis. If hypo-or hypernatremia can be excluded, 
lumbar puncture must be done. The treatment of convulsions depends on the 
cause. Symptomatic control of seizures can be achieved either with diazepam 
(0.2 mg/kg/dose IV, max. 5 mg) phenobarbitone (5 to 10 mg/kg dose IM), or 
phenytoin (10 mg/kg/initially I.V. slowly followed by 5 mg/kg/day). 
Prevention 
Two simple measures decrease the risk of intesyinal infection in children. The first 
is to encourage prolonged breast-feeding. The second measure is to educate families in 
handwashing techniques, especially after defecation and before food preparation and 
consumption. Chlorinated water, proper sanitary systems, and adequate food hygiene 
practices are necessary to prevent nontyphoidal salmonellosis in humans. Handwash-
ing is of paramount importance in controlling person-to-person transmission by means 
of food. Individuals with symptomatic or asymptomatic excretion of Salmonella 
strains should be excluded from activities that involve food preparation or childcare 
until repeated stool cultures are negative. Control of the transmission of Salmonella 
infections to humans requires control of the infection in the animal reservoir. 
 
PART 4  INFECTIOUS DISEASES OF ELEMENTARY TRACT (Campy-
lobacter, Yersiniosis, Rotavirus and other agents of viral gastroenteritis) 
Initially considered animal pathogens only, Campylobacter organisms are now recognized 
as an important cause of bacterial gastroenteritis and of systemic infections, primarily in neonates 
and compromised patients. 
Etiology. The genus Campylobacter (meaning curved rod) includes 14 species, of 
which eight are considered pathogenic for humans: C. jejuni, C. fetus, C. coli, C. hy-
pointestinalis, C. laridis, C. cinaedi, C. fennelliae, and C. upsaliensis. There are more than 
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90 different serotypes of C. jejuni. Helicobacter pylori (formerly C. pylori) is a new genus, 
differentiated from Campylobacter by RNA sequence differences. The clinical presentation 
depends on the species of campylobacter organisms. Intestinal disease is usually associated 
with C. jejuni, and extraintestinal and systemic infections are associated with C. fetus. Less 
frequently, enteritis is caused by C. coli, C. laridis, or C. fetus; systemic infections may 
rarely be caused by C. jejuni or C. coli. Campylobacter organisms are thin, gram-negative 
rods; they are short and S-shaped or long, multispiraled, and filamentous. In older cultures, 
coccal forms may be seen. The organism is motile, with a flagellum at one or both poles. 
The organisms appear as small (0.51 mm), slightly raised, smooth colonies on solid media. 
Visible growth in blood culture is often not apparent until 5-14 days after the initial inocu-
lation. Campylobacter organisms are microaerophilic, requiring reduced oxygen tension 
for growth, with optimal growth occurring in 5-6 % oxygen. They neither oxidize nor fer-
ment carbohydrates. 
Epidemiology. Campylobacter infections are among the most frequent causes of bac-
terial gastroenteritis worldwide. In developed countries, C. jejuni gastroenteritis is usually 
more common than Salmonella or Shigella infections. C. coli also causes gastroenteritis, 
although the frequency is about 400-fold lower than for C. jejuni. Population-based studies 
in the United States showed isolation rates of Campylobacter ranging from 28 to 71 per 
100,000 inhabitants annually. 
Campylobacter gastroenteritis occurs most often in summer and fall; in subtropical areas, it peaks 
in the rainy season. 
The age distribution of Campylobacter gastroenteritis in developed countries is 
bimodal, with one peak in children younger than 4 yr of age and a second in adoles-
cents and young adults. The highest incidence occurs in the first year of life. In devel-
oping countries, infections occur early in life, usually below the age of 5 yr. Many 
infections are asymptomatic, especially in older children. 
Campylobacter enteritis is a worldwide zoonosis. The gastrointestinal tract of 
many domestic and wild animals is the main reservoir of infection. C. jejuni has been 
isolated from the feces of 30100 % of chickens, turkeys, and water fowl. Most farm 
animals, meat sources, and pets can harbor the organisms. Transmission of C. jejuni 
from animals to persons occurs most often by the fecal-oral route by ingestion of con-
taminated food, especially undercooked poultry, unpasteurized milk, and untreated 
water. Perinatal and person-to-person transmission occurs but is much less common. 
Household transmission from young dogs and cats with diarrhea also occurs. Out-
breaks of Campylobacter diarrhea are reported in nurseries and day-care centers. 
Communicability is greatest during the acute phase of the illness and can last as 
long as 2–3 wk, but appropriate antibiotic treatment can shorten this period to 2–3 
days. Chronic carriage is uncommon. Homosexual men are at increased risk for C. 
cinaedi and C. fennelliae infections. 
Pathology. C. jejuni infection involves the terminal ileum and colon, often 
producing inflammatory diarrhea. Macroscopically, mucus, pus, and blood are 
present in the lumen of the bowel, with friable, ulcerated mucosa. Microscopi-
cally, rectal biopsies of such patients demonstrate colitis with acute inflamma-
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tory infiltrates and swelling of the lamina propria and crypt abscesses. These 
findings are similar to those seen in shigellosis. Damage to the intestinal mu-
cosa may also be minimal. 
Pathogenesis. Invasion, enterotoxin production, and cytotoxin production 
have been demonstrated in C. jejuni infections. Mucosal invasion, which is me-
diated by bacterial surface proteins and occurs after specific binding, seems to 
be the most important virulence trait. Low levels of cytotoxins that damage 
mammalian cells are produced by some isolates and may help in the invasion 
process. Some strains of C. jejuni produce a cholera-like enterotoxin, which 
may explain the watery diarrhea seen clinically. It is not clear that all C. jejuni 
possess virulence traits. Asymptomatic infection may reflect this phenomenon. 
C. fetus tends to penetrate the intestinal mucosa without significantly damaging 
it, reaching the reticuloendothelial system and bloodstream. This organism con-
tains a surface protein capsule that inhibits opsonophagocytosis and enables a 
systemic infection. 
Clinical manifestations. Several clinical presentations of Campylobacter 
infections are possible, depending on the species involved and host factors, such 
as age, immunosuppression, and underlying conditions. 
Acute Gastroenteritis. This is the most common presentation of Campylobacter infec-
tions, usually caused by C. jejuni (95-99 % of cases); C. coli and C. laridis are responsible for 
the remaining 1-5 % of cases. The incubation period is 1-7 days. Diarrhea consists of loose, 
watery stools or blood- and mucus-containing stools (typically dysentery). Blood appears in 
the stools 2–4 days after the onset of symptoms. Fever, vomiting, malaise, and myalgia are 
common. Fever may be the only initial manifestation, but 6090 % of older children also com-
plain of abdominal pain. The abdominal pain is periumbilical; cramping may precede other 
symptoms or persist after the stools return to normal. Abdominal pain mimics appendicitis or 
intussusception. 
Mild infection lasts only 1 to 2 days and resembles viral gastroenteritis. Most patients 
recover in less than one week, but 20 % have a relapse or prolonged or severe illness. Per-
sistent or recurrent Campylobacter gastroenteritis and emergence of erythromycin resis-
tance during therapy are reported in patients with hypogammaglobulinemia (congenital or 
acquired) and acquired immunodeficiency syndrome (AIDS). Persistent infection mimics 
acute inflammatory bowel disease. Fecal shedding of the organisms in untreated patients 
usually lasts for 2-3 wk, with a range of a few days to several months. 
Bacteremia. Bacteremia without localized infection is the most common systemic 
infection caused by Campylobacter. C. jejuni or C. coli gastroenteritis rarely (<1 %) 
cause bacteremia. C. fetus usually causes bacteremia without diarrheal symptoms; 
diarrhea caused by this organism is seen in debilitated or immunocompromised pa-
tients. 
Bacteremia presents with fever, headache, and malaise. Relapsing or intermittent 
fever is associated with night sweats, chills, and weight loss when the illness is pro-
longed. Lethargy and confusion are common, but specific neurologic signs are un-
usual in the absence of cerebrovascular disease or meningitis. Abdominal pain is fre-
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quent; diarrhea, jaundice, and hepatomegaly are less common. Cough may occur, but 
pulmonary parenchymal involvement is unusual. There may be a moderate leukocyto-
sis. Transient asymptomatic bacteremia that clears without antibiotic therapy occurs, 
as does rapidly fatal septicemia. Prolonged bacteremia of 8-13 wk is described with 
spontaneous remissions and relapses, especially in the immunocompromised host. 
Focal Extraintestinal Infections. Focal infections caused by C. jejuni such as men-
ingitis, pancreatitis, cholecystitis, urinary tract infection, arthritis, and peritonitis occur 
mainly in neonates or immunocompromised patients. C. fetus bacteremia is more 
often associated with focal infections. This organism shows a predilection for vascular 
endothelium, causing endocarditis, pericarditis, thrombophlebitis, and mycotic aneu-
rysms; focal infections include meningitis, septic arthritis, urinary tract infections, lung 
abscess, and cholangitis. 
Perinatal Infections. Severe perinatal infections are usually caused by C. fetus and 
rarely by C. jejuni. C. fetus tends to colonize the genital tract and infect fetal tissue. 
Maternal C. fetus and C. jejuni infections, which may be asymptomatic, cause abor-
tion, stillbirth, premature delivery, or neonatal infection with sepsis and meningitis. 
Newborn infection with C. jejuni is associated with diarrhea that may be bloody; C. 
fetus rarely causes diarrhea. 
Complication. Guillain-Bar syndrome has been reported 1-3 wk after cul-
ture-proven C. jejuni gastroenteritis. Stool cultures obtained from patients with 
Guillain-Bar syndrome at the onset of neurologic symptoms have yielded C. 
jejuni in more than 25 % of the cases. Serologic studies suggest that 20-40 % of 
patients with Guillain-Bar syndrome have evidence of recent C. jejuni infection. 
Reactive arthritis is an immunoreactive complication seen in adolescents and adults; it 
appears 5-40 days after onset of diarrhea, involves mainly large joints, and resolves in 1-21 
wk without any sequelae. Typically, the arthritis is migratory, but the child is afebrile. 
Synovial fluid is always sterile. Reiter syndrome (i.e., reactive arthritis with conjunctivitis, 
urethritis, and rash) and erythema nodosum occur less commonly. IgA nephropathy and 
immune complex glomerulonephritis with C. jejuni antigens in the kidneys are reported. 
Other complications are hemolytic anemia and rectal bleeding. 
Diagnosis. The diagnosis of Campylobacter is usually confirmed by identification of 
the organism in culture. Selective media, such as Skirrow's or Batzler's media, microaero-
philic conditions (5-10 % oxygen), and, for C. jejuni, an optimal temperature of 42 C are 
necessary. For rapid diagnosis of Campylobacter enteritis, direct carbolfuchsin stain of 
fecal smear, indirect fluorescence antibody test, darkfield microscopy, or latex agglutina-
tion can be use. Species-specific DNA probes and specific gene amplification by PCR 
have been described, although clinical experience is limited. Serologic diagnoses have been 
reported, using enzyme-linked immunoassays to measure antibody (IgG, IgM, IgA) levels 
to C. jejuni. This method may help delineate individuals with acute, chronic, or no expo-
sure to C. jejuni antigens but is not yet a standard diagnostic approach. 
Treatment. Fluid replacement, correction of electrolyte imbalance, and supportive care 
are the mainstays in the management of children with Campylobacter gastroenteritis. An-
timotility agents may cause prolonged or fatal disease and should not be used. Controversy 
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exists regarding the need for antibiotic therapy in patients with uncomplicated gastroenteritis. 
Several studies showed no improvement in clinical symptoms or shortening of the course of 
the disease. When erythromycin ethylsuccinate suspension is initiated early in the course of 
the disease in patients with the dysenteric form of Campylobacter enteritis, the duration of 
symptoms and shedding is shortened. Antibiotic therapy significantly shortens fecal excretion 
of Campylobacter from 2-3 wk without treatment to about 2 days with treatment. 
Erythromycin (50 mg/kg/24 hr in four divided doses for 5 days) is the drug of 
choice. Late therapy (4 or more days after onset of symptoms) does not cause clinical 
improvement, although it still decreases shedding. Alternative antibiotic agents are 
tetracycline (useful in children >7 yr), ciprofloxacin (useful in older adolescents >17 
yr), and furazolidone. The new macrolides, clarithromycin and azithromycin, show 
good in vitro activity, but clinical evaluation is needed. Antibiotics are recommended 
for patients with the dysenteric form of the disease, high fever, or a severe course; 
children attending childcare centers or other institutions; and children who are immu-
nosuppressed or have underlying disturbances. 
Campylobacter bacteremia or extraintestinal infection caused by C. fetus requires 
parenteral antibiotic therapy for 3-4 wk. Gentamicin is the recommended treatment 
until antibiotic susceptibility of the isolate is known; C. fetus isolates resistant to eryth-
romycin are reported. 
Prognosis. Although Campylobacter gastroenteritis is usually self-limited, 
immunosuppressed children, including those with AIDS, may experience a pro-
tracted, prolonged, or severe course. Septicemia in the newborn and immuno-
compromised host has a poor prognosis, with an estimated mortality rate of 30-
40 %. 
Prevention. As with many enteric infections, prolonged breast-feeding de-
creases the risk of symptomatic Campylobacter infection. Proper food handling, 
particularly of chicken, decreases the frequency of C. jejuni infections. 
 
Yersinia enterocolitica 
Infections due to Y. enterocolitica far outnumber infections due to Y. pseudotu-
berculosis and Y. pestis. Disease is usually manifested as an acute enteritis with fever, 
diarrhea, abdominal pain, nausea, and vomiting. Stools may be mucoid and bloody or, 
less commonly, watery. 
Etiology. The genus Yersinia was transferred from the family Pasteurellaceae to the 
family Enterobacteriaceae on the basis of DNA-DNA hybridization studies and the 
presence of the enterobacterial common antigen. They resemble "atypical" coliforms 
morphologically and biochemically. Y. enterocolitica organisms are oxidase-negative, 
non-lactose-fermenting, gram-negative bacilli that are motile at 22 C but not at 37 C. 
Strains resembling Y. enterocolitica are isolated from extraintestinal infections and stool 
from asymptomatic patients or patients with mild gastroenteritis. These strains are con-
sidered to be nonenteropathogenic in that they lack the genes required for invasion and 
have now been assigned to a new species. 
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Epidemiology. Animals, food, and water are the major reservoirs for Y. enterocolitica. 
Many animal species harbor Yersinia, but swine, cattle, goats, dogs, and cats are more 
commonly involved. Y. enterocolitica has been isolated or detected by the polymerase 
chain reaction in commercial meat products, especially pork. Infections occur primarily in 
children and young adults, with most occurring in children under 7 yr of age. Infecting 
serogroups show variable geographic distributions with O:3, O:5, O:8, and O:9 strains 
predominant. Disease is more common in the colder months and in males than females. 
Common source outbreaks due to contaminated food or water are reported with incubation 
periods ranging from 1 to 11 days. Institutional and hospital person-to-person spread, in-
cluding neonatal transmission from a symptomatic mother and transfusion-related disease 
from red blood cell-containing products are reported. Extraintestinal infections due to Y. 
enterocolitica are rare. 
Pathology and pathogenesis. Y. enterocolitica pathogenesis is multifactorial, involv-
ing chromosomal and plasmid genes. All strains pathogenic for humans carry a related 
virulence plasmid that encodes several calcium- and thermally regulated virulence factors. 
The essential mechanisms involved in pathogenesis appear to be adherence, toxin produc-
tion, and invasion. Adherence and production of a heat-stable enterotoxin appear to 
be sufficient to produce a watery diarrhea, with elaboration of cytotoxin and 
one or more invasin genes necessary to produce the classic enteric pathology: a 
superficial ulcerative ileocolitis with mesenteric adenitis, lymphoid hyperplasia, 
and abscesses of the Peyer patches. Necrotizing granulomas in the mesenteric 
nodes seen with Y. pseudotuberculosis are absent. 
Several features of the organism are important for transfusion-acquired disease. 
First, pathogenic strains require iron and survive only in red blood cell-containing 
products. This cold-enhanced growth is useful for isolating the organism from mixed 
sources, such as stool, but increases the bacterial load in stored meat products and 
blood products. 
Clinical manifestations. The most common presenting signs and symptoms 
are fever (occasionally to 40{degree} C), abdominal pain (usually colicky), and 
diarrhea (watery or mucoid with fecal leucocytes). Illness may be as short as 2 
days or persist for 3-4 wk. It is usually self-limiting in older children, but bac-
teremia develops in 20-30 % of infants younger than 3 mo of age. Fever occurs 
in 40-50 % of cases, abdominal pain in 20-80 %, and diarrhea in 80-95 %. As-
ymptomatic infections are readily detected in family contacts. 
Complications are uncommon in children. Erythema nodosum, hemolytic anemia, 
thrombocytopenia, and bacteremic spread to other sites with meningitis, hepatic abscess, 
and pneumonia have all been reported, but the most frequent complication is reactive ar-
thritis. Joints of the extremities are usually affected, with one to four joints involved. Intact 
organisms are not detected in synovial specimens known to contain bacterial antigen, sug-
gesting only stable degradation products or immune complexes trapped from the circula-
tion are associated with Yersinia-triggered reactive arthritis. 
Diagnosis. The history may suggest enterocolitis due to Y. enterocolitica 
based on contact with animals or ingestion of uncooked meat products, espe-
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cially pork. Direct examination of diarrheal stool for fecal leukocytes is helpful 
in establishing invasive diarrhea. Culture is the most useful diagnostic test. Be-
cause many laboratories do not routinely culture for Yersinia, it is important to 
notify the laboratory of suspected cases. Yersinia-selective agar is inoculated 
with stool and incubated at reduced temperatures of 25 or 32 C. Some laborato-
ries use cold enrichment methods and subculture material held at 4 C for as long 
as 4 wk. Isolations from nonstool sources and sterile body fluids may be made 
on routine media. Speciation is important from nonenteric sources. Pathogenic 
stool strains of Y. enterocolitica can be differentiated from nonpathogenic 
strains using Congo red-magnesium oxalate agar, the pyrazinamidase test, 
salicin fermentation, and esculin hydrolysis. 
Serotyping of isolates and serodiagnosis in culture-negative cases is of value for epidemiologic 
purposes only. 
Differential diagnosis. Enterocolitis due to Y. enterocolitica is similar in 
clinical presentation to invasive diarrheal disease due to other enteric patho-
gens, such as Shigella or enteroinvasive Escherichia coli, mesenteric adenitis 
due to Y. pseudotuberculosis, inflammatory bowel disease, and reactive arthritis 
due to other causes. 
Prevention. Infection is preventable by careful attention to the preparation 
of meat, especially the slaughter of swine, and by avoiding ingestion of un-
cooked meat, precooked pork products held at 4 C, potable water of question-
able purity, and unpasteurized milk or milk products made from unpasteurized 
milk. Person-to-person transmission can be reduced by careful personal hy-
giene, especially handwashing, and institution of enteric precautions in hospital-
ized patients. Vaccines are not available. 
Treatment. Uncomplicated enterocolitis due to Y. enterocolitica is a self-
limited disease, and the benefit of antimicrobial therapy has not been estab-
lished. Culture-proven septicemia at any age and patients under 3 mo of age 
who have a high rate of septicemia should be treated. In one retrospective study, 
aminoglycosides in combination with third-generation cephalosporins, fluoro-
quinolones, or other agents, such as rifampin and trimethoprim-sul-
famethoxazole, were effective, whereas other b{beta}-lactams, such as amox-
icillin with or without clavulanate and benzylpenicillin were associated with 
treatment failures. 
 
Rotavirus and other agents of viral gastroenteritis 
Diarrhea is probably the leading cause of childhood mortality in the world, accounting 
for 5–10 million deaths per year. In early childhood, the single most important cause of 
severe dehydrating diarrhea is rotavirus infection. Rotavirus and other gastroenteritis vi-
ruses are not only major causes of pediatric mortality but also lead to significant morbidity 
as a result of malnutrition. Worldwide, up to 1 million deaths per year are estimated to oc-
cur from rotavirus infection alone. In the United States, rotavirus causes millions of epi-
sodes of diarrhea per year with 70,000 hospitalizations and more than 100 deaths. 
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Etiology. Rotavirus, astrovirus, adenovirus, and caliciviruses, are the 
known, medically important pathogens of human viral gastroenteritis such as 
the Norwalk agent,. 
Rotaviruses are classified by group (A, B, C, D, E), subgroup (I or II), and sero-
type. Group A, which has no antigenic relationship to the other groups, includes the 
common human pathogens as well as a variety of animal viruses. Group B rotavirus is 
reported as a cause of severe disease in infants and adults in China but not elsewhere. 
Occasional human outbreaks of group C rotavirus are reported. The other groups are 
limited to animal strains. Astroviruses are the second most important agent of viral gas-
troenteritis in young children. The recent availability of convenient immunoassays for as-
trovirus infection has allowed investigators to demonstrate its high incidence in both the 
developing and developed worlds. There are five known human serotypes. Enteric adeno-
viruses are the third most common cause of viral gastroenteritis in infants and chil-
dren. Although many adenovirus serotypes exist and are found in stool, especially 
during and after typical upper respiratory tract infections, only serotypes 40 and 41 
cause gastroenteritis. These strains do not cause respiratory symptoms and are very 
difficult to grow in tissue culture. Other caliciviruses may cause a rotavirus-like illness 
in young infants.  Several other viruses that may cause diarrheal disease in animals 
have been postulated but not yet well established as human gastroenteritis viruses. 
These include coronaviruses and pestiviruses. 
Epidemiology. Rotavirus infection is most common in winter months in temper-
ate climates. Peak incidence spreads from the west to the east in the United States. 
Unlike other winter viruses such as influenza, this wave of increased incidence is not 
due to a single prevalent strain or serotype. Typically, several serotypes predominate 
in a given community for one or two seasons while nearby locations may harbor unre-
lated strains. Most clinical cases occur in children younger than 2 yr (but older than 3 
mo), with serologic evidence of infection developing in virtually all children by age 4 
or 5 yr. Subclinical infections are common in newborn nurseries and in adults with 
intimate contact with infected children. Some rotavirus strains have stably colonized 
newborn nurseries where for years virtually all newborns have been infected with the 
colonizing strain without any overt illness. Rotavirus and the other gastroenteritis vi-
ruses spread efficiently via a fecal-oral route, and outbreaks are common in children's 
hospitals and day-care centers. The virus is shed in stool at very high concentration 
before and for days after the clinical illness. Very few infectious virions are needed to 
cause disease in a susceptible host. 
The epidemiology of astroviruses is not as thoroughly studied as rotavirus, but it is 
a common cause of mild to moderate watery diarrhea in children and infants and an 
uncommon pathogen in adults. Hospital outbreaks are common. Enteric adenovirus 
gastroenteritis occurs year-round, mostly in children younger than 2 yr. Nosocomial 
outbreaks occur but are less common than in rotavirus and astrovirus. Norwalk virus is 
best known for causing large explosive outbreaks among older children and adults, 
particularly in settings such schools, cruise ships, and hospitals. Often a single food, 
such as shellfish or water used in food preparation, is identified as a source. 
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Pathology and pathophysiology. Viruses that cause human diarrhea selec-
tively infect and destroy villus tip cells in the small intestine. Biopsies of the 
small intestines show variable degrees of villus blunting and round cell infiltrate 
in the lamina propria. Observed pathologic changes may not correlate with the 
severity of clinical symptoms and usually resolve before the resolution of diar-
rhea. 
In the small intestine, the upper villus enterocytes are differentiated cells, which 
have both digestive functions such as hydrolysis of disaccharides and absorptive func-
tions such as the transport of water and electrolytes via glucose and amino acid co-
transporters. The crypt enterocytes are undifferentiated. Selective viral infection of 
intestinal villus tip cells thus leads to (1) an imbalance of the ratio of intestinal fluid 
absorption to secretion, and (2) malabsorption of complex carbohydrates, particularly 
lactose. Most evidence supports the first mechanism as the most important factor in 
the genesis of viral diarrhea. Viral enteritis greatly enhances intestinal permeability to 
luminal macromolecules and has been postulated to increase the risk of food allergies. 
Clinical manifestations. Rotavirus infection typically begins after an incubation pe-
riod of fewer than 48 hr with mild to moderate fever and vomiting followed by the onset of 
frequent watery stools. Vomiting and fever typically abate during the 2nd day of illness, but 
diarrhea often continues for 5–7 days. The stool is without gross blood or white cells. De-
hydration may develop and progress rapidly, particularly in infants. Malnourished children 
and children with underlying intestinal disease such as short-bowel syndrome are particu-
larly likely to acquire severe rotavirus diarrhea. Rarely, immunodeficient children will ex-
perience severe and prolonged illness. Although most newborns infected with rotavirus are 
asymptomatic, some outbreaks of necrotizing enterocolitis have been associated with the 
appearance of a new rotavirus strain in the affected nurseries. 
The clinical course of astrovirus appears to be quite similar to that of rotavirus with the nota-
ble exception that the disease tends to be milder, with less significant dehydration. Adenovirus 
enteritis tends to cause diarrhea of longer duration, often 10 -14 days. The Norwalk virus has a 
short (12-hr) incubation period. Vomiting and nausea tend to predominate in illness associated 
with the Norwalk virus, and the duration is brief, usually 1-3 days of symptoms. The clinical and 
epidemiologic picture of Norwalk virus often closely resembles so-called food poisoning from 
preformed toxins such as Staphylococcus aureus or Bacillus cereus. 
Laboratory findings. Isotonic dehydration with acidosis is the most common finding in 
children with severe viral enteritis. The stools are free of blood and leukocytes. Although the 
white cell count may be moderately elevated secondary to stress, the marked left shift seen 
with invasive bacterial enteritis is absent. 
Diagnosis and differential diagnosis. The differential diagnosis includes other infectious 
causes such as bacteria and protozoa. Occasionally surgical conditions such as appendicitis, 
bowel obstruction, and intussusception may initially mimic viral gastroenteritis. In most cases, a 
satisfactory diagnosis can be made on the basis of the clinical and epidemiologic features. 
Commercial immunoassays, which offer approximately 90 % specificity and sensitivity, are 
available for group A rotavirus and enteric adenovirus. More obscure cases can be studied by 
electron microscopy of stools, RNA electrophoresis, nucleic acid hybridization, and polymerase 
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chain reaction assays. The diagnosis of viral gastroenteritis should always be questioned in pa-
tients with persistent high fever, blood or white cells in the stool, or persistent severe or bilious 
vomiting (especially in the absence of diarrhea). 
Treatmen. Avoiding and treating dehydration are the main goals in treat-
ment of viral enteritis.A secondary goal is maintainance of the nutritional status 
of the patien. 
Rehydration can be accomplished in most patients via the oral route. Modern re-
hydration solutions containing appropriate quantities of sodium and glucose promote 
optimum absorption of fluid from the gut. There is no evidence that a particular car-
bohydrate source (i.e., rice) or addition of amino acids improves the efficacy of these 
solutions for children with viral enteritis. Other clear liquids such as flat soda, fruit 
juice, and sports drinks are inappropriate for rehydration of young children with sig-
nificant stool loss. Rehydration via the oral (or nasogastric if needed) route should be 
done over 6-8 hr and feedings begun immediately thereafter. Rehydration solution 
should be continued as a supplement to make up for ongoing excessive stool losses. 
Initial intravenous fluids are required for the infant in shock or the occasional child 
with intractable vomiting. 
After rehydration has been achieved, resumption of a normal diet for age has been 
shown to result in a more rapid recovery from viral gastroenteritis. Prolonged (>12 hr) 
administration of exclusive clear liquids or dilute formula is without clinical benefit 
and actually prolongs the duration of diarrhea. Breast-feeding should be continued 
even during rehydration. Selected infants may benefit from lactose-free feedings (such 
as soy formula or lactose-free cow's milk) for several days, although this is not neces-
sary for most children. The use of hypocaloric diets low in protein and fat such as 
BRAT (bananas, rice, cereal, applesauce, and toast) have not been shown to be supe-
rior to a regular diet. There is no role for drug treatment of viral gastroenteritis. Con-
trolled studies have shown no benefit from antiemetics or antidiarrheal drugs, and 
there is a real risk of serious side effects. Obviously, antibiotics are similarly of no 
benefit. Immunoglobulins have been administered orally to both normal and immuno-
deficient patients with severe rotavirus gastroenteritis, but this treatment is currently 
considered experimental therapy. 
Рrevention. Good hygiene reduces the transmission of viral gastroenteritis, but 
even in the most hygienic societies virtually all children become infected as a result of 
the efficiency of infection of the gastroenteritis viruses, particularly rotavirus. Strict 
hand-washing and isolation procedures can help control nosocomial outbreaks. The 
role of breast-feeding in prevention or amelioration of rotavirus infection is probably 
small given the variable protection observed in a number of studies. 
The most promising prospect for prevention is the development of an effective 
vaccine. To date, a number of live rotavirus vaccine candidates have been extensively 
tested. Most have been animal or human-animal hybrid rotaviruses that are attenuated 
in humans. None have consistently protected infants in a variety of settings, but new 
candidates are under development. A successful rotavirus vaccine would substantially 
reduce morbidity and mortality among children throughout the world. 
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PART 5  EXANTHEMAS (measles, rubella) 
 
Measles, an acute communicable disease, is characterized by three stages: (1) an in-
cubation stage of approximately 10–12 days with few, if any, signs or symptoms; (2) a 
prodromal stage with an enanthem (Koplik spots) on the buccal and pharyngeal mucosa, 
slight to moderate fever, mild conjunctivitis, coryza, and an increasingly severe cough; 
and (3) a final stage with a maculopapular rash erupting successively over the neck and 
face, body, arms, and legs and accompanied by high fever. 
Etiology. Measles is an RNA virus of the family Paramyxoviridae, genus Morbil-
livirus. Only one antigenic type is known. During the prodromal period and for a short time 
after the rash appears, it is found in nasopharyngeal secretions, blood, and urine. It can re-
main active for at least 34 hr at room temperature. 
Measles virus may be isolated in cultures of human embryonic or rhesus monkey 
kidney tissue. Cytopathic changes, visible in 5–10 days, consist of multinucleated giant 
cells with intranuclear inclusions. Circulating antibody is detectable when the rash ap-
pears. 
Infectivity. Maximal dissemination of virus is by droplet spray during the prodromal 
period (catarrhal stage). Transmission to susceptible contacts often occurs prior to diagnosis 
of the original case. An infected person becomes contagious by the 9th-10th day after ex-
posure (beginning of prodromal phase), in some instances as early as the 7th day. Isolation 
precautions, especially in hospitals or other institutions, should be maintained from the 7th 
day after exposure until 5 days after the rash has appeared. 
Epidemiology. Measles is endemic over most of the world. In the past, epidemics 
tended to occur irregularly, appearing in the spring in large cities at 2- to 4-yr intervals as 
new groups of susceptible children were exposed. Measles is very contagious; approxi-
mately 90 % of susceptible family contacts acquire the disease. It is rarely subclinical. 
Prior to the use of measles vaccine, the age of peak incidence was 5-10 yr; most adults 
were immune. At present in the United States, measles occurs most often in unimmu-
nized preschool-aged children and in teenagers and young adults who have been immu-
nized. Epidemics have occurred in high schools and colleges where immunization levels 
were high. These epidemics are thought to be due primarily to vaccine failure. A preva-
lence of more than 90 % immunization of infants has been shown to produce disease-
free zones. 
Pathology. The essential lesion of measles is found in the skin; in the mucous mem-
branes of the nasopharynx, bronchi, and intestinal tract; and in the conjunctivae. Serous 
exudate and proliferation of mononuclear cells and a few polymorphonuclear cells occur 
around the capillaries. There is usually hyperplasia of lymphoid tissue, particularly in the 
appendix, where multinucleated giant cells of up to 100 m{mu}m in diameter (Warthin-
Finkeldey reticuloendothelial giant cells) may be found. In the skin, the reaction is particu-
larly notable about the sebaceous glands and hair follicles. Koplik spots consist of serous 
exudate and proliferation of endothelial cells similar to those in the skin lesions. A general 
inflammatory reaction of the buccal and pharyngeal mucosa extends into the lymphoid tis-
sue and the tracheobronchial mucous membrane. Interstitial pneumonitis resulting from 
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measles virus takes the form of Hecht giant cell pneumonia. Bronchopneumonia may be 
due to secondary bacterial infection. 
In fatal cases of encephalomyelitis, perivascular demyelinization occurs in areas of 
the brain and spinal cord. In Dawson subacute sclerosing panencephalitis (SSPE), there 
may be degeneration of the cortex and white matter with intranuclear and intracytoplas-
mic inclusion bodies. 
Clinical manifestations. The incubation period of measles is usually from 8 to 17 
days. In children who have had serum prophylaxis, or been treated with blood or plasma 
transfusion, the incubation period may even be as long as 21 days. 
The onset of the disease is characterized by symptoms of the initial catarrhal period, 
viz. a rise in temperature up to 38-39°G, headache, rhinitis, and a hacking cough, coryza, 
and conjunctivitis. These nearly always precede Belsky-Filatov-Koplik spots, the 
pathognomonic sign of measles, by–3 days. An enanthem or red mottling is usually 
present on the hard and soft palates. Belsky-Filatov-Koplik spots are grayish white dots, 
usually as small as grains of sand, with slight, reddish areolae; occasionally they are 
hemorrhagic. They tend to occur opposite the lower molars but may spread irregularly 
over the rest of the buccal mucosa. Rarely they are found within the midportion of the 
lower lip, on the palate, and on the lacrimal caruncle. They appear and disappear rapidly, 
usually within 12–18 hr. As they fade, red, spotty discolorations of the mucosa may re-
main. The conjunctival inflammation and photophobia may suggest measles before Bel-
sky-Filatov-Koplik spots appear. In particular, a transverse line of conjunctival inflam-
mation, sharply demarcated along the eyelid margin, may be of diagnostic assistance in 
the prodromal stage. As the entire conjunctiva becomes involved, the line disappears. 
There is general malaise, adynamia, poor appetite, and insomnia; the child is listless 
and fretful. The temperature usually falls on the second or third day, sometimes to a sub-
febrile level. But the symptoms of affection of the mucous membrane increase. The cold 
in the nose gets worse; the patient begins sneezing an5 there is a more or less copious 
serous discharge. A perturbing dry hacking cough develops, and there is a sensation of 
irritation in the respiratory tract. Hoarseness is sometimes noted, and with it a change in 
the cough, which becomes hard and harsh. Conjunctivitis expresses itself in hyperaemia 
of the conjunctiva, watering of the eyes, and photophobia, which may be so strong that 
the eyelids close spasmodically and involuntary (blepharospasm). The look of the patient 
is characteristic: the face is swollen, the eyelids slightly hyperaemic and oedematous, the 
eyes water, photophobia is apparent, and there is a serous discharge from the nose. 
Very typical alterations of the mucous membranes of the mouth and soft palate oc-
cur. One or two days before the outbreak of rash on the skin red irregular spots varying 
in size from the head of a pin to a lentil can be seen on the mucosa of the soft, and in part 
of the hard, palate. This eruption, known as enanthema, is an important early diagnostic 
sign of measles. Fusing in one or two days, these spots become indistinguishable against 
the general background of hyperaemic mucosa.  
The eruptive stage begins with a new rise of temperature, which reaches its maximum 
on the second or third day, and falls to the normal in a short irregular lysis towards the fifth 
to seventh day of eruption. 
 42 
The appearance of the rash coincides with the rise of temperature. Its first elements 
are found behind the ears and in the centre of the face. Within 24 hours it spreads rapidly 
over the whole face, neck, and upper part of the chest; it also covers the skin of the cir-
cumoral region. On the second day the exanthema rapidly spreads over the trunk and the 
proximal parts of the extremities and on the third day covers the limbs. This order of 
succession in the spread of the eruption is typical of measles. Outbreak of the rash may, 
however, sometimes be accelerated or retarded, or may appear first on the trunk. 
At first the elements of the rash look like pink papules of a soft consistency, the size 
of a grain of millet or buckwheat. Within a few hours each papule becomes surrounded 
by a zone of bright erythema. Soon adjacent maculopapules become confluent, forming 
large blotches of irregular outline, with the initial papules in the centre. Large maculo-
papular elements have a tendency to fuse further. The unaffected pale areas of the skin 
show up distinctly against the background of the bright rash.  
Elements of the rash 'effloresce' for three days; from the fourth day they begin to 
fade in order of their appearance. Quite often the rash on the face loses its brightness 
on the third day when it appears on the extremities. The subsiding rash becomes less 
prominent and assumes a cyanotic tinge; its elements, gradually fading, leave spots of 
a light-brown pigmentation which persists for one or two weeks. Fine branny des-
quamation (on the face and trunk) sometimes is following the subsidence of eruption 
lasts around five to seven days. 
The general malaise and symptoms of functional disturbance of the central nervous 
system first seen-during the catarrhal stage progress during the eruptive stage. General 
inhibition and adynamia are observed; headache becomes worse; there is loss of appetite. 
Sleep is disturbed and the child is sometimes restless and delirious during the night. The 
catarrh of the mucosa of the respiratory passages and conjunctiva (running nose, cough, 
suffused eyes, and intolerance of light) becomes more pronounced.  
At the end of the incubation period the blood picture shows mild leucocytosis and 
netrophilosis, at the end of the catarrhal stage leucopenia and neutropenia, and at the 
eruptive stage leucopenia, often with a relative neutropnilosis, eosinopenia and throm-
bopenia. 
During convalescence, even when all clinical manifestations of the disease have already 
subsided, the restorative process is far from completed. The indices of general immunological 
reactivity have fallen sharply. 
Lymph nodes at the angle of the jaw and in the posterior cervical region are usually 
enlarged, and slight splenomegaly may be noted. Mesenteric lymphadenopathy may cause 
abdominal pain. Characteristic pathologic changes of measles in the mucosa of the appen-
dix may cause obliteration of the lumen and symptoms of appendicitis. Changes of this 
type tend to subside with the disappearance of Koplik spots. Otitis media, bronchopneu-
monia, and gastrointestinal symptoms, such as diarrhea and vomiting, are more common in 
infants and small children (especially malnourished ones) than in older children. 
Clinical Forms. Mild, moderately severe, and severe forms of measles are distin-
guished, according to its severity. Atypical forms (measles with a toxic, abortive, or rudi-
mentary course) are also encountered. 
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The severe form has marked symptoms of toxaemia (hyperthermia, affection of the 
nervous system with disturbances of consciousness, adynamia, and acute cardiovascular 
failure). In the hemorrhagic type of measles (black measles), bleeding may occur from 
the mouth, nose, or bowel 
An abortive or rudimentary form of measles is encountered quite rarely among the 
unimmunized.  
Measles sometimes runs an atypical (but not mitigated) course in children treated 
with antibiotics.  
In children subjected to serum prophylactic|immunization mitigated (attenuated) mea-
sles is observed, in which the incubation period is protracted to a maximum of 21 days, but 
the initial and eruptive periods are shortened. Catarrhal symptoms in the mucous mem-
brane are usually mild or absent; and the enanthema and Belsky-Filatov-Koplik spots may 
also not appear. Rash is usually sparse or even represented by a few elements. Temperature 
is sometimes only subfebrile and lasts for two or three days. The patient's general condition 
is usually not disturbed, or only slightly affected. In mild cases the rash may be less macu-
lar and more nearly pinpoint, somewhat resembling that of scarlet fever or rubella. 
The diagnosis. Тhe diagnosisof measles is frequently delayed in adults because 
practitioners providing health care for adults are not used to encountering the disease and 
rarely include it in the differential diagnosis.Diagnosis is based on the clinical symptoms, 
with due account of the epidemiological anamnesis laboratory confirmation is rarely 
needed. This is usually made from the typical clinical picture; laboratory confirmation is 
rarely needed. During the prodromal stage multinucleated giant cells can be demon-
strated in smears of the nasal mucosa. Virus can be isolated in tissue culture, and diag-
nostic rises in antibody titer can be detected between acute and convalescent sera. The 
white blood cell count tends to be low with a relative lymphocytosis. Lumbar puncture 
in patients with measles encephalitis usually shows an increase in protein and a small 
increase in lymphocytes. The glucose level is normal. In the catarrhal stage diagnosis of 
measles must rest on the presence of the typical complex of catarrhal symptoms. An 
important early diagnostic symptom is spotty enanthema on the palatal mucosa. The 
finding of Belsky-Filatov-Koplik spots is indisputable evidence of measles. 
The catarrhal stage of measles can simulate influenza and other respiratory viral infec-
tions. When measles is suspected the patient should be isolated and observed for a day or two 
until diagnosis is clarified by the appearance of typical symptoms. 
During the eruptive stage there are usually no difficulties in recognizing measles, and 
errors can only occur when its course is atypical. 
In developing countries and in recent outbreaks in the United States, measles frequently occurs in 
infants younger than 1 yr; possibly because malnutrition is concomitant there, the disease is very severe 
and has a high mortality. 
Differential diagnosis. The rash of rubeola must be differentiated from exanthem subi-
tum, rubella, infections resulting from echovirus, coxsackie virus, and adenovirus, infectious 
mononucleosis, toxoplasmosis, meningococcemia, scarlet fever, rickettsial diseases, serum 
sickness, Kawasaki disease, and drug rashes. 
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Koplik spots are pathognomonic for rubeola, and the diagnosis of unmodified 
measles should not be made in the absence of cough. 
Roseola infantum (exanthem subitum) is distinguished from measles in that the rash 
of the former appears as the fever disappears. The rashes of rubella and of enteroviral 
infections tend to be less striking than that of measles, as do the degree of fever and se-
verity of illness. Although cough is present in many rickettsial infections, the rash usu-
ally spares the face, which is characteristically involved in measles. The absence of 
cough or the history of injection of serum or administration of a drug usually serves to 
identify serum sickness or drug rashes. Meningococcemia may be accompanied by a 
rash that is somewhat similar to that of measles, but cough and conjunctivitis are usually 
absent. In acute meningococcemia the rash is characteristically petechial purpuric. The 
diffuse, finely papular rash of scarlet fever with a "goose flesh" texture on an erythema-
tous base is relatively easy to differentiate. 
The milder rash and clinical picture of measles modified by gamma globulin or by 
partial immunity induced by measles vaccine, or in infants by maternal antibody, may be 
difficult to differentiate. 
Complications. The chief complications of measles are otitis media, pneumonia, 
and encephalitis. Noma of the cheeks may occur in rare instances. Gangrene elsewhere 
appears to be secondary to purpura fulminans or disseminated intravascular coagulation 
following measles. 
Pneumonia may be caused by the measles virus itself; the lesion is interstitial. 
Measles pneumonia in patients with HIV infection is often fatal and not always ac-
companied by rash. Bronchopneumonia is more frequent, however; it is due to secon-
darily invading bacteria, particularly the pneumococcus, streptococcus, staphylococ-
cus, and Haemophilus influenzae. Laryngitis, tracheitis, and bronchitis are common 
and may be due to the virus alone. 
One of the potential dangers of measles is exacerbation of an existing tuberculous 
process. There may also be a temporary loss of hypersensitivity to tuberculin. 
Myocarditis is an infrequent serious complication; transient electrocardio-
graphic changes are said to be relatively common. 
Neurologic complications are more common in measles than in any of the other 
exanthems. The incidence of encephalomyelitis is estimated to be 1-2/1,000 reported 
cases of measles. There is no correlation between the severity of the measles and that 
of the neurologic involvement or between the severity of the initial encephalitic proc-
ess and the prognosis. Rarely, encephalitis has been reported in association with mea-
sles modified by gamma globulin or by live attenuated measles virus vaccine. Infre-
quently, encephalitic involvement is manifest in the pre-eruptive period, but more 
often the onset occurs 2-5 days after the appearance of the rash. The cause of measles 
encephalitis remains controversial. It is suggested that when encephalitis occurs early 
in the course of the disease, viral invasion plays a large role, although measles virus 
has rarely been isolated from brain tissue; encephalitis that occurs later is predomi-
nantly demyelinating and may reflect an immunologic reaction. In this demyelinating 
type the symptoms and course do not differ from those of other parainfectious en-
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cephalitides. Fatal encephalitis has occurred in children receiving immunosuppressive 
treatment for malignancies. Other central nervous system complications, such as Guil-
lain-Barrй{acute-e} syndrome, hemiplegia, cerebral thrombophlebitis, and retrobulbar 
neuritis, are rare. 
Subacute sclerosing panencephalitis is due to measles virus. 
Prognosis. Case fatality rates in the United States have decreased in recent years 
to low levels for all age groups, largely because of improved socioeconomic condi-
tions but also because of effective antibacterial therapy for the treatment of secondary 
infections. 
When measles is introduced into a highly susceptible population, the results may 
be disastrous. Such an occurrence in the Faroe Islands in 1846 resulted in the deaths of 
about one fourth, nearly 2,000, of the total population regardless of age.  
Treatment. Sedatives, antipyretics for high fever, bed rest, and an adequate fluid 
intake may be indicated. Humidification of the room may be necessary for laryngitis 
or an excessively irritating cough, and it is best to keep the room comfortably warm 
rather than cool. The patient should be protected from being exposed to strong light 
during the period of photophobia. The complications of otitis media and pneumonia 
require appropriate antimicrobial therapy. 
With complications such as encephalitis, subacute sclerosing panencephalitis, giant cell 
pneumonia, and disseminated intravascular coagulation, each case must be assessed indi-
vidually. Good supportive care is essential. Gamma globulin, hyperimmune gamma globu-
lin, and steroids are of limited value. Currently available antiviral compounds are not effec-
tive. Treatment with oral vitamin A (400,000 IU) reduces morbidity and mortality in chil-
dren with severe measles in the developing world. 
Prophylaxis. Quarantine is of little value because of the contagiousness during its 
prodromal stage, when measles may not be suspected. 
Active Immunization. The initial measles immunization may be given at 12 to 15 
mo but may be given earlier in areas where disease is occurring. Because the serocon-
version rate following immunization is not 100 % and there may be some waning of 
immunity with time, a second immunization against measles, usually given as mea-
sles-mumps-rubella (MMR), is indicated. This dose can be given when the child en-
ters school or later on entry to middle school. Adolescents entering college should also 
have received a second measles immunization. 
The response to live measles vaccine is unpredictable if immune globulin has been 
administered in the 3 mo preceding immunization. Anergy to tuberculin may develop 
and persist for 1 mo or longer after administration of live, attenuated measles vaccine. 
A child with active tuberculous infection should be receiving antituberculosis treat-
ment when live measles vaccine is administered. A tuberculin test prior to or concur-
rent with active immunization against measles is desirable. 
Use of live measles vaccine is not recommended for pregnant women or for chil-
dren with untreated tuberculosis. Live vaccine is contraindicated in children with leu-
kemia and in those receiving immunosuppressive drugs because of the risk of persis-
tent, progressive infection such as giant cell pneumonia. After exposure of these sus-
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ceptible children to measles, measles immune globulin (human) should be given in-
tramuscularly in a dose of 0.25 mL/kg as soon as possible. A larger dose may be ad-
visable in children with acute leukemia, even those in remission. Children with HIV 
infection should receive measles vaccine because mortality from measles is high in 
this group and they tolerate the vaccine well. Despite a history of having received 
measles immunization, these children should receive gamma globulin after exposure 
to measles in a dose of 0.5 mL/kg (maximum 15 mL). This is twice the usual recom-
mended dose. Measles vaccine can be given following exposure to the disease. Reac-
tions are not increased, and measles may be prevented. The use of inactivated (killed) 
virus vaccine is not recommended. 
Passive Immunization. Passive immunization with pooled adult serum, pooled 
convalescent serum, placental globulin, or gamma globulin of pooled plasma is effec-
tive for prevention and attenuation of measles. Measles can be prevented by using 
immune serum globulin (gamma globulin) in a dose of 0.25 mL/kg given intramuscu-
larly within 5 days after exposure but preferably as soon as possible. Complete protec-
tion is indicated for infants, for children with chronic illness, and for contacts in hospi-
tal wards and children's institutions. Attenuation may be accomplished by the use of 
gamma globulin in a dosage of 0.05 mL/kg. Gamma globulin is approximately 25 
times as potent in antibody titer as pooled adult serum, and it avoids the risk of hepati-
tis. Attenuation is variable, and the modified clinical patterns may vary from those 
with few or no symptoms to those with little or no modification. Encephalitis may 
follow measles modified by gamma globulin. 
After the 7th-8th day of incubation the amounts of antibody administered must be 
increased greatly for any degree of protection. If the injection is delayed until the 9th, 
10th, or 11th day, slight fever may already have started and only slight modification of 
the disease may be expected. 
Rubella 
Rubella is a common communicable disease of childhood characterized ordinarily 
by mild constitutional symptoms, a rash similar to that of mild rubeola or scarlet fever, 
and enlargement and tenderness of the postoccipital, retroauricular, and posterior cer-
vical lymph nodes. In older children and adults, especially adult women, the infection 
may occasionally be severe, with manifestations such as joint involvement and pur-
pura. 
Rubella in early pregnancy may cause severe congenital anomalies. The congeni-
tal rubella syndrome is an active contagious disease with multisystem involvement, a 
wide spectrum of clinical expression, and a long postnatal period of active infection 
with shedding of virus. 
Etiology. Rubella is caused by a pleomorphic, RNA-containing virus currently 
listed in the family Togaviridae, genus Rubivirus. The virus is usually isolated in tis-
sue culture, and its presence is demonstrated by the ability of rubella-infected African 
green monkey kidney (AGMK) cells to resist challenge with enterovirus. During 
clinical illness the virus is present in nasopharyngeal secretions, blood, feces, and 
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urine. Virus has been recovered from the nasopharynx 7 days before exanthem and 7–
8 days after its disappearance. Patients with subclinical disease are also infectious. 
Epidemiology. Humans are the only natural host of rubella virus, which is spread 
by oral droplet or transplacentally through congenital infection. Prior to institution of 
the rubella vaccine program in 1969, the peak incidence of the disease was in children 
5–14 yr of age. Now most cases occur in susceptible teenagers and young adults. 
Large outbreaks have been reported among college students and in unvaccinated 
populations, such as Amish communities. Hospital epidemics among employees, with 
transmission to susceptible patients, have prompted hospitals to require that employ-
ees having contact with patients be immune to rubella. Health care personnel in physi-
cians' offices should also be screened for rubella antibody and, if necessary, immu-
nized. Maternal antibody is protective for the first 6 mo of life. Boys and girls are 
equally affected. In closed populations, such as institutions and military barracks, al-
most 100 % of susceptible individuals may become infected. In family settings the 
spread of the virus is less: 50–60 % of susceptible family members acquire the dis-
ease. Many infections are subclinical, with a ratio of 2:1 inapparent to overt disease. 
Rubella usually occurs during the spring. It can be difficult to diagnose clinically be-
cause enteroviral and other rashes may produce a similar appearance. A single attack 
usually confers permanent immunity. Epidemics occurred every 6–9 yr before vaccine 
was available. Serologic studies prior to the use of rubella vaccine showed that about 
80 % of adult populations in the United States and other continents had antibody to 
rubella. In island populations, such as those of Trinidad and Hawaii, only 20 % of 
adults screened had detectable antibody. 
The epidemiology of the congenital rubella syndrome is discussed in Chapters 96 
and 97. Infants with rubella are a source of infection for older children who are not 
immune and for nonimmune adults, including pregnant women and nursery person-
nel. 
Clinical manifestations. The incubation period is 14–21 days. The prodromal 
phase of mild catarrhal symptoms is shorter than that of measles and may be so mild 
as to go unnoticed. The most characteristic sign is retroauricular, posterior cervical, 
and postoccipital adenopathy. No other disease causes the tender enlargement of these 
nodes to the extent that rubella does. An enanthem may appear just before the onset of 
the skin rash. It consists of discrete rose spots on the soft palate that may coalesce into 
a red blush and extend over the fauces. 
Lymphadenopathy is evident at least 24 hr before the rash appears and may re-
main for 1 wk or more. The exanthem is more variable than that of rubeola. It begins 
on the face and spreads quickly. Its evolution is so rapid that the rash may be fading on 
the face by the time it appears on the trunk. Discrete maculopapules are present in 
large numbers; there are also large areas of flushing which spread rapidly over the 
entire body, usually within 24 hr. The rash may be confluent, particularly on the face. 
During the 2nd day the rash may assume a pinpoint appearance, especially over the 
trunk, resembling that of scarlet fever. Mild itching may occur. The eruption usually 
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clears by the 3rd day. Desquamation is minimal. Rubella without a rash has been de-
scribed. 
The pharyngeal mucosa and the conjunctivae are slightly inflamed. In contrast to 
rubeola, there is no photophobia. Fever is slight or absent during the rash and persists 
for 1, 2, or occasionally 3 days. The temperature seldom exceeds 38.4C. Anorexia, 
headache, and malaise are not common. The spleen is often slightly enlarged. The 
white blood cell count is normal or slightly reduced; thrombocytopenia is rare, with or 
without purpura. Especially in older girls and women, polyarthritis may occur with 
arthralgia, swelling, tenderness, and effusion but usually without any residuum. Any 
joint may be involved, but the small joints of the hands are affected most frequently. 
The duration is usually several days to 2 wk; rarely it persists for months. Paresthesia 
also has been reported. In one epidemic, orchidalgia was reported in about 8 % of 
infected college-aged males. 
Differential diagnosis. Because similar symptoms and rashes can occur with 
many other viral infections, rubella is a difficult disease to diagnose clinically except 
when the patient is seen during an epidemic. A history of having had rubella or rubella 
vaccine is unreliable; immunity should be determined by testing for antibodies. Par-
ticularly in its more severe forms, rubella may be confused with the mild types of scar-
let fever and rubeola. Roseola infantum (exanthem subitum) is distinguished from 
rubella by the severity of the fever and by the appearance of the rash at the end of the 
febrile episode rather than at the height of the signs and symptoms. Drug rashes may 
be extremely difficult to differentiate from rubella. The characteristic enlargement of 
the lymph nodes strongly supports a diagnosis of rubella. In infectious mononucleosis 
a rash may occur that resembles that of rubella, and enlargement of the lymph nodes 
in each disease may lead to confusion. The hematologic findings in infectious mono-
nucleosis should be sufficient to distinguish the two diseases. Enteroviral infections 
accompanied by a rash can be differentiated in some instances by respiratory or gas-
trointestinal manifestations and the absence of retroauricular adenopathy. 
Diagnostic tests include isolation of virus from various tissues and serologic tests. 
Hemagglutination-inhibition (HI) antibody has been the usual method of determining 
immunity to rubella. Several newer tests including latex agglutination, enzyme immu-
noassay, passive hemagglutination, and fluorescent immunoassay appear to be equal 
or superior to the HI test in sensitivity. Rubella-specific immunoglobulin (Ig) M can be 
present in the blood of affected newborn infants. 
Complications and prognosis. Complications are relatively uncommon in childhood. 
Neuritis and arthritis occur occasionally. Resistance to secondary bacterial infection is not 
altered significantly. Encephalitis similar to that seen with rubeola occurs in about 1/6,000 
cases. The prognosis of childhood rubella is good; that of congenital rubella varies with the 
severity of the infection. Only about 30 % of infants with encephalitis appear to escape 
residual neuromotor deficits, including an autistic syndrome. 
Prevention. In a susceptible person, passive protection from or attenuation of the dis-
ease may be variably afforded by intramuscular injection of immune serum globulin (ISG) 
given in large dosage (0.25–0.50 mL/kg or 0.12–0.20 mL/lb) within the first 7–8 days after 
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exposure. The effectiveness of immune globulin is not predictable. It apparently depends 
upon the antibody content of the product used and upon unknown factors. The value of 
ISG has been questioned also because in some instances rash was prevented and clinical 
manifestations were absent or minimal though viable virus was demonstrable in the blood. 
This form of prevention of rubella is not indicated, except in nonimmune pregnant women. 
Since 1979 live-virus vaccine RA 27/3 (human embryonic lung fibroblasts of the 
WI-38 line) has been used exclusively for active immunization against rubella in the 
United States. RA 27/3 vaccine has many advantages over other rubella vaccines used 
in the past because it produces nasopharyngeal antibody and a wide variety of serum 
antibodies, provides better protection against reinfection, and more closely resembles 
the protection provided by natural infection. The vaccine virus is heat and light sensi-
tive; therefore, the vaccine should be stored in the refrigerator at 4 C and used as soon 
as it is reconstituted. Vaccine is administered as a single subcutaneous injection.  
Antibody develops in about 98 % of those vaccinated. Although virus may persist, especially in 
the nasopharynx, and shedding occurs from 18–25 days after vaccination, communicability does 
not appear to be a problem. 
The duration of persistence of rubella antibody following vaccination with RA 
27/3 is uncertain but is probably lifelong. Preventive measures are of the greatest im-
portance for the protection of the fetus. It is especially important that girls have immu-
nity to rubella before reaching child-bearing age, either by contracting the natural dis-
ease or by active immunization. The immune status can be evaluated by appropriate 
serologic tests. 
The rubella vaccine program in the United States calls for immunization of all boys 
and girls between the ages of 12 and 15 mo and puberty and of nonpregnant postpubertal 
females. Immunization is effective at 12 mo of age but may be delayed until 15 mo and 
given as measles-mump-rubella (MMR) vaccine. Rubella immunization should be offered 
to potentially susceptible postpubertal women at any health care visit. For women who say 
they might be pregnant immunization should be deferred. Pregnancy testing is not rou-
tinely necessary, but counseling about the advisability of avoiding pregnancy for 3 mo after 
immunization should be provided. The current immunization policy has successfully inter-
rupted the usual epidemic cycle of rubella in the United States and decreased the reported 
incidence of congenital rubella syndrome to only 20 cases in 1994. However, it has not 
resulted in a decrease in the percentage of women of child-bearing age who are susceptible 
to rubella. 
Pregnant women should not be given live rubella virus vaccine, but inadvertent 
immunization should not ordinarily be a reason to interrupt the pregnancy. The infants 
of more than 200 women immunized during pregnancy with RA 27/3 vaccine have 
been studied; no cases of clinically evident congenital rubella syndrome were found to 
occur. Other contraindications include immune deficiency states, severe febrile illness, 
hypersensitivity to vaccine components, and therapy with antimetabolites, corticoster-
oids, and steroid-like substances. 
Clinical manifestations that may follow rubella immunization include fever, typical lym-
phadenopathy, rash, and arthritis and arthralgia. The last two occur more frequently in older girls 
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and adult women and may last for weeks. Two unusual syndromes have been reported in asso-
ciation with rubella vaccine: one with paresthesia of the hand or arm that occurs at night lasts for 
up to 1 hr and may recur frequently during the night; the other is manifested by pain behind the 
knee and limitation of motion. Symptoms are worst in the morning, diminishing during the day. 
They may last for up to 5 wk. Both syndromes may recur. 
Management of Pregnant Women Exposed to or Acquiring Rubella. Pregnant 
women, especially early in pregnancy but also during the entire gestational period, 
should avoid exposure to rubella regardless of history of the disease during childhood 
or of history of active immunization. Exposure of pregnant women to infants with 
congenital rubella syndrome should be especially guarded against because of pro-
longed shedding of virus. Risk of damage to the fetus decreases after the 14th wk of 
gestation. 
Because approximately 80 % of women of child-bearing age are immune to ru-
bella as a result of the natural infection or of immunization, the immune status to ru-
bella of women who may become pregnant should be determined. 
If a pregnant woman whose immune status is unknown is exposed to rubella, an 
antibody test should be performed immediately as an emergency measure. If deter-
mined to be immune, she can be reassured that the pregnancy can be continued with-
out added risk. If she is found to be susceptible and therapeutic abortion is unaccept-
able or unavailable to her, passive immunization with ISG, 20–30 mL intramuscu-
larly, should be attempted immediately. Active immunization of pregnant women is 
not advised. 
If exposure to rubella occurs in a susceptible pregnant woman to whom abortion is 
available and desirable because of significant potential hazard to the fetus, it is proba-
bly advisable to withhold ISG, observe her carefully, and repeat the rubella antibody 
test. If rubella then develops at a stage of pregnancy at which she feels the risk is 
greater than she wants to assume or if serial antibody tests show that subclinical infec-
tion has occurred, abortion may be induced. 
Reinfection. The incidence of reinfection on exposure of individuals who are 
serologically immune to wild virus is 3–10 % among those demonstrating serologic 
immunity without a history of immunization and 14–18 % among those immunized 
with RA 27/3 vaccine. Infection has been demonstrated among the fetuses of rein-
fected pregnant women as well as among pregnant women who had received rubella 
vaccine. The relevance of reinfection of serologically immune pregnant women to the 
production of congenital malformations remains to be determined. Until these ques-
tions are answered, all pregnant women should make every effort to avoid exposure to 
rubella. 
Treatment. Unless bacterial complications occur, treatment is symptomatic. 
Adamantanamine hydrochloride (amantadine) has been reported to be effective in 
vitro in inhibiting early stages of rubella infection in cultured cells. An attempt to treat 
a child having congenital rubella with this drug was unsuccessful. Because aman-
tadine is not recommended for pregnant women, its usefulness is very limited. Inter-
feron and isoprinosine have been used with limited success. 
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PART 6  EXANTHEMAS (scarlet fever, pseudtuberculosis) 
 
Streptococci are among the most common causes of bacterial infection in infancy 
and childhood. Infection during the first 3 mo of life with group B b{beta}-hemolytic 
streptococci is common and may present as bacteremia, meningitis, osteomyelitis, or 
septic arthritis.  
Etiology. Streptococci are gram-positive cocci that grow in pairs or variable length 
chains, classified on the basis of their ability to hemolyze red blood cells: those with 
hemolysins producing complete hemolysis (b{beta}-hemolytic), those producing par-
tial hemolysis (α {alpha}-hemolytic), and those producing no hemolysis (g{gamma}-
hemolytic). α{alpha}-Hemolysis produces a green color on sheep erythrocytes (viri-
dans group). 
Lancefield further separated the streptococci on the basis of differences in carbohydrate 
components (C-carbohydrate) within the cell wall; streptococcal groups A through H and 
K through V have been identified so far. important is M protein Group A b{beta}-
hemolytic streptococci can be divided into more than 80 immunologically distinct types 
that are based on differences in the M protein. 
Streptococci elaborate toxins, enzymes, and hemolysins. More than 20 extracellu-
lar antigens released by group A hemolytic streptococci growing in human tissues 
have been identified. The extracellular products of greatest clinical significance are 
pyrogenic (formerly erythrogenic) exotoxins (A, B, and C), streptolysin O, strep-
tolysin S, NADase, streptokinases, DNase, hyaluronidase, proteinase, amylase, and 
esterase. Pyogenic exotoxins are responsible for the rash of scarlet fever and for shock 
in toxic shocklike illness. Generally, the elaboration of pyogenic exotoxins depends on 
bacteriophage infection (lysogeny) of the streptococcus. Extracellular digestive en-
zymes liquefy pus and, together with hyaluronidase, facilitate rapid spreading of strep-
tococci through tissue planes. The proteinase, in particular, is associated with tissue 
destruction of severe invasive streptococcal disease. Antibodies to streptolysin O 
(ASO), DNase B, hyaluronidase, NADase, and streptokinase are useful in the serodi-
agnosis of group A streptococcal disease. M-type specific antibodies are detectable 4-
8 wk after infection; antibiotic therapy ablates this response. 
Epidemiology. Generally, incidence is lowest among infants, who may be protected 
by transplacental acquisition of type-specific antibodies and a lack of pharyngeal receptors 
for streptococcal binding. Streptococcal infection of the skin is most common in children 
younger than 6 yr; streptococcal pharyngitis is most common between 5 and 15 yr of age. 
Streptococcal disease, including scarlet fever, is uncommon in children less than 3 yr of 
age, The incidence of streptococcal pharyngitis is higher in temperate climates; incidence 
and severity appear to increase in cold weather. Streptococcal skin disease is more preva-
lent in tropical climates and in warmer weather in temperate climates. 
Group A b{beta}-hemolytic streptococci are spread from person to person. Infec-
tion may be spread by droplets; nasal and pharyngeal carriers are effective dissemina-
tors. Infection also may be spread by contact with skin lesions or transmitted by food, 
milk, and water. The sources of infection in scarlet fever are patients and carriers. The 
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patient is infective from the first hours of the disease. The most important forms in the 
epidemiology of scarlet fever are the so-called formes frustes, healthy carriers. These 
forms often escape diagnosis; the patients are not isolated and therefore serve as 
sources of infection. The main way of transmission is aerial-droplet. Infection can also 
occur through infected articles, or through an intermediary. The last depends on the 
known stability of the causative agent, i.e. on its ability to removable for some time. 
Susceptibility. The portal of entry of scarlet-fever infection is i the mu-
cous^membranes of the fauces and pharynx, and the primary |focus of infection de-
velops there; but the causative agent can some-times penetrate the organism through 
damaged is kin or the mucous / membrane of the genital organs (the extrabuccal or 
extrapharyngeal form).   
Susceptibility to scarlet fever varies considerably with age. Children between two and 
six or seven years of age are mostly affected; the disease is rare among adolescents over 15 
and in adults. The well known, almost absolute immunity of babies under three months to 
scarlet fever cannot be explained by specific immunity acquired through mother's placenta. 
Even being in a constant and close contact with the nursing mother with scarlatina, infants 
of this age do not develop scarlet fever, thus showing complete insusceptibility to this dis-
ease, which is probably the result of the specific reactivity of the neonates. 
Pathogenesis. After inhalation or ingestion, streptococci attach themselves to res-
piratory epithelial cells by their surface fibrils and cell wall lipoteichoic acid. Fibrils 
contain antiphagocytic epitopes of type-specific M proteins, which with capsular hya-
luronic acid resist phagocytosis. Extracellular digestive enzymes facilitate the spread 
of infection by interfering with local thrombosis (streptolysins) and pus formation 
(DNase) and enhancing connective tissue digestion (hyaluronidase, proteinase). Sup-
purative complications follow local inflammation (peritonsillar abscess, retropharyn-
geal abscess), direct extension (otitis media, sinusitis), lymphangitic spread (lympha-
denitis), or bacteremia (sepsis, osteomyelitis, pneumonia). 
According to A. Koltypin, three principal components can be schematically dis-
tinguished in the pathogenesis of scarlet fever: toxic, infectious (septic), and allergic. 
They are closely interrelated, their distinction is, of course, rather artificial, and they 
are manifested in a different degree. In some cases toxic phenomena, and in others 
septic, predominate; in some cases there may be allergic waves and in others none. 
The toxaemia caused by the scarlatinal toxin is expressed by a complex of charac-
teristic symptoms (central and vegetative disorders, hyperthermia, exanthema, and 
cardiovascular disturbances).  
The action of the streptococcus itself is thought to condition the development of 
the infectious (septic) component of scarlet fever, which is expressed in an inflamma-
tory-necrotic process at the portal of entry, a septic condition, and complications of a 
septic order (purulent lymphadenitis, purulent otitis, sinusitis, septic metastases, etc.). 
Given preliminary sensitization of the organism, signs of allergy begin to develop 
from the very onset of the disease. Moreover, sensitization during the first stage result-
ing from the action of various allergens (streptococci and their breakdown products) 
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creates favourable conditions for the development of late complications if there is re-
infection.  
Clinical manifestations.The most common infections caused by group A 
b{beta}-hemolytic streptococci involve the respiratory tract, skin, soft tissues, and 
blood. 
Scarlet Fever is the result of infection by streptococci that elaborate one of three 
pyrogenic (erythrogenic) exotoxins. The incubation period ranges from 1–7 days, with 
an average of 3 days. The onset is acute and is characterized by fever, vomiting, head-
ache, toxicity, pharyngitis, and chills. Within 12-48 hr the typical rash appears. 
Generally, temperature increases abruptly and may peak at 39.6on the 2nd day and 
gradually returns to normal within 5-7 days in the untreated patient; it is usually normal 
within 12-24 hr after initiation of penicillin therapy. The tonsils are hyperemic and edema-
tous and may be covered with a gray-white exudate. The pharynx is inflamed and covered 
by a membrane in severe cases. The tongue may be edematous and reddened. During the 
early days of illness the dorsum of the tongue has a white coat through which the red and 
edematous papillae project (i.e., white strawberry tongue). After several days the white coat 
desquamates; the red tongue studded with prominent papillae persists (i.e., red strawberry 
tongue, raspberry tongue). The palate and uvula may be edematous, reddened, and covered 
with petechiae. 
The exanthem is red, is punctate or finely papular, and blanches on pressure. In some 
individuals, it may be palpated more readily than it is seen, having the texture of gooseflesh 
or coarse sandpaper. The rash appears initially in the axillae, groin, and neck but within 24 
hr becomes generalized. Punctate lesions generally are not present on the face. The fore-
head and cheeks appear flushed, and the area around the mouth is pale (i.e., circumoral pal-
lor). The rash is most intense in the axillae and groin and at pressure sites. Petechiae may oc-
cur owing to capillary fragility. Areas of hyperpigmentation that do not blanch with pressure 
may appear in the deep creases, particularly in the antecubital fossae (i.e., pastia lines). In se-
vere disease, small vesicular lesions (miliary sudamina) may appear over the abdomen, hands, 
and feet. 
Desquamation begins on the face in fine flakes toward the end of the 1st wk and proceeds over 
the trunk and finally to the hands and feet. The duration and extent of desquamation vary with the 
intensity of the rash; it may continue for as long as 6 wk. 
Scarlet fever may follow infection of wounds (i.e., surgical scarlet fever), burns, or streptococcal 
skin infection. Clinical manifestations are similar to those just described, but the tonsils and pharynx 
generally are not involved. A similar picture may be observed with certain strains of staphylococci 
that produce an exfoliative toxin. 
Clinical Forms. The clinical picture of scarlet fever varies considerably in 
severity and in the character of its symptoms. Along with very mild rudimen-
tary cases, hypertoxic forms with a fulminant course are encountered. But apart 
from these extreme forms, there are many-clinical variants. A number of au-
thors (V. Molchanov, A. Koltypin, M. Danilevich) distinguish the following 
forms of scarlet fever, according to the severity of its course: mild, moderately 
severe, and severe. Depending on the predominance of toxic or septic phenom-
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ena, the severe form is distinguished as toxic or septic. If both components are 
present, the scarlet fever is defined as mixed or toxicoseptic. In addition to the 
principal forms, there are also atypical ones: hypertoxic, abortive, and ex-
trapharyngeal (extrabuccal). In mild scarlet fever the toxaemia is weak. The 
temperature is within the range of 38-38.5C. The patients' general condition is 
little disturbed. There may sometimes be no vomiting at the onset. The angina 
has a catarrhal character. Rash is typical, but sometimes pale and sparse. Fever 
and all acute manifestations disappear toward the fourth or fifth day. This is the 
commonest form of scarlet fever, which lately occurs in 80 or even 90 per cent 
of cases revealed. Complications are rare, but are possible, mainly during the 
second period (lymphadenitis, otitis, nephritis). Moderately severe scarlet fever 
has an acute onset, with a complete set of symptoms. Toxaemia is marked; the 
temperature rises to 39C, and even to 40C on individual days. There are 
headache, lassitude, malaise, and sometimes delirium at night. Vomiting is fre-
quent during the first days and may recur. Tachycardia: pulse rate is up to 140-
160 per min. There is no depression of cardiac activity. Angina is catarrhal and 
there are sometimes films on lacunae and slight necroses. The rash is bright and 
abundant. The onset of the severe toxic form is violent. It is characterized by repeated vomit-
ing, which may continue during the second and third day. Diarrhoea is not infrequent. Fever is 
high, up to 40-41C. The patient is in a state of strong excitation or, on the contrary, of depres-
sion. Consciousness is clouded, and there is delirium; there may be convulsions and men-
ingeal symptoms. Rash is abundant and bright. The lips are dry, the sclera of the eyes injected, 
and the pupils contracted. In the severe septic form toxaemia is not of primary importance. 
The disease is chiefly characterized by severe lesions in the fauces (necrotic angina), an ex-
ceptionally marked inflammatory reaction in the regional lymph nodes and extremely fre-
quent septic complications. Severe toxicoseptic scarlet fever has a combination of the symp-
toms of the two forms described above. It usually begins as a toxic form, but on the third to 
fifth day signs of a septic character aggravate it.. In the hypertoxic or fulminant form the 
symptoms of severe toxaemia described above progress with extreme rapidity; the patient 
lapses into a comatose state and dies in the first days, sometimes even during the first 24 
hours.  
A rare variety of toxic form—haemorrhagic scarlet fever—lias been described, in 
which severe nervous and cardiovascular phenomena are accompanied with extensive 
haemorrhages into the skin and mucous membranes. This form is usually fatal. 
The rudimentary form is the mildest form of scarlet fever and lias very weakly ex-
pressed symptoms. 
In extrabuccal or extrapharyngeal forms of scarlet fever the portal of entry of in-
fection is not the fauces, but damaged skin or mucosa in various regions. The follow-
ing variants can be distinguished according to the portal of entry and the mechanism 
of infection: (a) burn (in burns of the 2nd and 3rd degree); (b) wound, or traumatic; (c) 
surgical; (d) puerperal; (e) complicating various exposed purulent foci on the skin. 
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Diagnosis. Although 30 % of children with sore throat have a positive throat cul-
ture for group A streptococci,. Streptococcal pharyngitis is suggested by age greater 
than 5 yr, high fever, exudates, tender anterior cervical lymphadenopathy, scarlatini-
form rash, and a history of exposure. A positive result for a throat culture may indicate 
streptococcal pharyngitis, but hemolytic streptococci are common inhabitants of the 
nasopharynx in well children. Isolation of a group A streptococcus from the pharynx 
of a child with pharyngeal infection does not necessarily indicate that the disease is 
caused by this organism. Treatment is, however, recommended for all children with 
pharyngitis and a positive throat culture or rapid antigen test for group A streptococci, 
even though in some cases the streptococci represent colonization. 
The immunologic response of the host after exposure to streptococcal antigen can 
be assessed by measuring antistreptolysin O (ASO) titers. ASO titers may be very 
high in patients with rheumatic fever; in contrast, they are weakly positive or not ele-
vated at all in patients with streptococcal pyoderma; responses in patients with glome-
rulonephritis are variable who develop an antibody response to this organism, indicat-
ing that subclinical infection. Anti-DNase (deoxyribonuclease) B provides the best 
serologic test for streptococcal pyoderma; responses to hyaluronidase, but antihyalu-
ronidase (AH) titers are elevated with less regularity than are ASO titers. 
Differential diagnosis. As a result of its deviations from the classic symptom 
complex, the clinical picture of scarlet fever can resemble other diseases accompanied 
with rash: viz. rubeola scarlatinosa, measles, German measles, the prodromal rash of 
chickenpox and smallpox, miliaria, drug and toxic eruptions (toxicodermia), pseudo-
tuberculosis or Far-East scarlatina-like fever, etc.  
Measles differs from scarlet fever in the presence of an initial catarrhal period with 
fever, catarrhal phenomena, enanthema, and Belsky-Filatov spots on the oral mucous 
membrane. The rash, which appears in stages, usually breaks out on the fourth day. Its 
elements are small at first, but later change to large maculopapules of irregular shape 
with a marked tendency to confluence. The skin between the individual elements re-
mains unaffected. After fading of the rash a spotty pigmentation is apparent, followed 
by fine, branny desquamation. Leucopenia, neutropenia, eosinopenia, or aneosino-
philia are revealed in the blood. 
German measles (rubeola) are characterized by low fever in the absence of constitu-
tional disturbances. Rash elements are small and pink, with only a slight tendency to 
fuse, and are localized chiefly on the trunk and the extensor surfaces of the limbs; the 
area around the mouth and nose is also affected. There are no petechial haemorrhages on 
the skin or subsequent desquamation. There is a swelling of the lymph nodes (mi-
cropolyadenitis), particularly of the occipital and posteriorly located cervical nodes. 
Blood findings are leucocytosis, neutropenia, and the presence of plasma cells. 
 
Pseudotuberculosis. 
Pseudotuberculosis - infection due to Y. pseudotuberculosis is most often seen as a 
Far-East scarlatina-like fever and pseudoappendicitis syndrome without diarrhea.  
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Far-East scarlatina-like fever. This is anthropozoonotic disease classified as yersin-
iasis caused by the pseudotuberculous microbe Yersinia pseudotuberculosis (V. Zna-
mensky et all). Like scarlatina, it is characterized by an acute onset of the disease, ele-
vated temperature (sometimes to 39-40C) that persists for 3-5 days, fine (scarlatina-
like) rash with subsequent peeling of the skin on the hands and soles. Vomiting occurs 
as well. Changes in the blood are the same: leucocytosis, neutrophilosis, insignificant 
eosinophilia. As distinct from scarlatina, true angina is absent, and only hyperaemia of 
the faucial mucosa occurs; the tonsils are unaffected. Almost all patients complain of 
pain in the joints and muscles of the extremities and in the lumbar region; gastrointes-
tinal disorders are frequent, and some patients complain of acute pain in the iliac re-
gion (mesenteric adenitis). 
The disease affects mostly adults. The diagnosis is verified by the agglutination 
test with the pseudotuberculosis bacillus; other laboratory tests, such as immunofluo-
rescence and indirect haemagglutition tests are also recommended for differential di-
agnosis. 
Pseudoappendicitis syndrome (mesenteric adenitis) Children usually present with 
fever and abdominal pain that is diffuse or localized to the right lower quadrant. Fre-
quently, there is tenderness over the McBurney point and strong clinical suspicion of 
appendicitis. At surgery, the terminal ileum is thickened and shiny with enlarged mes-
enteric nodes, which may appear necrotic. The appendix is normal or only mildy in-
flammed. The pathology is similar to that described for Y. enterocolitica, with ileal 
and colonic mucosal ulceration and mesenteric adenitis. Necrotizing, epithelioid 
granulomas are seen in the mesenteric nodes. The appendix is frequently grossly and 
microscopically normal. Mesenteric nodes are frequently the only source of positive 
cultures. Y. pseudotuberculosis antigens bind directly to HLA class II molecules and 
function as superantigens, which may partly explain the clinical syndromes resem-
bling Kawasaki syndrom. 
Mesenteric adenitis should be suspected in children with unexplained fever and 
abdominal pain. A characteristic picture of enlarged mesenteric lymph nodes, thicken-
ing of the terminal ileum, and no image of the appendix may appear on ultrasound. Y. 
pseudotuberculosis is rarely isolated. 
Appendicitis is the most common diagnosis. Inflammatory bowel disease and non-
specific intra-abdominal infections are also considered. 
The disease affects mostly adults. The diagnosis is verified by the agglutination 
test with the pseudotuberculosis bacillus; other laboratory tests, such as immunofluo-
rescence and indirect haemagglutition tests are also recommended for differential di-
agnosis. 
Scarlet fever may be differentiated from Kawasaki disease by an older age at onset, 
absence of conjunctival involvement, and recovery of group A streptococci. Streptococcal 
toxic shock like syndrome, associated with the pyrogenic toxins, produces toxicity, fever, 
shock, tissue injury (necrotizing fasciitis, myositis), pneumonia, rash (local or diffuse ery-
thema, maculopapular, petechial, desquamation), and multiorgan dysfunction (kidney, 
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lung, central nervous system). The shock, local tissue injury, older age, and nonscarlatini-
form rash differentiate this syndrome from scarlet fever.  
Arcanobacterium haemolyticum (formerly Corynebacterium haemolyticum) also pro-
duces tonsillitis, pharyngitis, and a scarlatiniform rash in adolescents and young adults.  
Severe sunburn can also be confused with scarlet fever. 
Acute pharyngitis or tonsilitis that is indistinguishable clinically from that caused by 
group A b{beta}-hemolytic streptococci may be caused by many viruses, including Ep-
stein-Barr virus (infectious mononucleosis). A viral cause may be suggested by failure to 
isolate streptococci and can be identified specifically by viral culture and serologic studies. 
Infectious mononucleosis may be suggested by the clinical manifestations, the presence of 
atypical lymphocytes in the peripheral blood, and a rise in heterophil and Epstein-Barr viral 
antibody titers. 
Acute pharyngitis similar to that caused by b{beta}-hemolytic streptococci may occur 
in patients with diphtheria, tularemia, toxoplasmosis, infection with Mycoplasma or A. 
haemolyticum, and, rarely, in individuals with tonsillar tuberculosis, salmonellosis, and 
brucellosis or infections caused by Neisseria gonorrhoeae, Neisseria meningitidis, and 
Yersinia enterocolitica. These diseases can be differentiated by appropriate cultures and 
serologic tests. 
Patients with infectious mononucleosis, have pharyngitis, tonsilitis, rash, lymphade-
nopathy, and splenomegaly as well as atypical lymphocytes. 
The exanthems produced by several enteroviruses can be confused with scarlet fever, but 
differentiation can be established by the course of the disease, the associated symptoms, and 
the results of culture. Roseola is characterized by the cessation of fever with the onset of rash 
and the transient nature of the exanthema. 
Complications. Complications are very frequent and varied in scarlet fever, and are 
distinguished as early and late according to when they occur. 
Early complications develop in the initial period of the disease, and are the result of the 
toxemia in streptococcal infection (otitis, Cervical lymphadenitis, mastoiditis, sinusitis, 
Adenophlegmon or hard phlegmon, pneumonia). Hematogenous dissemination of strepto-
cocci may cause meningitis, osteomyelitis, or septic arthritis. 
Late complications are generally encountered during the third or fourth week, and 
are apparently allergic in origin; streptococci play an important role in most of them 
(nephritis, myocarditis, and synovitis, rheumatism - rheumatic polyarthritis, endocar-
ditis). 
Treatment. Diet. During the initial feverish period, when there are difficulty in 
swallowing, disturbance of metabolism, and reduced secretory function of the diges-
tive glands, food should be fluid or semifluid, mainly carbohydrates with an adequate 
vitamin content, vitamin C in particular. 
Antibacterial (antistreptococcal) therapy. Antibiotics markedly accelerate the re-
moval of the streptococcus from the fauces, preclude complications. 
The penicillin dose depends on the age of the patient and gravity of the disease; it 
varies from 50 000 to 100 000 U/kg a day (for 2-4 intakes). The treatment should con-
tinue for 7 -10 days. The goals of therapy are to decrease symptoms and prevent sep-
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tic, suppurative, and nonsuppurative complications. Penicillin is the drug of choice for 
the treatment of streptococcal infections. All strains of group A b{beta}-hemolytic 
streptococci isolated to date have been sensitive to concentrations of penicillin achiev-
able in vivo. 
Children with streptococcal pharyngitis and tonsilitis should be treated with peni-
cillin (125–250 mg/dose three times a day) for 10 days. satisfactory blood levels are 
achieved even when the stomach is not empty. A single intramuscular injection of a 
long-acting benzathine penicillin G (600,000 U for children <60 lb and 1,200,000 U 
for children >60 lb) may be more effective for treatment or prevention of relapse and 
is indicated for all noncompliant patients or those having nausea, vomiting, or diar-
rhea. 
Erythromycin (40 mg/kg/24 hr), clindamycin (30 mg/kg/24 hr), or cefadroxil 
monohydrate (15 mg/kg/24 hr) may be used for treating streptococcal pharyngitis in 
patients who are allergic to penicillinr. Generally, relapse rates a e lower with regi-
mens other than penicillin. 
Treatment failure, defined as persistence of streptococci after a complete course of 
penicillin, occurs in 5–20 % of children and is more common with oral than with in-
tramuscular therapy. It may be due to poor compliance, reinfection, the presence of 
b{beta}-lactamase–producing oral flora, tolerant streptococci, or presence of a carrier 
state. Persistent carriage of streptococci predisposes a small number of patients to 
symptomatic relapse 
Intoxication should be controlled by intravenous administration of the Ringer solution, and a 
glucose solution. 
Antiallergenic therapy are used. Corticosteroids (in combination with antibiotics) are 
recommended to treat grave toxic and toxicoseptic forms of scarlet fever. Prednisolone 
should be given in a dose of 1-1.2 mg/kg daily; the dose should be gradually decreased in 
2-3 days. The treatment should continue for 5-7 days. Disintoxication therapy is also neces-
sary: intravenous infusion of colloidal solutions (polyglucin, neocompensan), glucose solu-
tion with strophanthin and vitamins, and other measures. These methods should be used in 
various combinations depending on each particular case. 
Prophylaxis. The isolation continues for at least ten days from the day of the onset 
of the disease, provided all signs of the acute period subside. Recovering children and 
adults who attend preschool children's institutions (and schoolchildren of the first two 
years) may be admitted to these institutions in 12 days after suspension of the isola-
tion.  
Treatment of contacts. When a patient is found to have scarlet fever all close contacts 
(members of the family and fellow-tenants) are given a thorough medical examination for 
abortive forms of the disease. 
A quarantine of seven days from the moment of isolation of the patient is imposed 
on contacts who attend children's institutions or are in the first two years at school. 
Regular concurrent disinfection should be carried out in premises where a patient has 
been home-treated. 
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Management of carriers of group A b{beta}-hemolytic streptococci is controver-
sial. It has been suggested that treatment of the carrier precludes the development of 
type-specific immunity, thereby leaving the individual susceptible to reinfection later 
in life. Children thought to have recurrent streptococcal infections may be carriers who 
have frequent viral respiratory infections masquerading as streptococcal infections. 
Treatment with a non-penicillin antibiotic (e.g., cephalosporin, erythromycin, clinda-
mycin) may be useful in eradicating the carrier state but should be reserved for the rare 
problem case. No streptococcal vaccines are available for clinical use. 
Prognosis.The prognosis for adequately treated streptococcal infections is excel-
lent; most suppurative complications are prevented or readily treated. When therapy is 
provided promptly, nonsuppurative complications are prevented and complete recov-
ery is the rule. In rare instances, particularly in neonates or in children whose response 
to infection is compromised, fulminant pneumonia, septicemia, and death may occur 
despite usually adequate therapy. 
 
PART 7   EXANTHEMAS (chickenpox, herpes zoster virus, herpes simplex virus) 
 
Primary infection with varicella-zoster virus (VZV) causes varicella (chickenpox). 
The virus establishes latent infection in dorsal root ganglia; its reactivation causes her-
pes zoster (shingles). 
Etiology. VZV is a human herpesvirus; it is classified as an alpha herpesvirus be-
cause of its similarities to the prototype for this group, which is herpes simplex virus 
(HSV). VZV is an enveloped, double-stranded DNA virus; the viral genome encodes 
more than 70 proteins, including proteins that are targets of immunity and a viral thymidine 
kinase, which makes the virus sensitive to inhibition by acyclovir and related antiviral agents. 
Pathology. Varicella begins with mucosal inoculation of virus transferred in respiratory 
secretions or by direct contact with skin lesions of varicella or herpes zoster. Inoculation is 
followed by an incubation period of 10 -21 days, during which subclinical viral spread occurs. 
Widespread cutaneous lesions result when the infection enters a viremic phase; peripheral 
blood mononuclear cells carry infectious virus, generating new crops of vesicles for 3-7 days. 
VZV is also transported back to respiratory mucosal sites during the late incubation period, 
permitting spread to susceptible contacts before the appearance of rash he transmission of 
infectious virus by respiratory droplets distinguishes VZV from other human herpes viruses. 
Visceral dissemination of the virus follows the failure of host responses to terminate viremia, 
which results in infection of lungs, liver, brain, and other organs. VZV becomes latent in dor-
sal root ganglia cells in all individuals who experience primary infection. Its reactivation 
causes a localized vesicular rash that usually involves the dermatomal distribution of a single 
sensory nerve; necrotic changes are produced in the associated ganglia, sometimes extending 
into the posterior horn. 
The histopathology of varicella and herpes zoster lesions is identical; infectious VZV is 
present in herpes zoster lesions, as it is in varicella lesions, but is not released into respiratory 
secretions. Varicella elicits humoral and cell-mediated immunity that is highly protective 
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against symptomatic reinfection. Suppression of cell-mediated immunity to VZV correlates 
with an increased risk of VZV reactivation as herpes zoster. 
Epidemiology. Annual varicella epidemics occur in winter and spring. Wild-type VZV 
strains that cause the annual epidemics of varicella do not exhibit changes in virulence as 
judged by the clinical severity of primary VZV infections from year to year. Household 
transmission rates are 80-90 %; more casual contact, such as school classroom exposure, is 
associated with attack rates of 30 % or less. 
Varicella is contagious from 24–48 hr before the rash appears and while uncrusted 
vesicles are present, which is usually 3-7 days. Susceptible children acquire varicella after 
close, direct contact with adults who have herpes zoster; this route of transmission maintains 
the circulation of the virus in the population. For unexplained reasons, varicella is much less 
common in tropical areas, so that susceptibility rates among adults are as high as 20-30 %. 
Herpes zoster shows no seasonal variation in incidence because it is due to the reactiva-
tion of endogenous, latent virus. Despite anecdotal reports, epidemiologic studies demonstrate 
that exposure to varicella does not cause herpes zoster. 
Herpes zoster is very rare in children younger than 10 yr except among those given im-
munosuppressive therapy for malignancy or other diseases, those who have human immuno-
deficiency virus (HIV) infection, and those who have been infected in utero or during the first 
year of life. The risk of severe or life-threatening primary or recurrent VZV infection is related 
primarily to host factors rather than variations in the pathogenicity of  VZV strains. 
Clinical manifestations of varicella or chickenpox. Although the incubation pe-
riod of varicella ranges from 10-21 days, the illness usually begins from 14-16 days 
after exposure. Almost all exposed, susceptible children experience a rash, but it may 
be limited to fewer than 10 lesions. 
Prodromal symptoms are common, particularly in older children; fever, malaise, 
anorexia, headache, and occasionally mild abdominal pain occur 24–48 hr before the 
rash appears. Temperature elevation is usually moderate, but may be as high ; fever and 
other systemic symptoms persist during the first 2-4 days after the onset of the rash. 
Varicella lesions appear first on the scalp, face, or trunk. 
The initial exanthem consists of intensely pruritic erythematous macules that 
evolve to form clear, fluid-filled vesicles. Clouding and umbilication of the lesions 
begin in 24–48 hr. While the initial lesions are crusting, new crops form on the trunk 
and then the extremities; the simultaneous presence of lesions in various stages of 
evolution is characteristic of varicella.Ulcerative lesions involving the oropharynx and 
vagina are common; many children have vesicular lesions on the eyelids and conjunc-
tivae, but serious ocular disease is rare. 
The average number of varicella lesions is about 300, but healthy children may 
have from fewer than 10 to more than 1,500 lesions. In secondary household cases 
and cases involving older children, more days of new lesion formation and more le-
sions are likely. The exanthem is more extensive in children with skin disorders, such 
as eczema or recent sunburn. Hypopigmentation of lesion sites persists for days to 
weeks in some children, but scarring is unusual. 
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The differential diagnosis of varicella includes vesicular rashes caused by other in-
fectious agents, such as enterovirus or Staphylococcus aureus, drug reactions, contact 
dermatitis, and insect bites. 
Complications of varicella. Secondary bacterial infections, usually resulting from 
S. aureus or Streptococcus pyogenes b-hemolytic streptococcus, are the most common 
complication of varicella. Cellulitis, lymphadenitis, and subcutaneous abscesses also 
occur. Varicella gangrenosa, usually resulting from S. pyogenes, is a rare but poten-
tially life-threatening consequence of secondary infection. Acute bacterial sepsis is 
uncommon, but transient bacteremia may cause focal infections, including staphylo-
coccal or streptococcal pneumonia, arthritis, or osteomyelitis. Encephalitis and cere-
bellar ataxia are well-described neurologic complications of varicella; the incidence of 
central nervous system morbidity is highest among patients younger than 5 yr and 
older than 20 yr. Meningoencephalitis is characterized by seizures, altered conscious-
ness, and nuchal rigidity; patients with cerebellar ataxia have a more gradual onset of 
gait disturbance, nystagmus, and slurred speech. Neurologic symptoms usually begin 
from 2–6 days after the onset of the rash but may occur during the incubation period 
or after resolution of the rash. VZV-related encephalitis and cerebellar ataxia may be 
immune mediated; the severe hemorrhagic encephalitis caused by HSV is very rare in 
children with varicella. Clinical recovery is typically rapid, occurring within 24 - 72 
hr, and is usually complete. Before the association of salicylates was documented, 
some children with varicella had neurologic symptoms caused by the encephalopathy 
associated with Reye syndrome. Varicella hepatitis is relatively common and is usu-
ally subclinical, but some children have severe vomiting, which must be differentiated 
from that associated with Reye syndrome. Acute thrombocytopenia, accompanied by 
petechiae, purpura, hemorrhagic vesicles, hematuria, and gastrointestinal bleeding, is a 
rare complication that is usually self-limited. Other rare complications of varicella 
include nephritis, nephrotic syndrome, hemolytic-uremic syndrome, arthritis, myocar-
ditis, pericarditis, pancreatitis, and orchitis. 
Progressive disease caused by primary VZV infection occurs in otherwise healthy 
adolescents and adults, immunocompromised children, pregnant women, and new-
born infants. Varicella pneumonia is very rare in children, but this complication ac-
counts for most of the increased morbidity and mortality in high-risk populations. 
Respiratory symptoms, which may include cough, dyspnea, cyanosis, pleuritic chest 
pain, and hemoptysis, usually begin within 1–6 days (average, 3 days) after the onset 
of the rash. Hypoxemia is often much more severe than is suggested by the physical 
findings; the chest radiograph may be normal or may show diffuse bilateral infiltrates. 
Varicella pneumonia is often transient, resolving completely within 24–72 hr, but in 
severe cases, the interstitial pneumonitis progresses rapidly to cause respiratory failure. 
Hemorrhage into the cutaneous lesions is a sign of severe varicella in high-risk pa-
tients, as is severe abdominal or back pain, although its pathogenesis is uncertain. 
The risk of progressive varicella is highest in children with malignancy if chemo-
therapy was given during the incubation period and the absolute lymphocyte count is 
less than 500 cells. In one large series, the mortality rate without antiviral therapy was 
 62 
7 %, and all varicella-related deaths occurred within 3 days after the diagnosis of 
varicella pneumonia. Hepatitis, encephalitis, and disseminated intravascular coagulo-
pathy are other frequent complications.  
The syndrome of inappropriate antidiuretic hormone secretion may accompany 
disseminated varicella with or without clinical encephalitis. Children who acquire 
varicella after organ transplantation are also at risk for progressive VZV infection. 
Children on long-term, low-dose steroid therapy usually have no complications, but 
fatal varicella has occurred in patients receiving high-dose steroids. Untreated varicella 
is severe or fatal in children with congenital immunodeficiency disorders, especially 
involving cell-mediated immunity. Unusual clinical findings of varicella, including 
lesions that develop a unique hyperkeratotic appearance and chronic new lesion for-
mation for weeks or months, have been described in children with HIV infection. 
In rare instances, maternal varicella results in the congenital varicella syndrome, 
associated with unusual cutaneous defects, atrophy of an extremity, microcephaly, 
ocular defects, and damage to the autonomic nervous system. Infants who are born 
within 4 days after or 2 days before the onset of maternal varicella may acquire pro-
gressive varicella.  
Clinical manifestations of herpes zoster. VZV reactivation is rare in childhood. 
When it occurs, it causes vesicular lesions clustered unilaterally in the dermatomal 
distribution of one or more adjacent sensory nerves, which are preceded or accompa-
nied by localized pain, hyperesthesias, pruritus, and low-grade fever. The rash is mild, 
with new lesions appearing for a few days, symptoms of acute neuritis are minimal, 
and complete resolution usually occurs within 1–2 wk. Immunocompromised children 
have more severe dermatomal disease and may experience viremia, causing pneumo-
nia, hepatitis, encephalitis, and disseminated intravascular coagulopathy. Severely 
immunocompromised children, particularly those with HIV infection, may have un-
usual, chronic, or relapsing cutaneous disease, retinitis, or central nervous system dis-
ease without rash. Transverse myelitis with transient paralysis is a rare complication of 
herpes zoster. In contrast to adults, postherpetic neuralgia is very unusual in children. 
Laboratory findings and diagnosis. Laboratory evaluation is not necessary for 
appropriate management of healthy children with varicella or herpes zoster. Abnormal 
laboratory values are common during varicella. Leukopenia is typical during the first 
72 hr; it is followed by a relative and absolute lymphocytosis. Liver function tests are 
also often moderately elevated. Patients with neurologic complications of varicella or 
uncomplicated herpes zoster have a mild lymphocytic pleocytosis and a slight to mod-
erate increase in protein; the cerebrospinal fluid glucose is usually normal. Rapid labo-
ratory diagnosis of VZV is often important in high-risk patients and can be accom-
plished by direct immunohistochemical staining of cells from cutaneous lesions. Mul-
tinucleated giant cells can be detected with nonspecific stains, but false-negative re-
sults are common, and these methods do not differentiate VZV and HSV infections. 
The definitive diagnosis of VZV infection requires the recovery of infectious virus 
using tissue culture. VZV immunoglobulin G (IgG) antibodies can be detected by 
several methods, but serologic diagnosis is retrospective; testing for VZV IgM anti-
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bodies is not useful for clinical diagnosis because commercially available methods are 
unreliable. VZV IgG antibody tests are valuable to determine the immune status of 
individuals whose clinical history of varicella is unknown or equivocal. 
Treatment. Acyclovir is the drug of choice for varicella and herpes zoster when 
specific therapy is indicated. Any patient who has signs of disseminated VZV includ-
ing pneumonia, hepatitis, thrombocytopenia, or encephalitis should receive immediate 
treatment with intravenous acyclovir. Acyclovir therapy given within 72 hr prevents 
progressive varicella and visceral dissemination in high-risk patients; the dosage is 
10mg/kg every 8 hr, administered intravenously for 7 days or until no new lesions 
have appeared for 48 hr. Delaying antiviral treatment until prolonged new lesion for-
mation is evident is not an option because visceral dissemination occurs during the 
same time period. Recent large, placebo-controlled clinical studies have shown that 
oral acyclovir diminishes the clinical symptoms of varicella in otherwise healthy chil-
dren, adolescents, and adults when it is administered within 24 hr after the appearance 
of the initial cutaneous lesions. Drug efficacy was established for all groups, but the 
clinical benefit may be considered more significant in older children and in secondary 
household cases. Acyclovir therapy does not interfere with the induction of VZV im-
munity. 
Acyclovir is also effective for treatment of herpes zoster in healthy and immuno-
compromised patients. Patients at high risk for disseminated disease should receive 500 
mg/m2 or 10 mg/kg every 8 hr intravenously. Onset of VZV reactivation reduces the 
duration of new lesion formation to only about 3 days. Oral acyclovir is an option for 
immunocompromised patients who are considered at low risk for visceral dissemination. 
Antiviral drug resistance is rare but has occurred in children with HIV infection; foscar-
net is the only drug now available for the treatment of acyclovir-resistant VZV infec-
tions. 
Prevention. VZV transmission is difficult to prevent because the infection is con-
tagious for 24–48 hr before the rash appears. Infection control practices, including 
caring for infected patients in isolation rooms with filtered air systems, are essential in 
hospitals that treat immunocompromised children. Susceptible health care workers 
who have had a close exposure to varicella should not care for high-risk patients dur-
ing the incubation period. 
Varicella-zoster immune globulin (VZIG) prophylaxis is recommended for im-
munocompromised children, pregnant women, and newborn infants exposed to ma-
ternal varicella. VZIG is distributed by the American Red Cross Blood Services; the 
dosage is one vial per 10 kg intramuscularly given within 96 hr or, if possible, within 
48 hr after exposure. Adults should be tested for VZV IgG antibodies before VZIG 
administration because many adults with no clinical history of varicella are immune. 
Because VZIG prophylaxis does not eliminate the possibility of progressive disease, 
patients should be monitored and treated with acyclovir if necessary. Immunocom-
promised patients who have received high-dose intravenous immune globulin (100–
400 mg/kg) for other indications within 2–3 wk before the exposure can be expected 
to have serum antibodies to VZV. Close contact between a susceptible high-risk pa-
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tient and a patient with herpes zoster is also an indication for VZIG prophylaxis. Pas-
sive antibody prophylaxis does not reduce the risk of herpes zoster or alter the clinical 
course of varicella or herpes zoster when given after the onset of symptoms. 
The live, attenuated varicella vaccine, made from the Oka strain, is the first human 
herpesvirus vaccine. The live, attenuated varicella vaccine (Oka-Merck strain) has 
been given to more than 8,500 healthy children and adults in clinical trials in the 
United States. The vaccine induced seroconversion rates of more than 95 %, with 
complete protection against disease in 85–95 % of exposures. Persistence of humoral 
and cell-mediated immunity has been documented in 94–100 % of vaccine recipients 
monitored for 1–6 yr. The Oka-Merck varicella vaccine can be given to children with 
acute leukemia in remission, with careful attention to the status of their underlying 
disease and immunosuppressive therapy regimens. VZV reactivation has been de-
scribed in a few healthy vaccine recipients, but the incidence of herpes zoster resulting 
from vaccine virus in children with leukemia was significantly lower than reactivation 
of naturally acquired VZV. Licensure of the Oka-Merck vaccine was approved in 
1995 in the United States; live, attenuated varicella vaccines have been approved for 
clinical use in Japan, Korea, and some European countries. 
 
Herpes simplex virus 
Herpes Simplex Virus (HSV) is common among humans, and has a variety of 
clinical manifestations involving the skin, mucous membranes, eye, central nervous 
system, and genital tract. It also causes generalized systemic disease. Disease manifes-
tations are in large part determined by the immune competence of the host. Two 
strains of the virus are identified: HSV-1 commonly infects skin and mucous mem-
branes above the waist. HSV-2 primarily infects the genitalia and the neonate. 
Two types of infection are recognized: 
1. Primary infection is the susceptible host's first experience with the virus, which 
in most instances is a subclinical infection; otherwise there are usually local superficial 
lesions (see later discussion) accompanied by varying degrees of systemic reaction. In 
newborn infants and severely malnourished infants, a serious systemic infection, often 
without superficial lesions, may occur. Circulating antibodies and a cell-mediated 
response develop in nonfatal cases. 
2. Recurrent herpetic lesions represent reactivation of a latent infection in an immune 
host with circulating antibodies. Reactivation follows such nonspecific stimuli as 
changes in the external milieu (e.g., cold, ultraviolet light) or in the internal milieu (e.g., 
menstruation, fever, or emotional stress). The lesions tend to be localized and, generally, 
are not associated with systemic reactions. Viral reactivation may take place in the ab-
sence of clinical recurrence, leading to asymptomatic viral shedding. 
Etiology. HSV is a double-stranded DNA containing enveloped virus. The icosa-
hedral protein core is surrounded by a lipid envelope in which is embedded a number 
of viral glycoproteins (e.g., glycoproteins B, C, D) responsible for viral–target cell 
interaction and infection. These glycoproteins are also key targets for the host humoral 
and cellular immune response. HSV grows rapidly in human and nonhuman cell lines 
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and produces characteristic cytopathic changes. HSV-1 and HSV-2 may be differenti-
ated by DNA analysis (endonuclease restriction analysis) and commercially by reac-
tivity with type-specific monoclonal antibodies in a variety of fluorescent and en-
zyme-linked immunosorbent (ELISA) assays. Several enzymes important for viral 
DNA synthesis, such as thymidine kinase and DNA polymerase, are useful targets for 
antiviral agents.  
Epidemiology. The virus develops an extremely compatible relationship with its 
host. In about 85 % of instances the infection is subclinical. Even when clinical mani-
festations are present, the host is only rarely seriously disabled. Occasionally, the pri-
mary or recurrent infection may lead to institutional or family outbreaks of stomatitis. 
This has been reported in orphanages and day-care center settings. HSV may also be 
transmitted by infection of digits (whitlows), during contact sports such as rugby or 
wrestling (herpes gladiatorum), and rarely in the hospital setting. The incubation pe-
riod is 2–12 days (average, 6 days). The spread of infection appears to be determined 
by two factors: close bodily contact and trauma such as teething or a break in the skin. 
The higher incidence of HSV antibodies in lower socioeconomic groups correlates 
with crowded living conditions. The epidemiology differs for the two types of HSV. 
Detailed serologic studies have been done primarily in low-income groups, in which 
most infants have transplacental antibody for about the first 6 mo of life. From 1–4 yr, 
there is a sharp rise in antibodies to HSV-1 and then a much slower rate of acquisition 
up to 14 yr. At this time, there is a second sharp rise in antibodies, mostly to HSV-2. 
By adult life HSV antibodies are seen in by far the majority of persons in the lower 
socioeconomic groups. HSV-1 antibodies are found in 30 % of university students. 
HSV-2 antibodies are found in up to 60 % of the lower socioeconomic status adults. 
The incidence of type 2 antibody in higher socioeconomic groups is about 10–30 % 
and in nuns about 3 %. 
Once infected, the majority of people continue to carry the virus in a latent state 
and maintain an almost constant level of circulating antibodies. The initial level of 
antibodies reached after a primary infection may fall, and several subclinical reinfec-
tions may occur before a stable antibody level is established. Carriers may distribute 
the virus without having any manifest lesion. Herpes simplex virus can be isolated 
from the pharynx of about 5 % of asymptomatic adults. 
Pathology. The pathologic changes vary with the tissue infected. In general, a spe-
cific lesion is characterized by the presence of intranuclear inclusion bodies, homogene-
ous masses lying in the midst of a severely disorganized nucleus in which the basic 
chromatin has marginated to the nuclear membrane. Around the specific lesion there is 
always evidence of an acute inflammatory reaction. In the skin and mucous membranes 
the typical lesion is a unilocular vesicle. In the skin the vesicle is tense. Ballooned epithe-
lial cells containing intranuclear inclusions can best be seen at the margins of the vesicle. 
The vesicular fluid contains infected epithelial cells, including multinucleated giant cells 
and leukocytes. In the corium there is no necrosis, but capillaries are dilated, and there is 
infiltration with mononuclear and polymorphonuclear cells. In the mucous membrane, 
because of maceration, there is early leakage of the vesicular fluid resulting in a col-
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lapsed vesicle, mainly filled with fibrin. The edematous roof cells form a gray membrane 
over the lesion. 
In otherwise healthy persons, the lesions are confined to the skin and mucous mem-
branes; viremia has rarely been described. Bloodstream spread of the virus with resultant 
widely disseminated disease is seen mainly in the newborn, in severely malnourished chil-
dren, in persons with skin diseases such as eczema, and in those with defects in cell-mediated 
immunity. In these patients the virus spreads hematogenously from the portal of entry to sus-
ceptible organs. Virus increases within these organs, and secondary viremia occurs with evi-
dence of extensive cell destruction. It is probable, however, that most cases of HSV-1 en-
cephalitis other than in the newborn are caused by neurogenic transmission of the virus to the 
brain. Healing begins with clearing of the viremia and a decrease in the production of virus 
within the cells. 
Clinical manifestations. HSV characteristically produces a vesicular lesion. Only 
rarely is there a viremic distribution that results in widespread systemic disease or neuro-
genic transmission that leads to meningoencephalitis. Furthermore, although the occur-
rence of primary and recurrent lesions is an accepted characteristic of herpetic infection, 
their distinction clinically is often not possible without knowledge of the presence or 
absence of serum antibodies in the patient. 
Lesions of the Skin and Mucous Membranes. On the skin the lesion consists of ag-
gregates of thin-walled vesicles on an erythematous base. These rupture, scab, and heal 
within 7{endash}–10 days without leaving a scar except after repeated attacks or secon-
dary bacterial infections; temporary depigmentation may occur in blacks. The local le-
sions may be preceded by mild irritation or burning at the local site or by severe neural-
gic pain in the region. In children the vesicles often become secondarily infected, intro-
ducing impetigo contagiosa into the differential diagnosis. The lesions tend to recur at 
the same site, particularly at mucocutaneous junctions, but may occur anywhere. 
Primary infection, especially in the immunocompromised patient, may, uncom-
monly, result in a generalized vesicular eruption in which the lesions are small and may 
continue to appear over a period of 2–3 wk. If the systemic manifestations are mild, the 
infection must be differentiated from varicella. 
Traumatic lesions of the skin can be infected by HSV. Primary lesions can also oc-
cur on apparently unbroken skin, as, for example, on the chin of a drooling infant with 
herpetic stomatitis, in whom scattered isolated vesicles appear, in contrast to the grouped 
vesicles of recurrent attacks. When the skin of a limb is infected, vesicles appear in 2–3 
days at the site of trauma. There is often centripetal spread along lymph channels, caus-
ing enlargement of regional lymph nodes and scattered vesicles on the intervening un-
damaged skin.  
The final clinical picture may be mistaken for that of herpes zoster, especially if 
accompanied by neuralgic pain, unless the lesions are recognized as not being con-
fined to a dermatome. The lesions heal slowly, often taking 3 wk; recurrences at the 
site of local trauma are common and may assume a bullous pattern. Wrestlers and 
medical personnel are prone to herpetic infections of superficial abrasions (herpes 
gladiatorum and herpetic whitlow). In the latter, infection of minor trauma about the 
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nails leads to extremely painful, deep-seated spreading lesions with vesicles that re-
solve spontaneously in 2–3 wk. Similar lesions occur on the fingers of thumb suckers 
who are suffering from herpetic gingivostomatitis. The lesions should not be incised. 
Acute Herpetic Gingivostomatitis (Catarrhal Stomatitis; Ulcerative Stomatitis; 
Vincent Stomatitis). This primary infection, probably the most common cause of 
stomatitis in children 1–3 yr of age, can also occur in older children and adults. The 
symptoms may appear abruptly, with pain in the mouth, salivation, fetor oris, refusal 
to eat, and fever, often as high as 40–40.6 0C. 
The onset may be insidious, with fever and irritability preceding the oral lesions by 
1–2 days. The initial lesion is a vesicle, which is seldom seen because of its early rup-
ture. The residual lesion is 2–10 mm in diameter and is covered with a yellow-gray 
membrane. When this membrane sloughs, a true ulcer remains. Although the tongue 
and cheeks are most commonly involved, no part of the oral lining is exempt. Except 
in edentulous infants, acute gingivitis is characteristic of the disease and may precede 
the appearance of mucosal vesicles. Submaxillary lymphadenitis is common. 
The acute phase lasts 4–9 days and is self-limited. Pain tends to disappear 2–4 
days before healing of the ulcers is complete. In some instances the tonsillar regions 
are involved early and appear exudative, and acute tonsillitis of bacterial origin or 
enterovirus-induced herpangina may be suspected. Negative cultures for Streptococ-
cus and other bacterial pathogens and failure of the lesion to respond to antibiotic ther-
apy differentiate a bacterial infection. The spread of the vesiculation to the buccal mu-
cosa and anterior portion of the mouth is atypical for herpangina. 
Recurrent Stomatitis and Herpes Labialis. The typical oral recurrence of HSV is 
one or a few vesicles grouped at the mucocutaneous junction. Lesions are usually 
accompanied by local pain, tingling, or itching and lasts 3–7 days. Systemic symp-
toms are unusual. Less commonly, localized lesions may occur on the palate in asso-
ciation with a febrile illness or on the mucosa adjacent to a lesion on the lip. Recurrent 
aphthous ulcers, however, are not caused by HSV. In some persons a generalized 
stomatitis recurs consistently 7–10 days after a recurrent herpetic lesion of the lip or 
elsewhere and is often accompanied by skin lesions of erythema multiforme. Indeed, 
recurrent HSV infection is one of the most common causes of recurrent erythema 
multiforme. 
Eczema Herpeticum (Kaposi Varicelliform Eruption; Juliusberg Pustulosis Vaccini-
formis Acuta). This, the most serious manifestation of "traumatic herpes," results from a 
widespread and usually primary infection of the eczematous skin with HSV. The severity 
of this complication varies; the lesion may be so mild as to be overlooked, or it may be 
fatal. In a typical severe primary attack, vesicles develop abruptly in large numbers over the 
area of eczematous skin. They continue to appear in crops for as long as 7–9 days. Isolated 
at first, they later become grouped and may occur on adjoining areas of normal skin. Wide 
denudation of the epidermis may occur. Scabs eventually form, and epithelialization oc-
curs. 
The systemic reaction varies, but temperatures of 39.4–40.6 for 7–10 days are not un-
common. Recurrent attacks develop on chronic atopic skin lesions. Death may result from 
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profound physiologic disturbances from loss of fluid, electrolytes, and protein through the 
skin, from dissemination of the virus to the brain and other organs, or from secondary bac-
terial invasion. A differentiation from eczema vaccinatum can usually be made by deter-
mining with reasonable certainty that the child has not been exposed to vaccinia and by the 
occurrence of crops of vesicles in herpes. The diagnosis can be accurately established by 
examination of vesicular fluid with rapid viral diagnostic techniques (see later discussion, 
Diagnosis). 
Ocular Lesions. Conjunctivitis and keratoconjunctivitis may occur as manifestations of 
either a primary or recurrent infection. The conjunctiva appears congested and swollen, but 
there is little, if any, purulent discharge. In primary infection the preauricular node is usu-
ally enlarged and tender. Cataracts, uveitis, and chorioretinitis have been described in new-
born infants and in the immunocompromised. 
Corneal lesions may be superficial, in the form of a dendritic ulcer, or deep, as a 
disciform keratitis. Dendritic keratitis is unique to HSV eye involvement. The diagno-
sis is suggested by the presence of herpetic vesicles on the lids; it is established by the 
isolation of the virus. The highly contagious epidemic keratoconjunctivitis (shipyard 
conjunctivitis) caused by any of several serotypes of adenovirus must be considered in 
the differential diagnosis. Recurrent herpetic corneal infection may result in scarring 
of the cornea and vision impairment. 
Genital Herpes. Genital infections with herpesvirus occur most commonly in ado-
lescents and young adults, are usually due to HSV-2, and are usually spread by sexual 
activity. Although hand to genital infection and autoinoculation are possible, genital or 
rectal herpes in a young child warrants a sensitive and careful appraisal of the possibil-
ity of child abuse. Ten to 25 % of cases of primary genital herpes are caused by HSV-
1. Almost all cases of recurrent genital herpes are due to HSV-2. In primary genital 
infection, when the patient has no antibody to either type of herpes (approximately 30 
% of cases), systemic symptoms such as fever, regional adenopathy, and dysuria are 
more likely to occur. In adult women, the vulva and vagina may be involved with 
vesicles and ulcers, but the cervix is the primary site of infection. Recurrence is com-
mon. Both primary and recurrent disease are frequently subclinical, but virus shed 
during this time may infect a sex partner or an infant during passage through the birth 
canal. 
In males herpetic vesicles or ulcers are usually seen on the glans penis, prepuce, or shaft of the 
penis. The scrotum is less frequently involved. Genital HSV is a risk factor for human immunode-
ficiency virus (HIV) infection. 
In the immunocompromised host. Unusually severe HSV infection may occur in a 
variety of hosts including the newborn ; the severely malnourished; and children with 
malignancies or other conditions necessitating immunosuppressive therapy, with ac-
quired immunodeficiency virus (AIDS), with burns, or with primary immunodefi-
ciency diseases that particularly impair cell-mediated immunity. In children receiving 
therapy for cancer or organ transplantation, the risk of severe HSV infection coincides 
with the time of maximum immunosuppression. The most common syndrome is local 
and chronic mucocutaneous disease. The lesions may resemble typical vesicles and 
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ulcers or progress to large necrotic painful erosions or atypical exophytic, wartlike lesions. 
Mucositis, esophagitis, proctitis and pneumonitis are less common. The most severe mani-
festation, usually a result of primary infection in the immunocompromised child, is wide-
spread disseminated disease involving the liver, lungs, adrenal gland, and central nervous 
system. These patients have a sepsis-like syndrome with leukopenia, disseminated in-
travascular coagulopathy, fever, or hypothermia and progression to death. Skin lesions may 
be localized to mucous membranes, widely disseminated, resembling varicella infection, or 
absent. This form of HSV infection has a high mortality rate even with therapy. 
Central Nervous System Infection. HSV has a predilection to infect the nervous sys-
tem. Both types 1 and 2 may cause a meningoencephalitis as part of neonatal HSV infec-
tion. In patients with primary genital herpes, usually resulting from HSV-2, an aseptic men-
ingitis syndrome may complicate the course. The cerebrospinal fluid reveals a lymphocytic 
pleocytosis, and the virus may be cultured from it in patients with this self-limited syn-
drome. HSV-1 is the most common cause of fatal sporadic encephalitis. It has a striking 
predilection to involve the frontal and parietal areas. 
Typical signs and symptoms include fever, altered consciousness, headache, personality 
changes, seizures, dysphasia, and focal neurologic signs. If untreated, the mortality rate is 
apparently 75 %, with severe sequelae in survivors. HSV is the cause of some cases of recur-
rent aseptic meningitis (Mollaret meningitis), on the basis of demonstration of HSV DNA in 
the cerebrospinal fluid by polymerase chain reaction (PCR). 
Laboratory data. Microscopic examination of scrapings from lesions (Tzanck stain) 
reveals multinuclear giant cells and intranuclear inclusions approximately 50 % of the time. 
Specific antigen detection methods such as ELISA and immunofluorescent techniques 
applied to these specimens can be useful in rapidly diagnosing herpes infection and in dif-
ferentiating the two types of herpes. Virus can be readily isolated from vesicles and from 
conjunctival swabs in 1–4 days. Cerebrospinal fluid is positive for virus in about one third 
of infected neonates but is rarely positive in older children with encephalitis. Brain biopsy is 
required for a definitive diagnosis and exclusion of other treatable entities. PCR permits 
detection of viral DNA in cerebrospinal fluid and, if positive, will make brain biopsy un-
necessary. At this writing, PCR for HSV is available through specialized research laborato-
ries only. 
Moderate polymorphonuclear leukocytosis occurs in acute herpetic gingivostoma-
titis, eczema herpeticum, and meningoencephalitis. In meningoencephalitis there are 
frequently red cells in the cerebrospinal fluid and an increase in lymphocytes, usually 
fewer than 100 but occasionally up to 1,000/mm3; the protein level is elevated, and 
the sugar is usually within the normal range. Electroencephalogram (EEG) and mag-
netic resonance imaging (MRI) may demonstrate a temporal lobe lesion in early en-
cephalitis. The computed tomographic (CT) scan may be normal in early encephalitis 
but becomes abnormal as the disease progresses. Thrombocytopenia and elevated 
liver function tests often occur with systemic infection. 
Diagnosis. The diagnosis is based on any two of the following: (1) a compatible 
clinical pattern; (2) isolation of the virus; (3) development of specific antibodies; (4) 
demonstration of characteristic cells, histologic changes, viral antigen, or HSV DNA 
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in scrapings or biopsy material. A rise in cerebrospinal fluid HSV antibody occurs in 
HSV encephalitis, but it is late in the illness and is useful only for retrospective diag-
nosis. HSV serologic changes (fourfold rise or seroconversion from negative to posi-
tive) usually occur after the critical period for diagnosis and therapy. Illnesses resulting 
from HSV recurrence may not demonstrate a diagnostic serologic rise, and neonates 
or severely immunocompromised individuals may fail to produce antibody during 
primary infection. Reliable antibody tests to differentiate HSV-1 from HSV-2 are not 
commercially available. HSV-1 and HSV-2 viral isolates may be typed by a variety of 
readily available antigen (ELISA, fluorescent antibody) and molecular techniques. 
HSV isolates that are unrelated epidemiologically are all slightly different at the nu-
cleic acid level, as discerned by DNA endonuclease restriction analysis. Using this 
technique, it is possible to confirm infection of one individual by another and to dem-
onstrate that apparent nosocomial outbreaks or viral transmission represent a chance 
collection of unrelated cases, which may be extremely important for counseling and 
medicolegal reasons. 
Course and prognosis. Primary localized infections with HSV in the normal host 
are self-limited, usually lasting 1–2 wk. Mortality rates are high in newborn infants 
who also have systemic infection and in older infants who are severely immunocom-
promised or malnourished. In patients with meningoencephalitis the prognosis for 
survival or for recovery without serious permanent residuals is guarded. Outcome is 
improved with early diagnosis and therapy. 
Attacks may frequently recur, but they seldom cause more than temporary incon-
venience except in the eye, where they may eventually cause scarring of the cornea 
and blindness. Recurrent herpes lesions can be a significant problem in immunocom-
promised patients. Recurrent genital disease may be associated with significant dis-
comfort and psychologic morbidity. The major complication of any form of genital 
HSV infection in a woman is infection of her newborn. 
Treatment. Acyclovir (9-[-2-hydroxyethoxymethyl] guanine, a purine nucleoside ana-
log) is the mainstay of therapy for HSV. Viral thymidine kinase will phosphorylate acy-
clovir, which is then triphosphorylated by cellular enzymes to act as an HSV DNA poly-
merase inhibitor and DNA chain terminator. Thymidine kinase{endash}–negative HSV 
isolates are resistant to acyclovir. Topical acyclovir may decrease the period of viral shed-
ding but has little effect on symptoms of oral or genital herpes. 
Topical trifluorothymidine, vidarabine, and idoxuridine are all usually effective in 
treating herpetic keratitis but do not reduce the recurrence rate. Topical corticosteroids 
may increase ocular involvement, if used alone, and should only be utilized with anti-
viral therapy. 
Patients with primary genital infection who are treated with oral acyclovir (200 mg 
five times daily for 5 days) have significantly less pain, itching, and time to crusting; a 
shorter duration of viral shedding; and fewer new lesions compared with control pa-
tients. A dose of 800 mg twice a day appears to be just as effective and well tolerated 
and is easier to administer. Those with recurrent genital infections who are treated 
similarly with oral acyclovir have a shorter duration of viral shedding and heal faster. 
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Therapy of primary attacks does not prevent recurrences. However, daily prophylactic 
administration of oral acyclovir can diminish the number of recurrences and may be 
prescribed if recurrences are frequent or severe. In small studies, oral acyclovir has 
modest effects in children with primary gingivostomatitis by decreasing drooling, gum 
swelling, pain, and new lesion formation compared with placebo. Therapy of recurrent 
oral herpes with oral acyclovir has limited effects. Acyclovir has no effect on HSV-
associated erythema multiform. Suppression of the HSV infection by prophylactic therapy 
as for genital disease prevents the erythema multiforme recurrences. Oral acyclovir therapy 
is useful for treating recurrent herpes whitlow and rectal herpes. 
Intravenously administered acyclovir (10 mg/kg/dose given over 1 hr every 8 hr for 
14–21 days) is the treatment of choice for herpes encephalitis. The drug is well tolerated. 
The best results are obtained when treatment is started early. Patients younger than 30 yr 
and those who are only lethargic compared with those who have progressed to coma have 
a better prognosis. Supportive care to minimize increased intracranial pressure, seizure ac-
tivity, and respiratory compromise requires an intensive care setting and a team of experts. 
Intravenous acyclovir (5–10 mg/kg/dose given over 1 hr every 8 hr [duration depending on 
clinical response]) is therapeutic for HSV infection in the immunocompromised host. The 
larger doses are used for severe and systemic infections. The lower dose may be used for 
localized mucocutaneous disease. As the patient responds, therapy may be switched to the 
oral route. Oral acyclovir, as used in genital disease, may be used to suppress HSV recur-
rences in seropositive patients during periods of maximum immunosuppression after organ or 
marrow transplantation or during induction therapy for leukemia, lymphoma, or solid tumors. 
Immunosuppressed patients with frequently recurring HSV infection, such as those with 
AIDS or primary immunodeficiencies, benefit from chronic suppressive oral therapy. In the 
neonate, all forms of HSV are treated with high doses (10–20 mg/kg/dose every 8 hr) of acy-
clovir for 14–21 days. 
Acyclovir-resistant HSV is rare in the normal host but occurs in the immunocompro-
mised host treated with multiple, intermittent courses of acyclovir. When immunocom-
promised patients have unresponsive or worsening HSV infection despite acyclovir ther-
apy, the virus should be forwarded to reference laboratories for drug susceptibility testing. 
The drug of choice for acyclovir-resistant HSV is intravenous foscarnet (phosphonoformic 
acid), 40 mg/kg/dose every 8 hr. This drug has serious side effects (azotemia, electrolyte 
disturbance, anemia, granulocytopenia). Acyclovir and foscarnet dosages must be modified 
in patients with renal impairment. 
Symptomatic and supportive therapy is of great importance. In infants especially, 
eczema herpeticum and stomatitis may lead to severe dehydration, shock, and hypo-
proteinemia, requiring replacement of fluids, electrolytes, and proteins. 
Oral lavage should be used for mouth care; Ceepryn 1:4,000 or Zephiran 1:1,000 
may be useful. Local analgesics, such as viscous lidocaine or benzocaine lozenges, are 
not advocated because they may cause the child to damage friable and anesthesized 
parts of the mouth. Genital lesions may be made less painful by using sitz baths. Local 
drying agents prolong healing and may increase secondary infection. Analgesics 
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should be used systemically as required. Antibiotics are useful only in treating secon-
dary bacterial infections. 
Food and fluid intake will be facilitated by acquiescing to the child's whims. Ice-
cold fluids, ice slush, or semisolids are often accepted when other food is refused. 
The child or adolescent with recurrent oral or genital herpes may have severe psy-
chologic problems and may benefit from anticipatory guidance or formal counseling. 
Genital disease should be destigmatized and safer sex practices emphasized. Parents 
of children with most types of HSV infection, such as gingivostomatitis or skin infec-
tion, should be reassured that common childhood HSV infections are not related to 
sexual activity or abuse. 
Prevention. Acyclovir administered during periods of high risk in immunocom-
promised hosts and chronically in individuals with frequently recurrent genital or oral 
disease markedly decreases the rate of recurrence. Acyclovir administered before a 
known trigger factor, such as intense sunlight, usually prevents recurrences. 
HSV spread can be limited by standard methods of infection control. Open lesions 
on skin, hands, and mucous membranes should be well covered. Wrestlers with possi-
ble HSV cutaneous lesions should be excluded from practice and competition until 
they are healed. Wrestling mats should be cleansed with a bleach solution at least 
daily. Children with immunodeficiencies or chronic skin diseases that predispose to 
severe HSV infection should not be cared for by persons with herpetic whitlow or 
active uncovered fever blisters. Active herpes lesions that can be covered are not a 
reason to exclude children from day-care or school activities. 
There is active research to develop a vaccine to prevent HSV infection. HSV may 
be prevented in some animal models by live, attenuated or subunit viral particle vac-
cines. Several purified HSV glycoprotein vaccines are antigenic in humans, but 
whether these vaccines will prevent disease or ameliorate recurrences is not known. 
 
PART 8  DIPHTHERIA 
 
The causative agent of diphtheria is Corynebacterium diphtheriae discovered in 
1883-4 by Klebs and Loeffler. Corynebacterium species are aerobic, nonencapsulated, 
non-spore-forming, mostly nonmotile, pleomorphic, gram-positive bacilli. The bacillus 
produces an exotoxin during growth that is the principal factor in its virulence. The dis-
ease is caused only by toxigenic strains of diphtheria bacillus. Avirulent strains are non-
pathogenic. Three biotypes (i.e., mitis, gravis, and intermedius), each capable of causing 
diphtheria, are differentiated by colonial morphology, hemolysis, and fermentation reac-
tions. 
Epidemiology. Spread is primarily by airborne respiratory droplets or direct con-
tact with respiratory secretions of symptomatic individuals or exudate from infected 
skin lesions. Asymptomatic respiratory carriers are important in transmission. A pa-
tient may prove to be contagious from the last days of the incubation period, and re-
mains so throughout the whole course of the disease, even after the-disappearance of 
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all its clinical manifestations. Transmission through contaminated milk and an in-
fected food handler have been proved or suspected. 
Portal of entry. C. diphtheria is an exclusive inhabitant of human mucous mem-
branes and skin. But the disease develops only when the infected subject is suscepti-
ble. Unsusceptibility depends on the presence of diphtheria antitoxin in the organism 
and on the state of nonspecific protective mechanisms. Outbreaks are associated with 
homelessness, crowding, poverty, poor hygiene, contaminated fomites, underlying 
dermatosis, and introduction of new strains from exogenous sources. 
Pathogenesis and pathological anatomy. Diphtheria bacilli invading the human 
organism settle on the mucous membranes of the fauces, nose, or respiratory passages, 
where they find favorable conditions for multiplication and production of toxin. The 
organism usually remains in the superficial layers of skin lesions or respiratory mucosa, 
inducing local inflammatory reaction. The major virulence of the organism lies in its 
ability to produce the potent polypeptide exotoxin, which inhibits protein synthesis and 
causes local tissue necrosis. A pathomorphological sign of the interaction between the 
macro-and the microorganism is fibrinous inflammation. Within the first few days of 
respiratory tract infection, a dense necrotic coagulum of organisms, epithelial cells, fi-
brin, leukocytes, and erythrocytes forms, advances, and becomes a gray-brown adherent 
pseudomembrane. Removal is difficult and reveals a bleeding edematous submucosa. 
There are dilatation and congestion of the blood vessels of the mucous membranes. Pa-
ralysis of palate and hypopharynx are early local effects of the toxin. Toxin absorption 
can lead to necrosis of kidney tubules, adrenal glands, thrombocytopenia, mycocardiopa-
thy, and demyelination of nerves. The regional lymph nodes are usually also involved. 
When the pathological process develops in a mucous membrane lined with single-
layer columnar epithelium forms croupous inflammation. When the pathological 
process develops in a mucous membrane lined stratified squamous epithelium, not 
only the epithelium, but also the connective tissue (tunica propria mucosae) forms 
diphtheritic inflammation. The most important protective reaction of the organism in 
response to diphtheria toxin is the production of antitoxin. 
Clinical picture. The incubation period of diphtheria is from two to ten days. De-
pending on the localization of the pathological process and its severity, there is a great 
variety of clinical forms of the disease: diphtheria of the fauces, nose, larynx, trachea 
and bronchi, eyes, external genitalia, skin, etc., is distinguished according to its lo-
calization. Simultaneous affection of the fauces and nose or of the fauces and larynx is 
not infrequent. These forms are known as combined. 
Faucial Diphtheria. Diphtheria of the fauces is the most common form of the 
disease. Three principal forms are distinguished:  
a) localized faucial diphtheria with membranous films coating the tonsils only, includ-
ing atypical insular (because the diphtheritic membrane on the tonsils resembles sepa-
rate islands) and catarrhal forms (without membrane);  
b) diffuse form with the membrane spreading beyond the tonsils to the palatine arches, 
uvula, and throat;  
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c) toxic form characterized by extensive lesions in the fauces, a marked reaction in the 
regional lymph nodes with toxic oedema of the tissues of the neck, and marked gen-
eral toxaemia. Subtoxic diphtheria is a subtype that is a kind of transition between the 
diffuse and toxic forms. Variants of toxic diphtheria with a particularly malignant 
course—hypertoxic and haemorrhagic— should be distinguished (as atypical forms). 
The localized form of faucial diphtheria is the most common. Its onset is charac-
terized by general malaise, loss of appetite, headache and a moderate rise in tempera-
ture. Slight pain on swallowing is usually noted. These phenomena are often mild, and 
there may be no pain in the throat at all. On examination of the fauces a mild or mod-
erate hyperaemia of the mucous membrane of the tonsils, palatine arches, and uvula is 
usually seen on the first day, more rarely on the second. The tonsils are enlarged and 
covered with a typical film, which has the appearance of a superimposition with 
smooth or wavy surface, with well-defined edges. The membrane may be white, yel-
lowish-white, or greish-white in colour; it adheres closely to the underlying tissues, 
and cannot be separated with a swab. At the same time the regional lymph nodes 
enlarge moderately; on palpation they are hard, with well-defined borders, and slightly 
or moderately tender. 
The diffuse form of faucial diphtheria is characterized the film, wich covers not only 
the swollen tonsils but also, to a greater or less extent, the mucous membrane of the pala-
tine arches, the uvula, and sometimes the whole of the soft palate and the walls of the 
throat. There are more pronounced general malaise, lassitude, weakness, anorexia, head-
ache, and disturbed sleep. The temperature rises to 38-39C. 
The toxic form of faucial diphtheria usually begins suddenly, the temperature rapidly rises 
to 39-40C, the patient turns pale sharply, and there are headache, general malaise, marked 
lassitude, sleeplessness, anorexia and, at times, vomiting and abdominal pain. Excitation, but 
more commonly, marked apathy and adynamia develop. Underlying soft tissue edema and 
enlarged lymph nodes can cause a "bull-neck" appearance. 
The mucous membrane of the soft palate and pharynx is edematous and slightly 
hyperemic. The tonsils are covered with a thick uneven membrane of a dirty white or 
brownish-grey colour that extends to soft palate and even to I lie hard. The patient's face 
is pale, the tongue is coated, while or brownish. The lips are parched. An unpleasant odour 
is smelt when examining the fauces. The process often spreads to the nasopharynx and 
nasal cavity. Quite characteristic changes appear in the superior cervical lymph nodes and 
the soft tissues around them. A painful infiltrate of a dense consistency and blurred outline 
is found in the area of the lymph nodes, while there is more or less extensive oedema of the 
soft, tissues above and around, the affected nodes (subcutaneous cellular tissue). The colour 
of the skin over the oedumatous tissue remains normal. Pressure on the area is painless and 
does not leave pits and when the tissue is percussed with the finger it shakes like a jelly. 
The oedema is usually bilateral occupying the whole submaxillary area; it can the ability to 
spread. Its intensity in the subcutaneous tissue depends on the degree of toxaemia, and it is 
therefore taken as the basis for the following classification of toxic diphtheria into three 
degrees: 
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Degree Extent of oedema: I) to the middle of the neck; II) to the clavicles; III) be-
low the clavicles 
The subtoxic form of faucial diphtheria: the oedema of the faucial mucosa is less 
pronounced and the false membrane less extensive, oedema of the tissues of the neck 
is usually seen only in the direct vicinity of the affected regional lymph nodes, and as a 
rule is unilateral. In the hypertoxic form, apart from the rapidly developing local proc-
ess characteristic of toxic diphtheria, there is grave toxaemia with a catastrophically 
progressing fall in cardiovascular activity. The patient usually dies within the first five 
days of the disease. The haemorrhagic form has a symptom complex of second or 
third degree toxic diphtheria combined with haemorrhagic diathesis. The affected 
mucosa tends to bleed and copious bleeding from the nose and haemorrhages into the 
skin are frequent. There is marked thrombopenia and increased blood coagulation 
time. The skin is pale or greyish and there is a rapidly progressing cardiovascular fail-
ure. This form has a very high death rate. 
Laryngeal Diphtheria or Diphtheritic Croup is still often encountered in young 
children (between a year and three or four years of age. Laryngeal diphtheria begins 
with a rise in temperature and general malaise. Hoarseness quickly develops and is 
followed by complete aphonia. Cough appears simultaneously, at first dry, hard and 
'barking', but as dysphonia develops it loses its resonant quality and becomes hoarse. 
Rare Clinical Forms of Diphtheria are Nasal Diphtheria, Conjunctival diphtheria, Diph-
theria of the external genitalia, Diphtheria of the skin and wounds. Nasal diphtheria occurs 
with faucial diphtheria (mixed form). 
Complications. Complications associated with specific toxaemia are distinctive of 
diphtheria, viz. cardiovascular disturbances, neuritis and polyneuritis, and nephrosis. 
Complications in the cardiovascular system. Early and late cardiovascular distur-
bances are distinguished. Subtle signs of myocarditis can be detected in most patients, 
especially the elderly, but the risk for significant complications correlates directly with 
the extent and severity of exudative local oropharyngeal disease and delay in admini-
stration of antitoxin. Characteristically, the first evidence of cardiac toxicity occurs in 
the 2nd to 3rd wk of illness as pharyngeal disease improves but can appear acutely as 
early as the 1st wk when a fatal outcome is likely, or insidiously as late as the 6th wk 
of illness. There are unfavorable sings of diphtheritic myocarditis by Molchanov –
gallop rhythm, abdominal pains and vomiting. 
Complications affecting the nervous system. Neurologic complications parallel the 
extent of primary infection and are multiphasic in onset. Acutely or 2–3 wk after onset 
of oropharyngeal inflammation, hypesthesia, and local paralysis of soft palate occur 
commonly. Weakness of the posterior pharyngeal, laryngeal, and facial nerves may fol-
low, causing a nasal quality in the voice, difficulty in swallowing, and risk of death from 
aspiration. Cranial neuropathies characteristically occur in the 5th wk and lead to oculo-
motor and ciliary paralysis, which manifest as strabismus, blurred vision, or difficulty 
with accommodation. Symmetric polyneuropathy has its onset 10 days to 3 mo after 
oropharyngeal infection and causes principally motor deficit with diminished deep ten-
don reflexes. Proximal muscle weakness of the extremities progressing distally and, 
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more commonly, distal weakness progressing proximally are described. Clinical and 
cerebrospinal fluid findings in the latter are indistinguishable from those of polyneuropa-
thy of Landry syndrome. Paralysis of the diaphragm can ensue. Complete recovery is 
likely. The forms presenting the greatest danger are paralysis and paresis of the laryngeal 
muscles, respiratory intercostal muscles, the diaphragm, and those resulting from lesions 
to the innervation mechanism of the heart (n. vagus). Renal complications-toxic nephro-
sis (proteinuria and a slight cylindruria). Pneumonia is a common complication of diph-
theritic croup. 
Diagnosis. Thorough clinical examination, case history, bacteriological tests are 
most important for early diagnosis. The morphological properties of the isolated mi-
crobe are determined in 24 hours and the laboratory can give a tentative conclusion. 
The final result of the investigation can be obtained in 48-72 hours after isolation of the 
pure microbe culture and determination of its cultural, biochemical, toxicogenic, and sero-
logical properties. The agglutination test with the patient's serum has been suggested as an 
aid to diagnosis. This method can be used for retrospective diagnosis. Protective titre is 
1:80 and higher in reaction of passiv agglutinaion or 0,03 AU/ml. 
Differential diagnosis. Follicular angina is distinguished by greyish-white or yellow-
ish-white round, purulent follicles, translucent through the mucous membrane of the ton-
sils, while lacunar angina is characterized by marked, crumbly, quite easily removed films 
in the lacunae of enlarged and loose tonsils. Both forms have a marked temperature reac-
tion, much pain on swallowing, bright widespread hyperaemia of the fauces, and a consid-
erable tenderness of the regional lymph nodes. They can be mistaken for the atypical form 
of insular faucial diphtheria particularly common in the immunized. But in the latter form 
of diphtheria the patient's general condition does not suffer much, the temperature reaction 
is mild, there is little or no pain on swallowing, the submaxillary lymph nodes are less pain-
ful or even painless, and faucial inflammation is not marked. The diphtheritic membrane is 
not only localized in the follicles and lacunae, but also outside them, is rather dense and can 
only be removed with difficulty. 
Fusospirillar angina (angina caused by 'bacilli and spirillae with tapering ends) was described 
by Simonovsky -Vincent. It differs from diphtheria in the unilateral affection of the tonsils and 
the presence of a deep ulcer with an uneven, dirty-grey or yellow necrotic floor. Bacterioscopy 
revealing a fusospirillar flora clears up the diagnosis. 
Infectious mononucleosis or mononuclear angina (Filatov's glandular fever) can easily be 
mistaken for faucial diphtheria. Infectious mononucleosis is the best-known clinical syndrome 
caused by Epstein-Barr virus (EBV). It is characterized by systemic somatic complaints con-
sisting primarily of fatigue, malaise, fever, sore throat, and generalized lymphadenopathy. 
Originally described as glandular fever, it derives its name from the mononuclear lymphocy-
tosis with atypical-appearing lymphocytes that accompany the illness. 
EBV infects up to 95 % of the world's population. It is transmitted in oral secretions by 
close contact such as kissing or exchange of saliva from child to child. EBV is shed in oral 
secretions for 6 mo or longer after acute infection and then intermittently for life. Healthy 
individuals with serologic evidence of past EBV infection excrete virus 10–20 % of the 
time. Immunosuppression may permit reactivation of latent EBV. After acquisition in the 
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oral cavity, EBV initially infects oral epithelial cells; this may contribute to the symptoms 
of pharyngitis. After intracellular viral replication and cell lysis with release of new virions, 
virus spreads to contiguous structures such as the salivary glands with eventual viremia and 
infection of B lymphocytes in the peripheral blood and the entire lymphoreticular system 
including the liver and spleen. The atypical lymphocytes that are characteristic of infectious 
mononucleosis are CD8+ T lymphocytes, which exhibit both suppressor and cytotoxic 
functions that develop in response to the infected B lymphocytes. This relative as well as 
absolute increase in CD8+ lymphocytes results in a transient reversal of the normal 2:1 
CD4+/CD8+ (helper-suppressor) T-lymphocyte ratio. Many of the clinical manifestations 
of infectious mononucleosis may result, at least in part, from the host immune response, 
which is effective in reducing the number of EBV-infected B lymphocytes to less than one 
per 106 of circulating B lymphocytes. EBV, like the other herpesviruses, establishes life-
long latent infection after the primary illness. The latent virus is carried in oropharyngeal 
epithelial cells and systemic B-lymphocytes as multiple episomes in the nucleus. Reactiva-
tion is apparently asymptomatic and not recognized to be accompanied by distinctive clini-
cal symptoms. Oncogenesis: EBV was the first human virus to be associated with malig-
nancy and, therefore, was the first virus to be identified as a human tumor virus. Malignant 
EBV-associated proliferations include nasopharyngeal carcinoma, Burkitt lymphoma, 
Hodgkin disease, and lymphoproliferative disorders and leiomyosarcoma in immunodefi-
cient states including AIDS. 
The incubation period of infectious mononucleosis in adolescents is 30–50 days. In 
children it may be shorter. The majority of cases of primary EBV infection in infants and 
young children are clinically silent. In older patients, the onset of illness is usually insidi-
ous and vague. Patients may complain of malaise, fatigue, fever, headache, sore throat, 
nausea, abdominal pain, and myalgia. This prodromal period may last 1–2 wk. The 
complaints of sore throat and fever gradually increase until patients seek medical care. 
Splenic enlargement may be rapid enough to cause left upper quadrant abdominal 
discomfort and tenderness, which may be the presenting complaint. The physical ex-
amination is characterized by generalized lymphadenopathy (90 % of cases), 
splenomegaly (50 % of cases), and hepatomegaly (10 % of cases). Lymphadenopathy 
occurs most commonly in the anterior and posterior cervical nodes, and submandibu-
lar lymph nodes and less commonly in the axillary and inguinal lymph nodes. 
Epitrochlear lymphadenopathy is particularly suggestive of infectious mononucleosis. 
Symptomatic hepatitis or jaundice is uncommon. Splenomegaly to 2–3 cm below the 
costal margin is typical; massive enlargement is uncommon. The sore throat is often 
accompanied by moderate to severe pharyngitis with marked tonsillar enlargement, 
occasionally with exudates. Petechiae at the junction of the hard and soft palate are 
frequently seen. The pharyngitis resembles that caused by streptococcal infection. 
Other clinical findings may include rashes and edema of the eyelids. Rashes are usu-
ally maculopapular and have been reported in 3–15 % of patients. Eighty per cent of 
patients with infectious mononucleosis will experience a rash if treated with ampicillin 
or amoxicillin; the reason for this phenomenon is unknown.  
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Routine Laboratory Tests. In more than 90 % of cases, there is leukocytosis of 
10,000–20,000 cells/mm3, of which at least two thirds are lymphocytes; atypical lym-
phocytes usually account for 20–40 % of the total number. Compared with regular 
lymphocytes microscopically, atypical lymphocytes are larger overall, with larger, 
eccentrically placed indented and folded nuclei with a lower nuclear-cytoplasm ratio.  
Heterophile Antibody Test. Heterophile antibodies agglutinate cells from species 
different from those in the source serum. The transient heterophile antibodies seen in 
infectious mononucleosis, also known as Paul-Bunnell antibodies, are IgM antibodies 
detected by the Paul-Bunnell–Davidsohn test for sheep red cell agglutination. The 
heterophile antibodies of infectious mononucleosis agglutinate sheep or, for greater 
sensitivity, horse red cells. 
Outcome and prognosis. The prognosis for a patient with diphtheria depends on the 
virulence of the organism (subspecies gravis has the highest fatality), age, immunization 
status, site of infection, and speed of administration of the antitoxin. Mechanical obstruc-
tion from laryngeal diphtheria or bull-neck diphtheria and the complications of myocar-
ditis account for most diphtheria-related deaths. 
Treatment. Bed rest is essential during the acute phase of disease, with a return to 
physical activity guided by the degree of toxicity and cardiac involvement. The com-
plications of airway obstruction and aspiration should be aggressively avoided at pa-
tients with oropharyngeal and laryngeal diphtheria, with an artificial airway estab-
lished pre-emptively. But in toxic diphtheria, even when there are no complications, 
patients are kept in hospital and strictly confined to bed for the following minimum 
periods: in subtoxic and toxic diphtheria of the first degree for 21 to 28 days; in toxic 
diphtheria of the second degree for 40 days; and in toxic diphtheria of the third degree 
for 50 days from the beginning of the disease. The complications of diphtheria like 
myocarditis and polyneuritis also call for prolonged absolute bed rest. A special diet is 
not necessary in diphtheria; only during the first days are fluids and semi-fluids pre-
scribed when there are marked lesions in the fauces. 
1. Treatment of diphtheria with antitoxic serum. Specific antitoxin is the mainstay 
of therapy and should be administered on the basis of clinical diagnosis, because it 
neutralizes only free toxin. Efficacy diminishes with elapsing time after the onset of 
mucocutaneous symptoms. In doubtful cases the physician can choose the expectant 
tactics only on the condition that the localized form of the disease can be suspected. 
The dose of antitoxin depends on the severity (clinical form) of the disease and the 
time lapse from its onset; the more severe the forms and the later treatment are started, 
the greater the dose should be. Age is only of relative significance in determining the 
required dose. Serum should be given by the modified Bezredka method - 0,1 ml is 
first given subcutaneously. Followed by 0,2ml dose in 30 minutes, and finally the 
remaining dose in 60 minutes. The intradermal test uses 0.02 mL of 1:100 saline-
diluted antitoxin or 1:1,000 saline-diluted antitoxin if the individual has a history of 
animal allergy or prior exposure to animal serum. An immediate reaction is defined as 
a wheal with surrounding erythema at least 3 mm larger than the negative control test 
result, read at 15 to 20 min. Desensitization is performed in those showing immediate 
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reactions according to protocol recommended by the American Academy of Pediatrics 
with successive doses every 15 min. For those with negative test results, a preliminary 
dose of 0.5 mL of antitoxin diluted in 10 mL of physiologic saline or 5 % glucose 
solution is given as slowly as possible with 30 min of observation; the remainder is 
then diluted 1:20 and given at a rate not to exceed 1 mL/min. Most authorities prefer 
the intravenous route with infusion over 30–60 min. The effect of antitoxin treatment 
begins to show within eight to twelve hours, or in 24 hours. In 24 to 36 hours the diph-
theritic membrane begins to shrink, and disappears in most cases toward the third or 
fourth day. In the toxic form it takes longer, from five to seven days, and even more.  
2. Antimicrobial therapy is indicated to halt toxin production, treat localized infection, 
and prevent transmission of the organism to contacts. Only penicillin or erythromycin is 
recommended; erythromycin is marginally superior to penicillin for eradication of naso-
pharyngeal carriage. Appropriate therapy is erythromycin given orally or parenterally (40–
50 mg/kg/24 hr; maximum, 2 g/24 hr), aqueous crystalline penicillin G given intramuscu-
larly or intravenously (100,000–150,000 U/kg/24 hr divided in four doses), or procaine 
penicillin (25,000–50,000 U/kg/24 hr divided in two doses) given intramuscularly. Antibi-
otic therapy is not a substitute for antitoxin therapy. Therapy is given for 14 days. 
3. Infusion of rheopolyglucin and other salt solutions in combination with a 10 % 
solution of glucose (1:1) is prescribed in toxic diphtheria. This treatment favours disin-
toxication.  
4. Some clinicians have had success in treating toxic diphtheria with glucocorti-
coids (hydrocortisone, prednisolone). The course of treatment takes from seven to 
twelve days. The effect of countering the toxaemia is more rapid and there is reduction 
of the incidence of grave complications. 
5.Vitamin therapy is widely employed in diphtheria, especially in its toxic forms. 
Nicotinic acid (Ac. nicotinicum) is widely used to treat toxic diphtheria as it improves 
metabolism in the tissues. Bed rest, strychnine, vitamin B6, nicotinic acid, cyanoco-
balamine (vitamin B12), glutamic acid, dibazol and proserine are indicated if diphther-
itic paralysis supervenes. 
Prophylaxis. Active immunization. Universal immunization with diphtheria 
toxoid throughout life to provide constant protective antitoxin levels and to reduce 
indigenous C. diphtheriae is the only effective control measure. Although immuniza-
tion does not preclude subsequent respiratory or cutaneous carriage of toxigenic 
C.diphtheriae, it decreases local tissue spread, prevents toxic complications, dimin-
ishes transmission of the organism, and provides herd immunity when at least 70–80 
% of a population is immunized. Serum antitoxin concentration of 0.01 IU/mL is con-
ventionally accepted as the minimum protective level, and 0.1 IU/mL provides the 
certain protective level. 
Immunization against diphtheria is now compulsory for all children. Adsorbed 
pertussis-diphtheria-tetanus vaccine (APDT) and diphtheria-tetanus toxoids (ADT) are 
used for immunization. The pediatric preparation (i.e., DTP, DT, DTaP) contains 6.7–
12.5 Lf units of diphtheria toxoid per 0.5-mL dose; the adult preparation (i.e., Td) 
contains no more than 2 Lf units of toxoid per 0.5-mL dose. Three doses (of 0.5 ml) 
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are given at intervals of 30 to 40 days in the primary immunization of babies. Children 
are reimmunized with the same dose (0.5 ml) 18 months. A third reimmunization is 
given with adsorbed diphtheria-tetanus toxoid at the age of 6, than – 11, 18 and adult. 
In USA, India and many other countries for children from 6 wk to the seventh birth-
day, give five 0.5-mL doses of diphtheria-containing (D) vaccine. The primary series 
includes doses at approximately 2, 4, and 6 mos of age. The fourth dose is an integral 
part of the primary series and is given approximately 6–12 mo after the third dose. A 
booster dose is given at 4–6 yr (unless the fourth primary dose was administered after 
the fourth birthday). For persons 7 yr of age or older, use three 0.5-mL doses of diph-
theria-containing (D) vaccine. The primary series includes two doses 4–8 wk apart 
and a third dose 6–12 mo after the second dose. 
Control of diphtheria carriers. When an asymptomatic carrier is identified, several 
steps are taken. First, antimicrobial prophylaxis is given for 7-10 days. Second, age-
appropriate preparation of diphtheria toxoid is administered immediately if there has 
not been a booster within 1 yr. Third, individuals are placed in strict isolation (respira-
tory tract colonization) or contact isolation (cutaneous colonization only) until at least 
two subsequent cultures taken 24 hr apart after cessation of therapy are negative. 
Fourth, repeat cultures are performed at a minimum of 2 wks after completion of ther-
apy for cases and carriers, and if positive, an additional 10-day course of oral erythro-
mycin should be given and follow-up cultures performed. 
The measures to be taken in an epidemic focus are as follows. (1) Patients with 
pharyngeal diphtheria are placed in strict isolation, and patients with cutaneous diph-
theria are placed in contact isolation until the cultures taken after cessation of therapy 
are negative. Elimination of the organism should be documented by at least two suc-
cessive cultures from the nose and throat (or skin) taken 24 hr apart after completion 
of therapy. But before they are re-admitted to a children's institution two negative sup-
plementary checks for carrier state are required. Carriers of nonvirulent bacilli are 
allowed to attend children's institutions, but carriers of virulent diphtheria bacilli are 
not given permission to attend children's institutions where all children are immunized 
until 30 days after detection of their carrier state. A commission, the epidemiologist 
including, decides it. (2) Prompt identification and investigation of close contacts are 
the highest priorities. Several steps are taken. First, these individuals are closely moni-
tored for illness through the 7-day incubation period. Second, cultures of the nose, 
throat, and any cutaneous lesions are performed. Third, antimicrobial prophylaxis is 
given, regardless of immunization status, using oral erythromycin (40–50 mg/kg/24 hr 
for 7–10 days) or, using intramuscular benzathine penicillin (600,000 U for those <30 
kg or 1,200,000 U for those 30 kg). The efficacy of antimicrobial prophylaxis is pre-
sumed but not proved. Fourth, diphtheria toxoid vaccine, in age-appropriate concen-
tration, is given to immunized individuals who have not received a booster dose 
within 5 yr. Some experts suggest that the longevity of protective antibody is variable 
enough that a booster should be given to close contacts if 1 yr has elapsed since im-
munization. Children who have not received their fourth dose should be vaccinated. 
Those who have received fewer than three doses of diphtheria toxoid or who lack 
 81
knowledge of immunization status are immunized with age-appropriate preparation on 
a primary schedule. (3) Terminal disinfection is carried out in the patient's home. 
 
PART 9  MUMPS (Epidemic Parotitis) 
 
Mumps is an acute, generalized viral disease in which painful enlargement of the 
salivary glands, chiefly the parotids, is the usual presenting sign. 
Etiology. The causative agent in mumps is a filterable virus from the group of 
myxoviruses (Paramyxovirus parotitidis) that varies in size, averaging 100-200 nm. 
Only one serotype is known. Primary cultures of human or monkey kidney cells are 
used for viral isolation. As seen by electron microscopy, it has a flat It contains ribo-
nucleic acid (RNA). The virus is of low stability and is rapidly inactivated by high 
temperatures, ultraviolet rays, weak formalin solutions, lyzol, and alcohol. It is grown 
on developing chick embryos. The mumps virus is pathogenic for monkeys, in which 
it produces a characteristic inflammation of the parotid glands. 
Virus has been isolated from saliva, cerebrospinal fluid, blood, urine, brain, and other 
infected tissues. 
Epidemiology. The source of infection is a patient. The research of recent years 
has shown that the virus is discharged only during the last days of incubation and the 
first days after onset of the illness. Patients cease to be contagious by the ninth day. 
Mumps is endemic in most urban populations; the virus is spread from a human 
reservoir by direct contact, airborne droplets, fomites contaminated by saliva, and 
possibly by urine. It is distributed worldwide and affects both sexes equally; 85 % of 
infections occurred in children younger than 15 yr prior to widespread immunization. 
Susceptibility to mumps is lower than to other infections spread by an aerial-droplet 
route (like measles and chickenpox), and is the greatest between the ages of five and 
fifteen. The index of susceptibility is 0.5-0.7. Its incidence is relatively low in small 
children, and babies under 12 months are 'remarkably insusceptible to parotitis' (N. 
Filatov). The disease is not uncommon in adults, particularly under the age of 25, and 
there are many reports of epidemic outbreaks in military units. 
Now disease often occurs in young adults, producing epidemics in colleges or in the 
work place. Epidemics appear to be primarily related to lack of immunization rather than to 
waning of immunity. 
Epidemics occur at all seasons but are slightly more frequent in late winter and 
spring. Sources of infection may be difficult to trace because 30-40 % of infections are 
subclinical. There has been a decrease in the incidence since the introduction of 
mumps vaccine in 1968. 
Virus has been isolated from saliva as long as 6 days before and up to 9 days after 
appearance of salivary gland swelling. Transmission does not seem to occur longer 
than 24 hr before appearance of the swelling or later than 3 days after it has subsided. 
Virus has been isolated from urine from the 1st-14th day after the onset of salivary 
gland swelling. 
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Lifelong immunity usually follows clinical or subclinical infection, although sec-
ond infections have been documented. Transplacental antibodies seem to be effective 
in protecting infants during their first 6-8 mo. Infants born to mothers who have 
mumps in the week prior to delivery may have clinically apparent mumps at birth or 
experience illness in the neonatal period. Severity ranges from mild parotitis to severe 
pancreatitis. The serum neutralization test is the most reliable method for determining 
immunity but is cumbersome and expensive. A complement-fixing antibody test is 
available (see Diagnosis). The presence of V antibodies alone suggests previous 
mumps infection. 
Pathogenesis. The pathogenesis and pathological anatomy of mumps have not yet 
been adequately studied. It is a general infection in which the virus develops not only 
in the salivary glands, but also in the blood and other organs. The possibility of pri-
mary infection in the menin-ges or testes has been established. All the data point to the 
view expressed long ago by N. Filatov that the virus invades the parotid glands not 
through Stensen's duct, but by way of the blood circulation.  
The portal of entry is apparently the mucous membrane of the mouth, nose, and 
pharynx from which the virus penetrates into the blood and is carried secondarily to 
the salivary glands and other organs where it predominantly affects the interstitial tis-
sue. The parotid gland is apparently the site of accumulation of the virus from which it 
is discharged into the environment with saliva. 
The antibodies, whose titre attains its maximum in 2-4 weeks, appear during the first days 
of the disease. 
Clinical manifestations.The incubation period of mumps lasts on average for 18 
to 20 days, but extremes of 11 and 23 days occur. In children, prodromal manifesta-
tions are rare but may be manifest by fever, muscular pain (especially in the neck), 
headache, and malaise. 
Its onset is characterized by elevation of temperature (up to 38° or 39°C) and 
swelling of the parotid gland (usually on one side, but sometimes on both). The swell-
ing obliterates the fossa retromaxil laris and may spread downwards anteriorly and 
posteriorly to the neck (Fig. 36). When the swelling is considerable the auricle is lifted 
upward. The centre of the swelling is elastic-solid on palpation and painful when 
pressed; the thickness and the tenderness of the swelling fall off toward the periphery. 
A painless or slightly tender inflammatory oedema is seen on the periphery. At times 
it spreads to the face and far to the neck. The skin over the inflamed gland is tense and 
lustrous, but remains usually of normal colour. Swelling of the parotid gland is ac-
companied with pain irradiating to the ear or neck, that becomes more intense during 
chewing or swallowing. 
In one or two days the parotid gland on the opposite side may become involved; 
and in about half the cases the submaxillary, and sometimes the sublingual, glands are 
affected. In submaxillitis palpation directly inward from the margin of the lower jaw 
displays a swollen, solid, and painful submaxillary gland, oval or round in shape (Fig. 
37). Submaxillitis is sometimes accompanied with extensive oedema of the cervical 
cellular tissue; cases of isolated inflammation of the submaxillary gland and of its 
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primary affection with subsequent supervention of parotitis have been observed.The 
swelling of the affected gland increases for the first three to five days, then begins to 
regress and subsides by the eighth to tenth day. Resolution of the inflammatory infil-
trate may be prolonged to several weeks, but as a rule the glands do not suppurate. 
Simultaneously with subsidence of inflammation the temperature falls, the pain de-
clines, and the patient's general condition improves. If several glands are affected one 
after the other the disease may last for two and more weeks. 
Mumps is sometimes attended, with bradycardia and enlargement of the spleen. 
Leucopenia or normocytosis, a relative lymphocytosis, and frequently monocytosis, 
are chief blood findings. The ESR usually falls or deviates a little from the normal. 
A variety of mumps that must be mentioned is the abortive forms expressed in 
mild swelling of the parotid gland with little or no rise of temperature. 
Pathological involvement of the nervous system and of various glandular organs is 
a typical feature of mumps. The lesions of these organs are more correctly considered 
a symptom rather than a complication of the disease, whose causative agent has a 
definite tropism. 
Orchitis, which occurs in 10 to 35 per cent of young men and boys at puberty, 
usually develops on the sixth to eighth day of the disease. Rise of temperature, often 
accompanied with chill, malaise, and adynamia, and sometimes with delirium, excita-
tion, and symptoms of circulatory failure are noted. More or less strong pain de-
veloping in one of the testes irradiates to the inguinal and lumbar regions. The testis 
enlarges, becomes tender and painful; the scrotum is oedematous and its skin is ofteq 
tense and red. A bilateral process is rare. The symptoms begin to subside in two or 
three days, and usually disappear completely by the end of the first week or the be-
ginning of the second. Primary orchitis without previous affection of the salivary 
glands has been reported. 
Oophoritis, mastitis and bartholinitis are rare manifestations of mumps in older girls and 
young women. 
Pancreatitis normally manifests by strong epigastric pains and pains in the region 
of the left hypochondrium. Girdle pain occurs sometimes. Palpation is markedly pain-
ful. Nausea, anorexia, sometimes vomiting and diarrhoea occur. The diastase of the 
blood and urine increases highly. The pancreas may be affected in the presence of 
only part of these symptoms, or the symptoms may be nonmanifest. Mumps dacryo-
cystitis have been described. 
Acute serous meningitis is not infrequent in mumps, and mostly arises when the 
affection of the salivary glands is mild or moderate. 
It usually develops at the height of the disease, and is characterized by symptoms 
of meningeal irritation (headache, frequent vomiting, rigidity of the occipital muscles, 
Kernig's and Brudzinsky's signs). The transparent or opalescent cerebrospinal fluid 
flowing in lumbar puncture is at normal or elevated pressure. Its protein content is 
normal or slightly increased, the cytosis is increased at the expense of lymphocytes 
(30-700 cells per mm3). The sugar and chloride content is normal. The mumps virus is 
often discovered in the cerebrospinal fluid. All these symptoms persist for 5-10 days 
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and then subside gradually leaving no traces. Residual phenomena remain however in 
some patients'for long periods of time. Primary serous meningitis with or without sub-
sequent affection of salivary glands has been encountered. The true nature of such 
meningitis is proved by the presence of characteristic epidemiological links, and by 
serological tests. 
Complications. Viremia early in the infection probably accounts for the widespread 
complications. 
Meningoencephalomyelitis. This is the most frequent complication in childhood. 
The true incidence is hard to estimate because subclinical infection of the central 
nervous system, as evidenced by cerebrospinal fluid pleocytosis, has been reported in 
more than 65 % of patients with parotitis. Clinical manifestations occur in over 10 % 
of patients. The incidence of mumps meningoencephalitis is approximately 
250/100,000 cases; 10 % of these cases occurred in patients older than 20 yr. The mor-
tality rate is about 2 %. Males are affected three to five times as frequently as females. 
Mumps is one of the most common causes of aseptic meningitis  
The pathogenesis of mumps meningoencephalitis has been described as (1) a pri-
mary infection of neurons and (2) a postinfectious encephalitis with demyelination. 
Injecting mumps virus into suckling hamsters has produced similar lesions. 
Mumps meningoencephalitis is clinically indistinguishable from meningoen-
cephalitis of other origins.Moderate stiffness of the neck is seen, but the remainder of 
the neurologic examination is usually normal. The cerebrospinal fluid (CSF) usually 
contains fewer than 500 cells/mm3, although occasionally the count may exceed 
2,000. The cells are almost exclusively lymphocytes, in contrast to enteroviral aseptic 
meningitis, in which polymorphonuclear leukocytes often predominate early in the 
disease. Mumps virus can be isolated from cerebrospinal fluid early in the illness. 
Atrophy of the optic nerve is encountered even more rarely. 
Orchitis, Epididymitis. Approximately 30–40 % of affected testes atrophy. Im-
pairment of fertility is estimated to be about 13 %, but absolute infertility is probably 
rare. 
Oophoritis. There is no evidence of impairment of fertility. 
Nephritis. Viruria has been reported frequently. In one study of adults, abnormal renal 
function occurred at some time in every patient, and viruria was detected in 75 %. The 
frequency of renal involvement in children is unknown. Fatal nephritis, occurring 10–14 
days after parotitis, has been reported. 
Thyroiditis. Although uncommon in children, a diffuse, tender swelling of the thy-
roid may occur about 1 wk after the onset of parotitis with subsequent development of 
antithyroid antibodies. 
Myocarditis. Serious cardiac manifestations are extremely rare, but mild infection of 
the myocardium may be more common than is recognized. Electrocardiographic tracings 
revealed changes, mostly depression of the ST segment, in 13 % of adults in one series. 
Such involvement may explain the precordial pain, bradycardia, and fatigue sometimes 
noted among adolescents and adults with mumps. 
Mastitis. This is uncommon in each sex. 
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Deafness. Unilateral, rarely bilateral, nerve deafness may occur; although the incidence is 
low (1:15,000), mumps is a leading cause of unilateral nerve deafness. The hearing loss may 
be transient or permanent. 
Ocular Complications. These include dacryoadenitis, painful swelling, usually bilateral, 
of the lacrimal glands; optic neuritis (papillitis) with symptoms varying from loss of vision 
to mild blurring with recovery in 10–20 days; uveokeratitis, usually unilateral, with photo-
phobia, tearing, rapid loss of vision, and recovery within 20 days; scleritis; tenonitis, with 
resultant exophthalmos; and central vein thrombosis. 
Arthritis. Arthralgia associated with swelling and redness of the joints is an infre-
quent complication; complete recovery is the rule. 
Thrombocytopenic Purpura. This sign is infrequent. 
Mumps Embryopathy. There is no firm evidence that maternal infection is damag-
ing to the fetus; a possible relationship to endocardial fibroelastosis has not been estab-
lished. Mumps in early pregnancy does increase the chance of abortion. 
Diagnosis.The diagnosis of mumps parotitis is usually apparent from the symp-
toms and physical examination. When the clinical manifestations are limited to those 
of one of the less common lesions, the diagnosis is not so clear but may be suspected, 
especially during an epidemic. The routine laboratory tests are nonspecific; there is 
usually leukopenia with relative lymphocytosis, but complications often result in po-
lymorphonuclear leukocytosis of moderate degree. An elevation of serum amylase is 
common; the rise tends to parallel the parotid swelling and then to return to normal 
within 2 wk or so. The etiologic diagnosis depends on isolation of the virus from the 
saliva, urine, spinal fluid, or blood or the demonstration of a significant rise in circulat-
ing complement fixation antibodies during convalescence. Serum antibodies to the S 
antigen reach their peak early in about 75 % of patients and are detectable at the time 
of the presenting symptoms. They gradually disappear within 6–12 mo; antibodies 
against the V or viral antigen usually reach a peak titer in about 1 mo, remain station-
ary for about 6 mo, and then slowly decline during the ensuing 2 yr to a low level, at 
which they persist. The presence of a high anti-S titer and a low anti-V titer during the 
acute stage of an otherwise undiagnosed meningoencephalitis, for example, strongly 
suggests a mumps infection, which would be confirmed if a convalescent serum 
(taken 14–21 days later) revealed a fourfold rise of anti-V antibodies accompanied by 
little change in the titer of anti-S antibodies. 
Differential diagnosis. Difficulties in diagnosing mumps occur in mild and abortive 
forms, and when only submaxillary glands are affected, or the meningitis or orchitis is its 
first manifestation. Diagnosis is established from the features of the clinical course de-
scribed above and the epidemiological data. 
The secondary parotitis developing in the course of severe acute infections (ty-
phoid fever and typhus, sepsis, pneumonia, etc.) is usually unilateral and, as a rule, 
suppurative. 
Toxic parotitis is met mainly in adults suffering from acute or chronic mercury, 
lead, or iodine poisoning; it develops slowly, does not run a cyclic course, and is often 
accompanied with changes in the buccal mucous membrane. 
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Cervical lymphadenitis is differentiated from mumps by an inflammatory focus in 
the fauces with localization of the swelling in the region of superior cervical lymph 
nodes. In mumps the swelling first obliterates the sulcus between the mandible and the 
mastoid process (directly under the auricle). Determination of diastase in the urine 
may be useful in diagnostication of pancreatitis. 
Primary meningitis of mumps aetiology can be confused with tuberculous menin-
gitis. The latter develops slowly and gradually, the pressure of the cerebrospinal fluid 
is increased and its sugar content lowered; it may contain Mycobacterium tuberculo-
sis. It is more difficult to differentiate primary meningitis of mumps aetiology from 
acute serous meningitis caused, for instance, by an enteroviris. Diagnosis is estab-
lished either on the basis of subsequent inflammation of the salivary glands, or when 
there is a history of exposure to mumps. An accurate diagnosis is made with the help 
of virological and serological methods. 
The complement-fixation and haemagglutination inhibition tests (isolation of the 
causative agent in the culture of cells) have been suggested as auxiliary methods for 
early diagnosis of mumps. Both reactions can be made with a standard antigen, a di-
agnostic culture, consisting of the virus grown on the membranes of a developing 
chick embryo. Both these tests should be made twice, once during the first week, and 
again at the end of the second week or during the third. Thus, elevation of antibody 
titre, which has special diagnostic value, is revealed. 
This includes parotitis of other origin, as in viral infections including human im-
munodeficiency virus (HIV) infection, influenza, parainfluenza 1 and 3, cytomega-
lovirus, or the rare instances of coxsackievirus A and lymphocytic choriomeningitis 
infections. These infections can be distinguished by specific laboratory tests; suppura-
tive parotitis, in which pus can often be expressed from the duct; recurrent parotitis, a 
condition of unknown origin, but possibly allergic in nature, which has frequent recur-
rences and a characteristic sialogram; salivary calculus, obstructing either a parotid or, 
more commonly, a submandibular duct, in which the swelling is intermittent; preauri-
cular or anterior cervical lymphadenitis from any cause; lymphosarcoma or other rare 
tumors of the parotid; orchitis resulting from infections other than mumps, for exam-
ple, the rare infections by coxsackievirus A or lymphocytic choriomeningitis viruses; 
and parotitis caused by cytomegalovirus in immunocompromised children. 
Prognosis is favourable. Mortality of mumps is remarkably low. Affection of the inter-
nal ear may lead to permanent deafness. Atrophy of the testes with subsequent aspermia 
can follow bilateral orchitis. 
Treatment. Treatment of parotitis is entirely symptomatic. Diet is restricted to fluids or 
semi-fluids to spare the affected glands. Heat is applied to the glands by means of cotton or 
wool bandages, Sollux lamp, etc. Ultra-high frequency therapy and ultra-violet irradiation 
are also recommended. 
The mouth should be rinsed with weak disinfecting solutions. In severe mumps 
some investigators recommend gamma-globulin (3-6 ml). Strict confinement to bed is 
called for in orchitis; the testis should be supported and cold applied. Corticosteroid 
preparations produce considerable alleviation of pain and subjective improvement. To 
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relieve the severe headache and other meningeal symptoms in concomitant meningitis 
lumbar puncture, which is also recommended when complications develop in the in-
ner ear. Dehydration therapy is carried out. 
Mumps arthritis may respond to a 2-wk course of corticosteroids or a nonsteroidal 
anti-inflammatory agent. Salicylates do not appear to be effective. 
Prophylaxis. Passive. Hyperimmune mumps gamma globulin is not effective in 
preventing mumps or decreasing complications. 
Active. Vaccinated children usually do not experience fever or other detectable 
clinical reactions, do not excrete virus, and are not contagious to susceptible contacts. 
Rarely, parotitis can develop 7–10 days after vaccination. The vaccine induces anti-
body in about 96 % of seronegative recipients and has a protective efficacy of about 
97 % against natural mumps infection. The protection appears to be long lasting. In 
one outbreak of mumps, several children who had been immunized with mumps vac-
cine in the past experienced an illness characterized by fever, malaise, nausea, and a 
red papular rash involving the trunk and extremities but sparing the palms and soles. 
The rash lasted about 24 hr. No virus was isolated from these children, but increases in 
the titer of mumps antibody were demonstrated 
 
PART 10   MENINGOCOCCAL INFECTION 
 
The causative agent of epidemic meningitis is Weichselbaum's meningococcus 
(Neisseria meningitidis). This microorganism has the form of a diplococcus 0.6-0.8 
mm in size, and is gram-negative, its growth is facilitated in a moist environment at 
35–37 0C. The meningococci have been divided into serogroups based on antigenic 
differences in their capsular polysaccharides. At least 13 serogroups have been identi-
fied, but groups A, B, C, W, and Y account for most meningococcal disease. The 
other serogroups often colonize the nasopharynx but rarely disseminate. Lipooligosac-
charides (e.g., endotoxin) and proteins that found in the outer membrane complex are 
also used to serotype meningococcal strains. 
Epidemiology. The sources of infection are sick persons and carriers who expel 
the causative agent with the secretions of the nasopharynx and upper respiratory pas-
sages. Since there are a great many more carriers than patients, the epidemiological 
role of the former is very great. 
The aerial-droplet route transmits infection. Children are mostly susceptible to the 
disease: about 70 % of incidence are infants under 5. The proportion of adults in-
creases in epidemics. Those who suffer from meningitis or meningococcal carrier 
state, develop immunity, and recurrent epidemic meningitis is rarity. 
The meningococcal infection is characterized by periodic rises of the incidence at 
10-15 or longer year intervals. Meningococcal disease, particularly group A, remains a 
major health problem in much of the developing world. Many areas, such as China 
and Africa, have an endemic rate of disease of 10–25 per 100,000 persons and major 
periodic epidemics (100–500 cases/100,000). Epidemic disease typically involves 
individuals who are older than those with endemic disease. 
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Seasonal variations in the incidence are also observed; it increases in winter and 
early spring months. The incidence depends on the specific immunity of the popula-
tion. High density of population, the absence of proper hygiene, and improper sanita-
tion favour the spreading of the disease. 
Pathogenesis and pathological anatomy. The portal of the infection entry is the 
nasopharyngeal mucosa. Colonization of the nasopharynx with meningococci usually 
leads to asymptomatic carriage, and only rarely does dissemination occur. Coloniza-
tion can persist for weeks to months. Carriage rates vary from 2–30 % in a normal 
population during nonepidemic periods. 
The carrier-state develops frequently then nasopharyngitis. For colonization to 
take place, meningococci must evade mucosal IgA and adhere to epithelial cells in the 
nasopharynx due to the secretion of proteases. The bacteria enter nonciliated epithelial 
cells by a parasite-directed endocytotic process and are carried across the cell in mem-
brane-bound vacuoles. 
Meningococci disseminate from the upper respiratory tract through the blood-
stream. Serum antibody leading to complement-mediated bacterial lysis has been 
shown to block this dissemination, and a deficiency of antimeningococcal antibody is 
associated with the development of meningococcemia. Individuals with primary or 
acquired complement deficiency have an increased risk of developing meningococcal 
disease and 50–60 % of individuals with properdin, factor D, or terminal-component 
deficiencies develop bacterial infections that are caused almost solely by N. meningi-
tidis. Bactericidal antibody is directed against the capsular polysaccharide, subcapsular 
protein, and lipooligosaccharide antigens. Newborn infants have protective antibody 
that is primarily IgG of maternal origin. As this antibody wanes, infants 3–24 mo of 
age experience the highest incidence of meningococcal disease. 
The generalized form of infection occurs only in 0.5-1 % of cases. Meningococcal 
bacteraemia or meningococcaemia manifests sometimes as sepsis. 
The important role in meningococcaemia belongs to marked intoxication with the 
endotoxin released during decomposition of the microbial bodies. The concentration 
of circulating endotoxin is directly correlated with activation of the fibrinolytic sys-
tem; development of disseminated intravascular coagulopathy, multiple organ system 
failure, septic shock, and death. Various organs are affected, in the first instance fine 
vessels.  
Cutaneous hemorrhages, ranging from petechiae to purpura, occur in most fatal in-
fections and are associated with acute vasculitis with fibrin deposition in arterioles and 
capillaries. Diffuse adrenal hemorrhage may occur at patients with fulminant menin-
gococcaemia (i.e., Waterhouse-Friderichsen syndrome). Acute inflammatory cells in 
the leptomeninges and perivascular spaces characterize meningitis. 
 
Clinical classification by V.Pokrovsky: 
1. Local forms  
 nasopharyngitis 
 healthy carrier 
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2. Generalized forms 
 meningitis 
 meningococcemia 
 meningoencephalitis 
 meningitis+meningococcemia 
3. Rаrе forms 
 arthritis 
 iridocyclitis 
 chorioiditis 
 pneumonia 
 
Clinical picture. The incubation period lasts for 3-5 days on average (maximum 
10 days). 
The most frequent form of the manifest meningococcal infection is nasopharyngi-
tis. Its symptoms are headache, painful swallowing, subfebrile temperature in some 
patients, hyperemia of the nasopharyngeal mucosa and hyperplasia of lymphoid folli-
cles, rhinitis with scanty discharge, and difficult nasal breathing. The clinical signs 
persist for 5-7 days. 
Meningitis. The onset of the disease is usually violent, and a considerable eleva-
tion of temperature accompanied by chill is noted; severe headache, vertigo, and vom-
iting also occur. Catarrh of the nasopharynx is common. Characteristic is hyperaesthe-
sia of the skin and increased sensitivity to light and sound. Disturbances of conscious-
ness are also frequent. In young children clonic and tonic convulsions are often. 
Rigidity of the occipital muscles develops very early (usually during the first 24 or 
48 hours), and Kernig's and Brudzinsky's signs become positive. The abdomen is re-
tracted. Anisocoria, strabismus, and paresis of the facial nerve are occasional. The 
patient's posture is usually typical: he is lying on his side with head tossed back and 
legs flexed to the abdomen. 
Red dermographism is very common and herpes often occurs on the lips. The 
pulse is initially rapid, but slows down later. Respiration is usually accelerated. Con-
stipation is common in older children, but diarrhea is often seen in infants. The blood 
shows marked hyperleucocytosis, neutrophilosis with a shift to the left, aneosino-
philia; the ESR is considerably increased. 
In lumbar puncture spinal fluid flows under increased pressure (300-500 mm 
H2O). During the first day of illness it may be transparent or slightly opalescent, but 
later becomes turbid and purulent. It displays marked neutrophilosis (from several 
hundreds to several thousands of cells per mm3) and a considerable protein content (up 
to 1-2 g/1 and more), sugar content is lowered. 
The meningococcaemia (septic form) occurs at patients of all ages. The onset is acute 
and violent, with intermittent fever. This infection is usually attended by skin rash, which is 
the most frequent symptom. The rash is haemorrhagic, often with macular (measles-like) 
lesions. The haemorrhagic lesions are stellar formations varying in size; they are hard to 
palpation and are often elevated over the skin level. They are usually localized on the but-
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tocks and lower extremities, less frequently on the arms, the trunk, and the face. Meningo-
cocci are found in blood smears taken from the periphery of the lesions. 
Significant haemorrhage into the skin is often followed by necrosis of the tissues 
with subsequent rejection of the necrotized tissue; scars remain on the skin.  
Arthritis in meningococcaemia is less frequent (5 % of cases). Several joints 
would be usually affected, with a purulent or a seropurulent exudate in the joint cap-
sule. Inflammation of the chorioidea (iridocyclochorioiditis) is a less common, but 
very typical, complication of meningococcaemia; its first sign is a change in the col-
our, which becomes sort of rusty. 
The hypertoxic (fulminating) form of meningococcal infection has a sudden turbulent 
onset and is characterized by grave toxemia (uncontrollable vomiting, convulsions, clouded 
consciousness, and cardiovascular weakness). The patient soon becomes comatose. Men-
ingeal symptoms are sharply pronounced or, on the contrary, rudimentary. Death usually 
ensues within 12 to 24 hours after the onset. Swelling of the brain and protrusion into the 
great foramen is one of the frequent causes of death. 
The fulminating form may develop as the Waterhouse-Friderichsen syndrome. 
Multiple petechiae and hemorrhage into the skin are characteristic. The arterial pres-
sure falls progressively; the pulse is rapid and hardly palpable. Cyanosis, vomiting 
(often with blood) and convulsions are other signs. The patient is prostrated and loses 
his consciousness. The patient dies in 16-30 hours after the onset of the disease unless 
an urgent and effective therapy is given. 
Next form is the meningoencephalitic form is seen mainly in infants and has a 
prevalence of cortical symptoms, namely disturbances of consciousness, convulsions, 
focal phenomena paresis, paralysis. The meningeal symptoms may be trivial. 
In the rudimentary (abortive) form all the symptoms are weakly expressed, includ-
ing the meningeal. The changes in the cerebrospinal fluid may be insignificant and 
transitory. 
Features peculiar to meningitis in nursing babies. Onset of the disease is accompanied 
with high temperature, general restlessness, vomiting, and refusal to suckle. There is 
marked hyperaesthesia and frequent dyspeptic disturbances. Infants scream loudly. Men-
ingeal symptoms and red dermographism are often mild or absent. Tension and protrusion 
of the unossified anterior fontanelle are apparent at the beginning of the disease. In the 
newly born the course of meningitis as a rule is atypical. High temperature, convulsions or 
tremor, and general muscular hypertension develop. Meningeal symptoms are absent or be-
come apparent only with further progress of the disease. Even with modern methods of treat-
ment mortality remains high among the newly born and babies less than three months old. 
Complications. Some patients develop complications associated with the bacterial super-
infection. Pneumonia develops mainly in grave meningococcaemia with disordered con-
sciousness: the patient runs a risk of aspiration of his vomit, and mucus from the pharynx and 
the upper airways.  
Chronic hydrocephalus, motor disorders (paralyses, pareses), retardation of mental 
growth are now rare. Asthenia, headache, and various functional disorders are observed. 
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Diagnosis. Diagnosis of epidemic meningitis is established from the distinctive features 
of the clinical symptomatology and course (acute onset and rapid development of meningeal 
symptoms). The most important diagnostic aid is lumbar puncture and examination of the 
cerebrospinal fluid. The diagnosis is indisputable when meningococcus is detected by bacte-
rioscopy or is found in a cerebrospinal fluid culture. 
Errors in recognizing epidemic meningitis in children are not infrequent: epidemic men-
ingitis can be confused with other forms of meningitis, with various diseases accompanied 
with meningism syndrome. 
Meningeal symptoms are usually mild in meningism and the cerebrospinal fluid 
unchanged. 
Tuberculous meningitis starts gradually and is accompanied with moderate py-
rexia; it is recognized from the anamnesis and the results of tuberculin tests. Miliary 
tuberculosis often shows up on X-ray pictures of the lungs. Cerebrospinal fluid is 
transparent or slightly opalescent; cell count is moderately increased through an in-
crease in the number of lymphocytes. When cerebrospinal fluid is allowed to stand a 
delicate web-like pellicle of fibrin forms on its surface. Mycobacterium tuberculosis is 
often found in the cerebrospinal fluid. 
Acute serous meningitis differs in the cerebrospinal fluid findings (complete trans-
parency; moderately increased cell count through a higher number of lymphocytes; 
normal sugar content). Acute serous meningitis is not infrequent in mumps, and 
mostly arises when the affection of the salivary glands is mild or moderate. 
It usually develops at the height of the disease, and is characterized by symptoms of men-
ingeal irritation. The transparent or opalescent cerebrospinal fluid flowing in lumbar puncture 
is at normal or elevated pressure. Its protein content is normal, there are 30-700 cells per mm3. 
The sugar and chloride content is normal. The mumps virus is often discovered in the cere-
brospinal fluid. All these symptoms persist for 5-10 days and then subside gradually leaving 
no traces. Primary serous meningitis with or without subsequent affection of salivary glands 
has been encountered. The true nature of such meningitis is proved by the presence of charac-
teristic epidemiological links, and by serological tests. 
In the meningeal form of poliomyelitis the cerebrospinal fluid is transparent. A slight or 
moderately increased cell count and normal or slightly increased protein content (cellular-
protein dissociation) is noted during the first five days; later the cell count drops, and a protein-
cellular dissociation is observed from the tenth day. Lymphocytes predominate among the 
cells. Diagnosis is facilitated if tendon reflexes disappear, and even more so if flaccid paralysis 
or paresis develops. 
In contrast to primary meningococcus meningitis, purulent meningitis caused by staphylo-
coccus, pneumococcus, Afanasyev-Pfeiffer bacillus, and streptococcus usually develops secon-
darily to purulent otitis, pneumonia, sepsis, etc. Gram-positive cocci and diplococci are found 
in the cerebrospinal fluid, which is purulent. 
Staphylococcal meningitis. This occurs usually in the newbom baby who often has asso-
ciated umbilical sepsis, pyoderma or septicemia. In older children it follows otitis media, mas-
toiditis, sinus thrombosis and septic lesions of the scalp. 
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Hemophilus influenzae meningitis. Usually the type B organisms are responsible. It is fre-
quent in children between the age of 3 and 12 months. Subdural effusions follow the initial 
illness. This complication should always be suspected in infants in whom focal neurological 
signs and fever persist. Convulsions are common. Residual auditory deficit is a common 
complication. 
Subarachnoid hemorrhage. Sudden headache and sensorial alteration occur without pre-
ceding fever. The course of illness is rapid and signs of meningeal irritation are marked. A CT 
scan and cerebrospinal fluid may reveal the diagnosis. Death occurs early if unrecognized and 
not treated. 
Difficulties in differential diagnosis of meningococcaemia arise in cases where it has no 
symptoms of meningitis, and may be mistaken for septicaemia of other etiology, throm-
bopenic purpura, and haemorrhagic vasculitis. It should be remembered that meningococcae-
mia is characterized by high temperature, pronounced intoxication, marked changes in the 
blood (hyperleucocytosis with the shift to the left); a stellar pattern of haemorrhagic eruption is 
typical. Accurate diagnosis is established bacteriologically. Meningococcus can be detected 
not only in the blood but also in the skin lesions. 
Prognosis. Despite the use of appropriate antibiotics, the mortality rate for disseminated 
meningococcal disease remains at 8–12 % and more. Poor prognostic factors include hypo-
thermia, hypotension, purpura fulminans, seizures or shock on presentation, leukopenia, 
thrombocytopenia, and high circulating levels of endotoxin and tumor necrosis factor. Some 
studies have included the development of petechiae within 12 hr of admission, hyperpyrexia, 
and the absence of meningitis. 
Treatment. Aqueous penicillin G is the drug of choice to treat meningitis and should be given 
in doses of 300000 - 400000 units per kg of body weight daily at intervals of three to four hours 
(infants under 3 months of age are given 400 000 - 500 000 U/kg). The treatment should be contin-
ued for 7-10 days without reducing the dose. 
Cefotaxime (200/mg/24 hr) and ceftriaxone (100 mg/kg/24 hr) are effective empirical 
therapy for meningococcal disease and may be useful in patients who are allergic to penicillin. 
A marked therapeutic effect can already be seen during the first two days. 
When to stop antibiotics therapy: 
- No fever for 5 days 
- Cerebrospinal fluid protein and sugar return to normal lev  els 
- Cell count in the cerebrospinal fluid is less then 30/mm3 and 70 % of than are lym-
phocytes. 
Children with meningococcemia can be given antibiotics of bacteriostatic action - laevo-
mycetin sodium succinate (50-100 mg/kg for 6-8 days) during first day of disease, simultane-
ously with big dozes of hormones.  
In addition to etiolotropic preparations, pathogenic and symptomatic therapies are also im-
portant. Toxicosis can be controlled by administration of large amounts of liquids (ample drink-
ing, intravenous infusion of physiological solution, glucose solution, plasma substitutes, and 
plasma); electrolyte balance and osmotic pressure should be taken into consideration. Dehydra-
tion therapy should be especially intensive in the presence of brain swelling (respiratory ar-
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rhythmia, convulsions, cyanosis, and arterial hypertension). Corticosteroids should be given 
simultaneously. Osmotic diuresis – 0.5 gm/kg of 20 % mannitol is administered every 4 hours. 
Seduxen, aminazine, phenobarbital, sodium oxybutyrate are given in the presence of 
convulsions. Vitamins should also be given. To correct metabolic acidosis, a 4 per cent so-
dium bicarbonate solution should be given to the patient; hypokalaemia can be corrected by 
potassium preparations (7.5 % potassium chloride solution, panangin). To improve the car-
diovascular function ATP, and cocarboxylase are indicated. 
The patient needs adequate care and supervision, and good nutrition. Grave forms of 
meningococcal infection require urgent aid and should be treated at resuscitation and intensive 
therapy departments. 
Prophylaxis. The following measures are carried out in an epidemic focus. The patient is 
hospitalized and isolated; he is discharged after the clinical manifestations of the disease sub-
side and two negative results of bacteriological studies of the pharyngeal mucus.  
Child contacts and exposed adults are quarantined (isolated at home). Only after a nega-
tive bacteriological report (examination of nasopharyngeal discharge) or after 7 days of sepa-
ration from the patient they admitted to children's institutions. 
It is advisable that contacts should be treated with sulphonamides or antibiotics (Ri-
fampin) for 5 days as a prophylactic measure, the standard dose being given. 
A quadrivalent vaccine composed of capsular polysaccharide of meningococcal groups 
A, C, Y, and W-135 is licensed in the United States. The vaccine is immunogenic in adults 
but is unreliable in children under 2 yr of age. The group B polysaccharide is poorly immuno-
genic in children and adults, and no vaccine is available against this serogroup. 
Immunization is useful to control outbreaks of meningococcal disease of the serogroups 
represented in the quadravalent vaccine. It is also recommended for travelers to countries with 
a high incidence of meningococcal disease. Individuals with anatomic or functional asplenia 
and those with complement component deficiencies should be immunized. 
 
PART 11   WHOOPING-COUGH (pertussis) 
 
The causative agent of whooping cough is the Bordet-Gengou bacillus Haemophi-
lus (Bordetelld) pertussis, discovered in 1906, a small, ovoid, non-motile rod 0.5 to 2.0 
urn long, gram-negative, strictly aerobic, and haemoglobinophilic. It grows best on a 
potato-glycerol blood agar (Bordet-Gengou culture medium). Other nutrients, how-
ever, particularly casein-carbon agar medium, are now widely used. When cultured, 
the bacillus forms small, round, lustrous colonies resembling drops of mercury. Its 
resistance is very low. B. pertussis and B. parapertussis are exclusive pathogens of 
humans (and some primates). B. bronchiseptica is a common animal pathogen. 
Sydenham first used the term pertussis (intense cough) in 1670; it is preferable to 
"whooping cough" since most infected individuals do not whoop. The most closely stud-
ied factors of the microbial cell evoking a response in the organism are agglutinogen 
(allergen), toxin, and haemagglutinin. 
Epidemiology. During the prevaccine era of 1922 - 1948, pertussis was the leading 
cause of death from communicable disease among children under 14 yr of age. 
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The source of infection in whooping-cough is a sick person. The disease is particularly 
infective in the initial stage, but gradually becomes less contagious. Patients continue to 
discharge H. pertussis up to the 28-30th day, and very rarely a little longer. Treatment with 
antibiotics shortens the period of infectivity. 
Susceptibility to whooping cough is high, but not as high as to measles (in non-
immune group the index of susceptibility is 0.7). Its heaviest incidence is in children 
between one and five, but unlike other infections it very often affects very young chil-
dren not sparing babies of a few months or even a few days old. Pertussis is extremely 
contagious, with attack rates as high as 100 % in susceptible individuals exposed to 
aerosol droplets at close range. B. Pertussis does not survive for prolonged periods in 
the environment. Chronic carriage by humans is not documented.  
Neither natural disease nor vaccinations provide complete or lifelong immunity 
against reinfection or disease. Protection against typical disease begins to wane 3–5 yr 
after vaccination and is unmeasurable after 12 yr. Subclinical reinfection undoubtedly 
contributes significantly to immunity against disease ascribed to both vaccine and 
prior infection.  
Patients with abortive forms and patients with asymptomatic forms of whooping-
cough (actually carriers) can also be sources of infection. It must be supposed that the 
absence of cough in carriers sharply reduces their infectivity. 
Infection is transmitted by the aerial-droplet route, but is possible only by direct, 
more or less lengthy, contact with a patient. Isolation of patient in separate wards or 
semicubicles, therefore, prevents dissemination of infection. Transmission via objects 
or intermediaries occurs only in exceptional cases owing to low viability of the causa-
tive agent. 
The high susceptibility of children and unfavourable housing and living conditions 
(overcrowding, for example) are conducive to epidemic spread of the infection. Regu-
lar and constant seasonal variations in its incidence are not characteristic, but either a 
spring-summer or a winter peak in the epidemic wave may occur depending on condi-
tions. 
Pathological anatomy. The commonest lesions are in the respiratory organs. 
Laryngoscopy reveals catarrh of the larynx and trachea during the catarrhal stage. This 
picture of common catarrh of the larynx, trachea, and bronchi is a postmortem finding 
at patients dying during the paroxysmal stage, and only in rare, particularly severe, and 
complicated cases is there superficial epithelial necrosis in the respiratory tract. There 
is the spastic condition of the bronchial muscles. Atelectases and microfocal and con-
fluent bronchopneumonia are apt to occur, but the pulmonary lesions have no features 
of any kind specific to whooping-cough. There is marked derangement of the blood 
and lymph circulation (lymphostasis and haemostasis). Congestion of the pulmonary 
circulation, dystrophic changes of the myocardium, and dilatation of the right ventricle 
of the heart with hypertrophy of its walls are not uncommon. A constant postmortem 
finding is lesions of the nervous system: the disturbance of circulation expressed 
mainly in marked dilatation of cerebral capillaries and oedema of the brain; haemor-
rhages into the brain matter are not uncommon. 
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Pathogenesis. The portal of entry of infection in whooping cough is the upper respira-
tory tract. H. Pertussis settles in the mucous membrane of the larynx, bronchi, and bronchi-
oles, and also in the pulmonary alveoli, but no bacteriaemia or penetration of the causative 
agent into the organs and tissues occurs. 
Only B. pertussis expresses pertussis toxin (PT), the major virulence protein. Sero-
typing is dependent upon heat-labile K agglutinogens. Of 14 agglutinogens, 6 are spe-
cific to B. pertussis. Serotypes vary geographically and over time. 
B. Pertussis produces an array of biologically active substances, many of which 
are postulated to play a role in disease and immunity. Following aerosol acquisition, 
filamentous hemagglutinin (FHA), some agglutinogens (especially FIM2 and FIM3), 
and a 69-kD nonfimbrial surface protein called pertactin (PRN) are important for at-
tachment to ciliated respiratory epithelial cells. Tracheal cytotoxin, adenylate cyclase, 
and PT appear to inhibit clearance of organisms. Tracheal cytotoxin, dermonecrotic 
factor, and adenylate cyclase are postulated to be predominantly responsible for the 
local epithelial damage that produces respiratory symptomatology and facilitates ab-
sorption of PT. PT has multiple proven biologic activities (e.g., histamine sensitivity, 
insulin secretion, leukocyte dysfunction), some of which may account for systemic 
manifestations of disease. 
The principal pathogenic factor is the toxin produced by H. pertussis, which brings 
the cough reflex into play by its intense irritation of the nervous receptors of the respi-
ratory mucosa. Toxin absorbed into the blood, on the other hand, has general effect 
(chiefly on the nervous system), expressed in marked tendency to generalized vascular 
spasm (arterial hypertension), spasm of the small bronchi and vocal cords, and in 
spasmodic twitching or even attacks of clonicotonic convulsions of the skeletal mus-
cles.  
The mechanism of one of the chief symptoms of whooping-cough the paroxysmal 
bouts of coughing is most fully and convincingly explained by the conception advanced 
by A. Dobrokhotova, I. Arshavsky, and V. Soboleva. Its essence is as follows. The con-
tinuous flow of impulses coming from receptors in the mucosa of the respiratory tract 
leads to the development of a stable focus of excitation in the central nervous system, 
characterized by signs of dominance by A. Ukhtomsky. Formation of this focus is ap-
parently aided by the effect of pertussis toxin upon the central nervous system already 
mentioned. Paroxysms of coughing result, therefore, not only from impulses arriving 
from the respiratory tract, but also in response to stimulation of receptor regions not con-
nected with the cough reflex; a fit can be provoked, for example, by examination of the 
throat, injections, or a loud noise, etc. Owing to the inert character of the dominant focus, 
paroxysms can persist for a long time after recovery from the infection. The dominant 
focus becomes inhibited when other, stronger centres of excitation arise. This mecha-
nism is probably responsible for the absence of fits of coughing during absorbing, inter-
esting games. The cough, being an unconditioned reflex action, can become established 
as a conditioned reflex action as the disease develops. A paroxysm may be provoked, for 
example when the doctor visits the ward or by the sight of a spatula, etc. 
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As a result of the frequent and prolonged paroxysms of coughing, and of the circu-
latory disturbances in the lungs, pulmonary ventilation becomes disturbed leading to 
hypoxaemia and hypoxia. When the latter develops, a major role is probably played 
by the lesions to the capillary wall (disturbance of its permeability) caused by the per-
tussis endotoxin. Such symptoms of the nervous system as convulsions are apparently 
associated with disturbed cerebral circulation and with the hypoxaemia resulting from 
reduced pulmonary ventilation; but a direct effect of the pertussis toxin on the central 
nervous system may also be responsible for their development. Inadequate supply of 
oxygen to the tissues, and disruption of oxidation processes, leads to the development 
of acidosis, while hypoxia and acidosis in turn aggravate the disturbed function of the 
nervous system. 
Secondary flora (pneumococcus, streptococcus, etc.) plays a major role in the de-
velopment of complications, which are particularly frequent when whooping-cough is 
combined with other infections, e.g. influenza, catarrh of the upper respiratory tract, 
measles or dysentery. 
Clinical picture. The incubation period of whooping-cough is 3 to 15 days and aver-
ages 5 to 8 days. The course of the disease can be divided into three stages: catarrhal, par-
oxysmal, and convalescent. 
The first, catarrhal stage is attended with a moderate rise in temperature, but the latter 
may sometimes be subfebrile, or even normal. Significant fever (above 39°C) is rare. A 
dry cough with no specific features develops in the first days. This symptom intensifies 
gradually, becoming the leading one in the clinical picture of the disease. By the end of 
the catarrhal period the cough takes on the character of more or less prolonged paroxys-
mal bouts, occurring mostly at night. Cold in the nose is also often noted during the ca-
tarrhal stage, but the patient's general state is not much disturbed, if at all. Appetite is 
normal. The catarrhal stage lasts for three to fourteen days, but may sometimes be 
shorter, especially in nursing babies. In other cases, on the contrary, it may be protracted. 
The transition to the second, paroxysmal stage is gradual. Fits of spasmodic or con-
vulsive coughing develop. At the height of the disease paroxysms are unmistakable; they 
begin suddenly, or after a brief precursor (aura)—a feeling of irritation in the throat, pres-
sure in the chest. The fit consists of a series of short coughs following one another in 
rapid succession without a break. Then the child makes an inspiration which, owing to 
laryngeal spasm, is accompanied with a crowing sound (whoop). The paroxysm is then 
repeated in the form of the same successive spells with a subsequent whoop. There may 
be several whoops during a bout. The more severe the whooping-cough, the more pro-
longed are the paroxysms and the greater the number of whoops. A bout often ends in 
expectoration of viscid, transparent mucus and sometimes vomiting. In severe fits the 
mucus may be bloodstained. Vomiting, however, is not an absolutely constant sign, but 
the more severe the whooping-cough, the more often it occurs. In mild forms there may 
be only occasional or no vomiting. Whoop (forceful inspiratory gasp) infrequently oc-
curs in infants under 3 mo that are exhausted or lack muscular strength to create sudden 
negative intrathoracic pressure. The outward appearance of the patient during a fit is 
characteristic. The face becomes red or even takes on a cyanotic hue; the cervical veins 
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become engorged; the eyes are injected and filled with tears; the tongue is forcibly pro-
truded to the limit, and it’s tip curves upward; and in severe bouts urine and faeces may 
be involuntarily passed. 
Adults describe a sudden feeling of strangulation followed by uninterrupted 
coughs, feeling of suffocation, bursting headache, diminished awareness, and then the 
chest heaves and air rushes into the lungs, usually without a whoop. Post-tussive eme-
sis is common in pertussis at all ages and is a major clue to the diagnosis in adoles-
cents and adults. Post-tussive exhaustion is universal. 
Various external stimuli (examination of the throat, dressing and undressing, feed-
ing, a loud noise, the crying of children, etc.) can provoke a fit. Many clinicians have 
noted that bouts occur mostly at night. For diagnostic purposes a fit of coughing can 
be provoked by pressing against the larynx and or by pressing the root of the tongue 
with a spatula. 
As a result of frequent paroxysms accompanied with disturbed circulation and 
congestion, the patient's face and eyelids become swollen, and haemorrhages some-
times appear in the skin and conjunctiva. In severe cases the oedema also involves the 
whole body, particularly the lower limbs. 
When the oral cavity is examined a shallow ulcer on the frenulum of the tongue is 
found, which soon becomes covered by a white protruding film. The ulcer results 
from mechanical rubbing of the frenulum against the sharp edges of the lower inci-
sors. 
In uncomplicated whooping-cough general condition is not disturbed in most pa-
tients, even when bouts are frequent, so that children lead their normal life playing 
between attacks; their appetite is not impaired. Temperature, which rises moderately 
in the catarrhal stage, usually falls to normal in most patients by the time coughing fits 
begin; only slight subfebrile elevations occasionally occur. Marked pyrexia during the 
paroxysmal stage is usually indicative of a complication. 
Signs of emphysema are often found during examination of the lungs. Auscul-
tation reveals dry and dull moist rales. Heightened transradiancy of lung tissue, low 
position and flatness of the diaphragm (signs of emphysema), increased shadow of 
hili, intensified pulmonary pattern, and reticulations or linear bands are revealed by X-
ray examination. Sometimes, mostly in older children, a shadow is distinguished in the 
form of a triangle, with its base on the diaphragm and the apex in the region of the 
hilus ('a basal triangle'). In the cardiovascular system an acceleration of pulse is noted 
during paroxysms, and an elevation of arterial and venous pressure. Capillary resis-
tance is reduced, which encourages haemorrhages into the skin and mucous mem-
branes. Signs of the nervous system involvement are irritability, in severe case inert-
ness, adynamia, disturbed sleep, convulsive twitching of the facial muscles, and some-
times dimmed consciousness. 
In the overwhelming majority of patients’ blood counts reveals marked leucocyto-
sis and lymphocytosis. The number of leucocytes may reach 20•109/1-70•109/1 and 
over. The leucocytosis to some extent depends on the severity of the disease: as a rule, 
the more serious the case, the higher the leucocyte count. The ESR is either lowered or 
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normal. These haematological shifts are already met in the catarrhal stage, and disap-
pear as the infectious process is overcome. The paroxysmal stage lasts from two to 
eight weeks. The frequency and severity of attacks gradually diminish as the disease 
passes into the third stage. 
During convalescence the cough is no longer paroxysmal and bouts gradually be-
come less frequent. The sputum becomes mucopurulent. As paroxysmal stage fades 
into convalescence, the number, severity, and duration of episodes diminish. All 
symptoms of the disease subside gradually. This stage lasts from two to four weeks, so 
that the overall duration of the disease varies between five and twelve weeks and even 
more protracted cases have been observed. 
Clinical forms. Three principal forms of whooping-cough are distinguished: mild, 
moderate, and severe. In the mild form the frequency of coughing fits is between five 
and fifteen a day; they are typical, but short, and only rarely end in vomiting. The pa-
tient's condition is undisturbed. In the moderate form the number of fits varies be-
tween 15 and 24; they are protracted, with 5-10 whoops, and often end in vomiting. 
The patient feels unwell, but is not seriously ill. In the severe form, there are numerous 
bouts of coughing (25 to 30, or more, a day). Paroxysms are severe and last up to 15 
minutes, with ten whoops, and almost always terminate in vomiting. Disturbed sleep, 
loss of appetite, loss of weight, adynamia and often a long febrile state are noted. In 
young children, even with a moderate frequency and short duration of fits, whooping-
cough can take a very serious course. 
An abortive form of pertussis, characterized by the absence of typical attacks with 
coughing relapses, and by a shortened course, often occurs in recent years in addition 
to the three main forms of the disease. These forms occur mostly in vaccinated chil-
dren.  
The course of whooping-cough in vaccinated children is usually mild or abortive, 
if compared to the unimmunized; complications are less common, haematological 
shifts are less pronounced, and the outcome is more favourable. Immunized children 
have foreshortening of all stages of pertussis. Adults have no distinct stages. 
In infants under 3 mo the catarrhal phase is usually a few days or not recognized at 
all when apnea, choking, or gasping cough herald the onset of disease. Convalescence 
includes intermittent paroxysmal coughing throughout the 1st yr of life including "re-
currences" with subsequent respiratory illnesses; these are not due to recurrent infec-
tion or reactivation of B. pertussis. 
Diagnosis. The most important condition for effective control of whooping-cough 
is its recognition at the initial (catarrhal) stage, when it is most infective. But diagnosis 
at that stage presents considerable difficulties. It is also sometimes difficult to establish 
the diagnosis when the disease runs an atypical course, especially in babies a few 
months old. 
In diagnosis of whooping-cough the distinctive features of it’s clinical course must 
be considered - it’s cyclic character, paroxysmal bouts of coughing with whoops, end-
ing with expectoration of viscid mucus and vomiting, typical appearance of the pa-
tient, ulcer on the frenulum of the tongue, etc.; and also typical haematological shifts; 
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the results of X-ray examination of the chest and analysis of the epidemiological situa-
tion are also of value. 
Bacteriological tests can also be of great diagnostic aid, particularly during the early 
stage of whooping-cough. Testing for H. pertussis is usually done by means of 'cough 
plates': an open Petri dish of nutrient medium is held five to eight centimetres from the 
patient's mouth during a paroxysm. A sterile cotton tampon is now used to take the mate-
rial from the nasopharynx for examination for the pertussis bacillus. Microbiological 
studies are very valuable for diagnosis of pertussis. It should be noted that when pertussis is 
treated with antibiotic cultivation of the pertussis bacillus for diagnostic purpose is effective 
only in rare cases. To accelerate diagnosis, an immunofluorescence method is now rec-
ommended by which the pertussis microbe can be detected directly in the mucus taken 
from the nasopharynx. Agglutination and complement-fixation reactions have also been 
suggested. They are particularly convincing when repeated tests show increasing immu-
nological shifts. But these reactions only become positive from the second week of the 
paroxysmal stage; they are often negative in nursing babies. The reactions are thus mainly 
employed for retrospective diagnosis. 
The catarrhal stage of whooping-cough has to be differentiated from influenza, viral ca-
tarrhs of the upper respiratory tract, and measles. It is distinguished by less pronounced 
nasal and conjunctival catarrh and by more frequent nocturnal fits of coughing; another 
distinctive sign is marked by leucocytosis. It diners from measles, in addition, in the ab-
sence of enanthema, of Belsky-Filatov-Koplik spots, and of marked pyrexia. The parox-
ysmal stage of whooping-cough is mistaken at times 1) for tracheobronchitis, which is 
accompanied with persistent cough, sometimes followed by vomiting; 2) for tuberculous 
bronchoadenitis, which causes compression of the vagus nerve and of the inferior laryngeal 
nerves; and 3) for a foreign body in the upper respiratory tract, which can occasionally be 
responsible for attacks of suffocating cough. In contrast to whooping-cough, however, 
there is no progressive increase in the strength of paroxysms, no whoops, no ulcer on the 
frenulum of the tongue, and none of the haematological shifts characteristic of whooping-
cough. 
Complications. Increased intrathoracic and intra-abdominal pressure during coughing 
can result in conjunctival and scleral hemorrhages, petechiae on the upper body, epistaxis, 
hemorrhage in the central nervous system and retina, pneumothorax and subcutaneous em-
physema, and umbilical and inguinal hernias. Laceration of the lingual frenulum is not un-
common. Rectal prolapse, once reported as a frequent complication of pertussis, was probably 
due to pertussis in malnourished children or missed diagnosis of cystic fibrosis. 
Prognosis. The overwhelming majority of deaths occur among children under one 
year of age. The cause of death is pneumonia and, less frequently, convulsive fits. The 
outcome of whooping-cough is aggravated by concomitant diseases (tuberculosis, rickets, 
or dystrophy), and by other acute supervening infections (influenza, measles, dysentery, 
etc.). Central nervous system abnormalities (absent-minded, backward at school, and even 
very retarded mentally) occur at a relatively high frequency and are almost always the re-
sult of hypoxemia or hemorrhage associated with coughing or apnea in young infants. 
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Treatment. Properly organized regimen and nursing are very important in the treat-
ment of whooping-cough. Bed rest is called for only when there is fever and severe com-
plications. Cold fresh air has a wonderful effect on patients. Continuous open-air treatment 
improves pulmonary ventilation and oxygen exchange, and apparently also has a powerful 
reflex effect on the central nervous system. Paroxysms become fewer and weaker. In 
summer children should be outdoors for most of the day, and in winter for several hours 
each day. In winter walks can be made in places protected from the wind, but only if nasal 
respiration is free. Patients are allowed outdoors at temperatures not lower than minus 
10°C. Individual tolerance of fresh air and low temperatures naturally has to be considered, 
and care must be taken to avoid chilling. It is also necessary to ensure that the sick-room is 
freely ventilated. 
Much attention should be given to educational work among older children; their leisure 
should be organized, with various lessons and occupations, games, reading of stories, and 
so on. Coughing is less frequent in children absorbed in games. The fact that paroxysms 
usually cause vomiting, which greatly interferes with the assimilation of food, must be 
taken into account in feeding the patients. Calorie-rich digestible, concentrated food, with 
plenty of vitamins, is prescribed. Patients should be fed small portions shortly after a par-
oxysm; care must be taken to protect children after feeding from external stimuli that can 
provoke a paroxysm, such as various diagnostic and therapeutic manipulations, examina-
tion of the throat, etc. When vomiting does occur soon after a meal, feeding should be re-
peated. 
The specific, limited goals of hospitalization are to 1) assess progression of disease and 
likelihood of life-threatening events at peak of disease, 2) prevent or treat complications, 
and 3) educate parents in the natural history of the disease and in care that will be given at 
home. For most infants without complications, this is accomplished in 48–72 hr. Heart rate, 
respiratory rate, and pulse oximetry are continuously monitored, with alarm settings so that 
every paroxysm is witnessed by health care personnel. Detailed cough records and docu-
mentation of feeding, vomiting, and weight change provide data to assess severity. Typical 
paroxysms that are not life threatening have the following features: duration less than 45 
sec; red but not blue color change; tachycardia, bradycardia (not <60 beats/min in infants), 
or oxygen desaturation that spontaneously resolves at the end of the paroxysm; whooping 
or strength for self-rescue at the end of the paroxysm; self-expectorated mucus plug; and 
post-tussive exhaustion but not unresponsiveness. Within 48–72 hr, the direction and sever-
ity of disease is usually obvious by analysis of recorded information. Many infants have 
marked improvement following hospitalization and antibiotic therapy, especially if they are 
early in the course of disease or have been removed from aggravating environmental 
smoke, excessive stimulation, or a dry or polluted heat source. Apnea and seizures occur in 
the incremental phase of illness and in those with complicated disease. 
Antibiotics are successfully used today as a specific (aetiotropic) therapy of whooping-
cough. Antibiotics are indicated in grave and medium-grave forms of the disease, in the 
presence of complications, and in infants in whom the complications are especially grave. 
Erythromycin, ampicillin, tetracyclines given in the catarrhal or early spasmodic period 
decrease the number and gravity of fits, lessen the course of the disease, and its gravity. 
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Erythromycin is given per os, 5 000-10 000 U/kg, 3-4 times a day. Ampicillin is given per 
os or intramuscularly, 25-50 mg/kg, four times a day. The therapy should continue for 8-10 
days. Tetracyclines are given 25 000-30 000 U/kg a day, for 10-12 days. They produce a 
favourable effect on the course of the disease. If the symptoms recur after suspension of the 
therapy, it should be repeated.  
In order to attenuate the pertussis attacks, neuroplegics are recommended: aminazine, 
propazine. The ampouled solution of aminazine is given intramuscularly, 1-3 mg/kg; propaz-
ine is given per os, 2-4 mg/kg a day. The daily dose is given for three intakes; the course con-
tinues for 10-12 days. The frequency and gravity of attacks of coughing decrease; vomiting 
stops or becomes less frequent; the spastic condition of the vessels decreases. Many physio-
therapeutic procedures are recommended, such as U-V rays, calcium ionophoresis, diather-
mia, inhalation of negative aerosols with proteolytic enzymes, etc. Oxygen therapy (oxygen 
tent) is especially valuable in pertussis, in particular in infants and neonates with marked signs 
of hypoxia. 
Symptomatic therapy and the treatment of complications are on general lines. Intra-
muscular injections of a 25 per cent solution of magnesium sulphate, and intravenous injec-
tions of hypertonic glucose solution (producing dehydration) are prescribed, in addition to 
oxygen therapy, for convulsions. 
Pneumonia is widely treated with antibiotics (antibiotics of tetracycline series, erythromy-
cin, gara-mycin, etc.) and oxygen. Hormonal preparations (prednisolone) with an anti-
inflammatory, desensitizing effect are also recommended in severe pneumonia. Respiratory 
arrest calls for prolonged artificial respiration. 
Stimulating therapy (gamma-globulin injections, vitamins, etc.) is prescribed when the 
course of whooping-cough tends to be sluggish and protracted. It is advisable to send chil-
dren convalescing from a severe attack to a sanatorium for two to three weeks after they 
cease to be infectious. 
Prophylaxis. Measures to be taken in an epidemic focus. The earliest possible isolation 
of the patient is imperative. In practice diagnosis of whooping-cough is often established 
only when whoops appear, so that isolation is delayed, reducing its epidemiological value. 
Early diagnosis is therefore essential for the success of the anti-epidemic measures. The 
patient is usually left at home, and put in a separate room or behind a screen. The patient is 
placed in respiratory isolation for at least 5 days after initiation of erythromycin therapy. 
Erythromycin, 40–50 mg/kg/24 hr, orally in four divided doses (maximum 2 g/24 hr) 
for 14 days should be given promptly to all household contacts and other close contacts, 
such as those in day care, regardless of age, history of immunization, or symptomatology. 
Close contacts younger than 7 yr who are underimmunized should be given a pertussis-
containing vaccine, with further doses to complete recommended series. Children younger 
than 7 yr who received a 3rd dose 6 mo or more before exposure, or a 4th dose 3 yr or 
more before exposure, should receive a booster dose. If infection with B. pertussis is 
documented at any age, the individual is exempted from routine pertussis immunization 
Hospitalization is indicated in severe and complicated forms of whooping-cough, par-
ticularly in children under two years of age, children from families living in poor condi-
tions, and from families where there are babies under six months of age that have not had 
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the disease. Patients are isolated for 30 days from the onset of the disease. The organization 
of the hospital regimen requires special attention. Patients must be carefully protected 
against secondary hospital infection, which is often the cause of exacerbations and compli-
cations. 
The quarantine period for unimmunized contacts under seven years of age that have 
not had whooping-cough is 14 days from the time of isolation of the patient. If the latter has 
not been isolated, and contact with him continued during the whole period of the disease, 
quarantine is imposed until the patient ceases to be infective. There is no need in complete 
terminal disinfection of the premises after isolation of a patient, because the causative agent 
is not viable and perishes rapidly; but thorough ventilation of the premises and disinfection 
of handkerchiefs, towels, and dishes are necessary. Favourable results have been obtained 
through prophylactic use of gamma-globulin, particularly of specific antipertussis gamma-
globulin with a high antibody content (3 to 6 ml twice, at an interval of 48 hours). 
Prevention. Universal immunization of children with pertussis vaccine, beginning in 
infancy, is central to the control of pertussis. 
Whole Cell Vaccine. The vaccine currently used for primary immunization recom-
mended by the World Health Organization for use throughout most of the world is a killed 
whole cell vaccine composed of a suspension of inactivated B. pertussis, combined with 
diphtheria and tetanus (DT) toxoids and aluminum-containing adjuvants (DTP vaccine). 
Vaccine potency is translated to opacity units (also a safety standard) or protective units. 
U.S. preparations contain 4–12 protective units and not more than 16 opacity units per 0.5-
mL dose. Efficacy of whole cell vaccine varies by case definition from 64 % for mild 
cough, to 81 % for paroxysmal cough, and to 95 % for severe clinical illness. Individuals 
over 7 yr of age are not routinely given pertussis-containing vaccine. When used in adults 
to control a hospital outbreak, whole cell vaccine was found to be less reactogenic than 
reported in children. 
Acellular Vaccine. Purified component acellular pertussis (aP) vaccines, originally de-
veloped in Japan, are immunogenic and associated with fewer adverse events when com-
pared with DTP. Vaccines provided by six manufacturers have been used exclusively in 
Japan since 1981, and their use has controlled pertussis. 
 
PART 12   ACUTE RESPIRATORY VIRAL INFECTIONS 
Influenza 
Influenza viruses are classified as Orthomyxoviridae. It contains ribonucleic acid 
(RNA). The influenza virus perishes rapidly outside the human organism and is very 
sensitive to the action of disinfectants, heating, ultra-violet rays, and desiccation. Three 
different types of the virus are known (A, B and C). Each type has several serological 
varieties. It is especially characteristic of influenza A virus and shows itself in varia-
tion of its surface antigens: haemagglutinin (H) and neuraminidase (N). Potentially 
any of 13 hemagglutinins and 9 neuraminidases residing in animal reservoirs may be 
introduced into humans. When a virus identified by a novel and serologically distinct 
hemagglutinin or neuraminidase enters the population, there is potential for a pan-
demic of influenza with excess morbidity and mortality on a global scale in a largely 
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nonimmune population. The most dramatic pandemic in recent history occurred in 
1918 when influenza was estimated to have killed more than 20 million people. Influ-
enza B has a lesser capacity for major antigenic change and no identified animal res-
ervoir. 
Epidemiology. The source of infection is the patient, who is particularly infective. 
It the height of the disease, during pyrexia. The contagious period lasts for four to 
seven days. Infection is chiefly conveyed by the aerial-droplet route. The susceptibility 
of man to influenza is very high, practically universal. Children are very susceptible to 
influenza from six months of age. Immunity against influenza A is effective in man 
for about two years, and against influenza B, three years.  
Pathological anatomy. Influenza causes a lytic infection of the respiratory epithe-
lium with loss of ciliary function, decreased mucus production, and desquamation of 
the epithelial layer. These changes permit secondary bacterial invasion. The pulmo-
nary tissue is readily involved in the inflammatory process and segmental oedema, 
focal and segmental (sometimes con- fluent) pneumonia with involvement of the in-
terstitial tissue develop. Influenza is attended by pronounced circulatory disorders in 
various organs, the lungs and the brain included: markedly excessive blood supply, 
vascular stasis, small haemorrhages. When influenza type B is accompanied by the 
administration of salicylates, the fatty liver, cerebral edema, and mitochondrial 
changes that are the hallmarks of Reye syndrome can be seen. 
Pathogenesis. The pathogenicity of the influenza virus is mainly expressed in its 
epitheliotropicity and toxicity. Toxaemia is a typical clinical feature of influenza, and 
is much more common in this disease. 
The virus attaches to sialic acid residues on cells via the hemagglutinin and, via 
endocytosis, makes its way into vacuoles, where, with progressive acidification, there 
is fusion to the endosomal membrane and release of the viral RNA into the cytoplasm. 
The RNA is transported to the nucleus and transcribed. Newly synthesized RNA is 
returned to the cytoplasm and translated into proteins, which are transported to the cell 
membrane. This is followed by budding of virus through the cell membrane. The 
packaging mechanisms for the segmented genome are not well understood. A prote-
olytic cleavage of the hemagglutinin occurs at some point in the assembly and release 
of the virus which is essential for successful reinfection and amplification of virus 
titer. 
The places most affected by the toxic action of the virus are the nervous system 
(central and vegetative) and blood vessels. A central place in the pathogenesis of in-
fluenza is taken by circulatory disturbances associated with lesions of the vegetative 
innervation and vascular system, disturbances that play a cardinal role in causing func-
tional derangement of the nervous system and pulmonary complications. Secondary 
bacterial flora invading the primary viral lesions can aggravate and prolong the course 
of the primary viral disease. 
The extremely short incubation period of influenza and its growth on the mucosal 
surface pose particular problems for invoking a protective immune response. Muco-
sally produced immunoglobulin (Ig) A antibodies are presumably directed at the same 
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antigenic sites and are thought to be the most effective and immediate response that 
can be generated to protect against influenza. 
Clinical picture. The incubation period of influenza is one or two days, but may 
sometimes be as short as a few hours. The onset of illness is abrupt and is marked by 
coryza, conjunctivitis, pharyngitis, and dry cough, with elevation of temperature and 
chill. The febrile reaction may vary according to the severity of the disease; the tem-
perature may be high (39-40°C and over), but may remain subfebrile when the course 
of the disease is mild. General toxaemia is characteristic, and is mainly expressed in 
symptoms of involvement of the central nervous system, namely strong headache, 
vertigo, hyperaesthesia, adynamia, and sleepiness or, on the contrary, excitation. High 
fever is often accompanied with dimmed consciousness, delirium, and hallucinations. 
Muscular and neuralgic pain is frequent. Vomiting, convulsions and loss of con-
sciousness (cerebral syndrome), and a syndrome of meningism are not uncommon in 
young children. Nursing babies stop gaining weight before the onset of influenza. 
Influenza toxaemia also produces marked changes in the cardiovascular system. A 
brief period of hypertension is followed by a fall of arterial pressure, tachycardia or 
bradycardia, arrhythmia, diminished heart sounds, and sometimes by cyanosis. Col-
lapse occurs in severe cases. There may be haemorrhage into the conjunctiva and mu-
cous membranes owing to involvement of capillaries. Epistaxis is not uncommon. 
Catarrhs of the upper respiratory tract are not constant in influenza, they are absent in 
20 - 30 % of the cases. But in the majority of patients, they (along with toxaemia) are 
the leading and appear from the first day. In others they develop on the second or third 
day. Signs of catarrh of the upper respiratory tract are the following: cold, dryness and 
irritation in the fauces, a dry cough, and not infrequently hoarseness and dyspnoea. 
The nasopharyngitis arising in nursing babies disturbs respiration considerably, and 
inhibits sucking; their appetite is poor, they sleep badly and lose weight. Laryngitis is 
sometimes encountered, most frequently in children under two years of age. In some 
cases influenza laryngitis is accompanied with stenosis. 
Croup in influenza patients develops mostly in infancy as a result of oedema of the 
laryngeal mucosa and the spasm of the laryngeal muscles. Its signs and course differ 
from those of diphtheric croup. In most cases its onset is sudden. Voice is normal or 
only slightly hoarse, coughing is loud, coarse and barking. Signs characteristic of la-
ryngeal stenosis develop: noisy respiration (especially during the inspiration), depres-
sions in the yielding parts of the chest, tension of the auxiliary respiratory muscles. In 
contrast to diphtheric croup, the croup attending influenza and also other respiratory 
viral infections is characterized by mild signs of laryngeal stenosis. Because of the 
absence of cyclic character, stages of laryngeal stenosis, rather than stages of croup, 
like in diphtheritis, are differentiated: I and II degrees are characterized by moderate or 
weak signs and the absence of respiratory insufficiency; III degree is characterized by 
permanent intense signs of marked stenosis and symptoms of respiratory insufficiency 
(cyanosis, drop of pulse at the height of the inspiration, restlessness of the patient); IV 
degree is characterized by a grave respiratory insufficiency, general cyanosis, and 
cardiovascular insufficiency. 
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Herpes may develop in some patients. The fauces are often hyperaemic. The 
granular character of the mucous membrane of the soft palate. 
Blood findings are typical for virus infection. 
Three main forms of influenza are distinguished according to the principal clinical 
syndromes reflecting the clinico-pathogenic nature of the disease. They are as follows: 
(a) toxic (and a subtoxic variant), (b) catarrhal, and (c) toxico-catarrhal. Additional 
syndromes may supplement the characteristic features of each of these forms (with  
Influenza may also be distinguished as mild, moderately severe, and severe accord-
ing to the gravity of its course. The syndromes of encephalopathy, meningism, hemor-
rhage accompany severe form. 
A variety of mild influenza is the abortive form; patients are ambulant, and it is 
therefore of great epidemiological significance. 
Complications. Pneumonia is a common and dangerous complication that de-
velops either during the first days of the disease or later, when it is the result of mixed 
viral-bacterial infection. Pleura may become implicated with resultant fibrinous or 
purulent pleurisy caused by secondary bacterial flora (mostly staphylococcus). Ab-
scesses of the lungs are sometimes the outcome of pneumonia. Various complications 
involving the nervous system, such as neuralgia, neuritis, or radiculitis, may occur. 
Clinical syndromes of encephalitis, meningoencephalitis, and purulent meningitis (the 
latter due to secondary infection) are occasionally met. Catarrhal otitis is not uncom-
mon in children. Other complications (highmoritis, ethmoiditis, sphenoidi-
tis).stomatitis, purulent otitis, pyelitis, cystitis, nephritis, keratitis, phlebitis, etc.) may 
also occur. 
Diagnosis and differential diagnosis. Typical signs of influenza are its acute onset, 
marked toxaemia, frequent catarrhs of the respiratory tract, and leucopenia following a 
transitory initial leucocytosis. 
Rapid diagnostic tests for influenza A are being introduced that use antigen cap-
ture in an enzyme-linked immunosorbent assay format. The diagnosis can be con-
firmed serologically with acute and convalescent sera drawn around the time of illness 
and tested by hemagglutination inhibition. 
Intoxication in para-influenza and respiratory syncytial and adenoviral infections is 
less pronounced, whereas the catarrh of the airways is more marked. Adenoviral infec-
tion is also characterized by a gradual onset, the presence of symptoms of pharyngitis, 
conjunctivitis and swelling of the cervical and submandibular lymph nodes. The lower 
respiratory ducts are often involved in the respiratory syncytial infection (bronchitis, 
bronchiolitis); the larynx becomes involved in para-influenza. 
Epidemiological data can be of great assistance, i.e. whether the same illness has 
occurred in the child's family or in the institution it attends. Diagnosis is much easier, 
of course, during an epidemic. 
The serological reactions are performed twice. A four-fold (or greater) increase of 
antibody titre is considered diagnostic. Immunofluorescent method is now being widely 
employed in clinical practice. 
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Prognosis. The outcome of influenza depends above all on the resistance of the 
organism. The course of the disease is most severe and has its highest mortality in 
infants, in children suffering from hypotrophy and with chronic infections.  
Treatment. Strict bed rest should be enjoined for children during the whole period 
of illness. The sick-room should be regularly and thoroughly ventilated. Warm or hot 
drinks are prescribed. Human leucocytic interferon is recommended for treatment of 
influenza. When there is a danger of complications from secondary bacterial infection in 
severe cases, it is advisable to prescribe antibiotics. 
In serious cases hormonal preparations are used. Vikasol, rutin and calcium prepara-
tions are given in haemorrhagic syndrome. To bring about dehydration in patients with a 
cerebral syndrome (racking headache, vomiting, convulsions, loss of consciousness), 
intramuscular injections of a 25 per cent solution of magnesium sulphate and diuretics 
are given as well as hypertonic glucose solution. 
Prophylaxis. The most important general sanitary-prophylactic measure during an 
influenza epidemic is the organization of a proper regimen and hygiene of children's 
institutions. 
In the presence of immediate danger of infection with influenza (e.g. in an epi-
demic focus), prophylactic use of interferon and 0.25 per cent oxolin ointment are 
recommended intranasal. 
The split-virus vaccine is recommended for children younger than 12 yr. Two 
doses of vaccine are recommended for primary immunization of children younger 
than 8 yr. The dosage is divided in half to a volume of 0.25 mL for children younger 
than 3 yr. Live, attenuated intranasally administered vaccines are in clinical trials and 
have been demonstrated to have an efficacy comparable to that of inactivated vaccine. 
Their ease of administration could serve to increase their use. The vaccination is car-
ried out 2-3 months before the expected epidemic rise. 
 
Para-influenzal infection 
According to the literature para-influenza accounts for between 10 to 30 per cent and 
over of the total number of viral respiratory illnesses in children. Viruses in the parain-
fluenza family are common causes of respiratory illness in infants and young children. 
They cause a spectrum of upper and lower respiratory tract illnesses, but are particularly 
associated with laryngotracheitis, bronchitis, and croup. 
The causative agents are para-influenza or haemadsorbing viruses (Myxouiruses 
parainfluenzae) They contain ribonucleic acid (RNA) Four serological types (1, 2, 3, 
and 4) are known. The major antigenic moieties are envelope spike proteins that ex-
hibit hemagglutinating (HN protein) and cell fusion (F protein) properties. 
Epidemiology. Infection is conveyed from a sick person by the aerial-droplet 
route. Type 3 is endemic and can cause disease in the infant younger than 6 mo. Types 
1 and 2 are more seasonal. They occur in the summer. Parainfluenza type 4 is more 
difficult to grow in tissue culture; thus, its epidemiology is less well defined. However, 
it does not appear to be a major cause of illness. 
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Clinical picture. Incubation continues for 3-4 days (from 1 to 7 days). The parain-
fluenza viruses account for 50 % of hospitalizations for croup and 15 % of cases of 
bronchiolitis and pneumonia. Parainfluenza type 1 causes more cases of croup, 
whereas parainfluenza type 3 causes a broad spectrum of lower respiratory tract dis-
eases. The onset of the disease is less acute than in influenza. The temperature eleva-
tion is moderate and in uncomplicated cases it persists only for 2-5 days. Laryngitis or 
laryngotrachitis is typical of para-influenzal infection. It shows in dry coarse cough 
and a slight or moderate coarseness of the voice. It attended by symptoms of the la-
ryngeal stenosis (the picture of croup). Croup develops in para-influenzal infection of 
any type. Stenotic phenomena (depression of the yielding parts of the chest during 
inspiration, tension of the respiratory muscles, etc.) are moderate. Para-influenzal 
rhinitis tends to a protracted course. It can persist for two weeks. Pneumonia is the 
most frequent complication of para-influenza in infants. 
Diagnosis. Direct immunofluorescent staining has been used in some centers to 
identify infected cells in secretions rapidly. 
In contrast to influenza, the onset of para-influenza is less acute. The intoxication symp-
toms are absent or only slightly pronounced, the catarrhal symptoms are more pronounced, 
frequent laryngeal affections are typical. The diagnosis becomes less difficult in epidemic 
outbreaks. Laboratory diagnosis is based on isolation of para-influenza viruses from naso-
pharyngeal washings and on serological methods. 
Epiglottitis is characterized by a fulminating course of high fever, sore throat, 
dyspnea, rapidly progressive respiratory obstruction, and prostration, although respira-
tory distress is frequently the first manifestation. Within a matter of hours, it may pro-
gress to complete obstruction of the airway and death unless adequate treatment is 
provided. With adequate treatment, the illness rarely lasts for more than 2–3 days. 
Often the child, particularly the younger patient, is apparently well at bedtime but 
awakens later in the evening with high fever, aphonia, drooling, and moderate or se-
vere respiratory distress with stridor. Usually no other family members are ill with 
acute upper respiratory disease. The older child often complains initially of sore throat 
and dysphagia. Severe respiratory distress may ensue within minutes or hours of the 
onset, with inspiratory stridor, hoarseness, brassy coughs (less commonly), irritability, 
and restlessness. Drooling and dysphagia are common. The neck may be hyperex-
tended, although other signs of meningeal irritation are absent. The older child may 
prefer a sitting position, leaning forward, with the mouth open and the tongue some-
what protruding. Some children may progress rapidly to a shocklike state character-
ized by pallor, cyanosis, and impaired consciousness. 
 
Respiratory syncytial infection (RS-viral infection) 
It belongs to the family Paramyxoviridae, along with parainfluenza, mumps, and 
measles viruses but is classified in a separate genus: the pneumoviruses. It contains 
RNA. Two serotypes of the RS-virus are now distinguished. Respiratory syncytial 
virus (RSV) is the major cause of bronchiolitis and pneumonia in infants younger than 
1 yr. It is the most important respiratory tract pathogen of early childhood. 
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Epidemiology. The occurrence of annual outbreaks and the high incidence of infec-
tion during the first months of life are unique among human viruses. The source of infec-
tion is a sick person. The infection is spread by the aerial-droplet route. The patient re-
mains contagious probably for 5-7 days. The susceptibility to the RS infection is very 
high. Most infants fall ill during their first two or four years of life. Seasonal variations 
are quite marked: the highest incidence occurs in the cold seasons. 
Pathology and pathogenesis. Bronchiolitis is characterized by virus-induced necrosis 
of the bronchiolar epithelium, hypersecretion of mucus, and round cell infiltration and 
edema of the surrounding submucosa. These changes result in formation of mucous plugs 
obstructing bronchioles with consequent hyperinflation or collapse of the distal lung tissue. 
In interstitial pneumonia, infiltration is more generalized, and epithelial necrosis may ex-
tend to both the bronchi and the alveoli. Infants are particularly apt to experience small 
airway obstruction because of the small size of the normal bronchioles. 
Clinical picture. The incubation period lasts for 3 to 7 days (5 days on the aver-
age). The onset is usually gradual, with affections of the upper and lower respiratory 
tracts. The affection of the upper airways is manifested by rhinitis with scanty serous or 
seromucous discharge, cough, sometimes hoarse voice. Lower respiratory tracts are very 
frequently involved in infants (especially in nurslings under one year of age). A picture 
of diffuse bronchitis and bronchiolitis is observed. Bronchiolitis is characterized by a 
strong dyspnoea of the mixed type with prevalence of difficult expiration. Marked asth-
matic syndrome is not infrequent. The examination of the lungs reveals fine or medium 
bubbling rales and symptoms of emphysema. The picture of respiratory insufficiency is 
supplemented by cyanosis. All these symptoms subside completely (or almost com-
pletely) in 2-6 days. The X-ray picture of the lung roots is more distinct, and the lungs 
appear inflated; focal changes are absent. The temperature is subfebrile and increases 
transiently to 38-39°C only in few patients. 
Most frequent complications are pneumonia and catarrhal otitis caused by secon-
dary bacterial flora. Grave pneumonia in infants is the cause of lethal outcomes. 
Most infants with lower respiratory tract illness shed virus for 5–12 days after hos-
pital admission. Excretion for 3 wk and longer has been documented.  
Diagnosis. During clinical diagnostication of the RS-infection in children, fre-
quent affections of the lower respiratory tract (bronchiolitis), that are characteristic of 
the disease. In addition to isolation of the RS-virus, serological methods are also used 
in the laboratory diagnostication.  
When bronchiolitis is mild or when infiltrates are absent by roentgenogram, there 
is little likelihood of a bacterial component. In infants 1–4 mo of age, interstitial 
pneumonitis may be caused by Chlamydia trachomatis. In this instance there may be a 
history of conjunctivitis, and the illness tends to be of subacute onset. Coughing is 
prominent; wheezing is not. There may also be eosinophilia. Fever is usually absent. 
Prognosis. The mortality of hospitalized infants with RSV infection of the lower 
respiratory tract is about 2 %. The prognosis is clearly worse in young, premature 
infants or those with underlying disease of the neuromuscular, pulmonary, cardiovas-
cular, or immunologic system. 
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Rhinoviral infection (acute contagious viral cold) 
There are 111 serologically distinct rhinoviruses, all members of the Picor-
navirus family of small RNA viruses (15-30 nm).  
Epidemiology. Infection is spread from a patient or virus carrier by the aerial-
droplet route. Virus persists for several hours in secretions on hands or other surfaces. 
Transmission probably occurs when infected secretions carried on contaminated fin-
gers are rubbed into the nasal or conjunctival mucosa. More recent evidence also im-
plicates spread through prolonged contact with aerosols produced by talking, cough-
ing, or sneezing. Contagiousness lasts not more than 5 or 7 days. All ages are suscep-
tible, but incidence is greatest in adults. Postinfectious immunity does not last long, its 
type is specific, and the antibody titre falls in two years. 
Clinical picture. There is an incubation period of 2-4 days; then sneezing, nasal 
obstruction and discharge, and sore throat ensue. Onset is characterized by the appear-
ance of copious watery discharge from the nose and sneezing; later the discharge be-
comes more viscid, mucous, or mucopurulent as a result of concomitant bacterial 
flora. Cough and hoarseness occur in 30–40 % of cases. Headache and other systemic 
symptoms are not as common as in influenza. Fever is neither as frequent nor as high 
as in primary infections with respiratory syncytial virus, parainfluenza virus, influenza 
virus, or adenovirus. Symptoms are worse in the first 2–3 days of illness and last for a 
week in a majority of patients; they persist for over 14 days in 35 % of young children. 
 
Adenoviral infection 
Adenoviruses are DNA viruses of intermediate size, which are classified into sub-
genera A to G. Types 1–39 are in subgenera A to E, type 40 is subgenus F, and type 
41 is subgenus G. Adenoviruses are characterized by location inside the cell nucleus, 
common complement-fixing antigen, and marked stability to environmental effects. 
Epidemiology. The source of infection is a sick person or a carrier of the virus. 
The causative agents are liberated with he secretion of the respiratory mucosa and 
faeces. Infection is spread through the aerial-droplet route, and also the routes charac-
teristic of intestinal infections. There is evidence that the infection can be transmitted 
through the eye conjunctiva in swimming pools. Children from six months to three 
years of age are particularly susceptible to these infections. 
Adenoviral infection occurs sporadically, but extensive epidemics have also been 
reported. 
Certain types tend to occur in epidemics, notably types 4 and 7 in epidemics of 
febrile respiratory disease, types 3, 7, and 21 in severe pneumonia, type 3 in pharyn-
goconjunctival fever, type 11 in cystitis, and types 8, 19, and 37 in epidemic kerato-
conjunctivitis.  
Pathogenesis and pathological anatomy. Adenoviruses infect the respiratory and 
intestinal mucosa. They are accumulated in the epithelial cells and lymph nodes. Viru-
saemia is probably important in the pathogenesis of the disease. 
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Clinical picture. The incubation period is between four and seven days, some-
times longer. Adenoviruses cause a wide array of syndromes. 
The principal clinical forms are pharyngo-conjunctival fever, catarrh of the respi-
ratory tract, and pneumonia, the intestine (intestinal form), and mesenteric nodes (me-
sadenitis) are less frequent. 
The onset of pharyngoconjunctival fever may be either acute or gradual. Tempera-
ture rises to 38-39°C, and there is usually moderate general toxaemia. Headache, ady-
namia, loss of appetite are noted. Constant symptoms are rhinitis with copious serous or 
seromucous discharge, bronchitis or tracheobronchitis, pharyngitis, and conjunctivitis. 
The fauces and posterior and lateral walls of the pharynx are hyperaemic; lymphatic 
follicles are swollen. The tonsils are rather enlarged, and a film sometimes covers the 
lacunae. Conjunctivitis may appear from the first day, but more often from the second or 
third. It usually starts on one side and may later spread to the other eye. Catarrhal, follicu-
lar, and membranous conjunctivitis are distinguished according to the character of the 
inflammation. The last-named is most typical of adenoviral infection. The conjunctiva of 
the eyelids looks hyperaemic, granular, and rather swollen. There is a sparse seromucous 
and seropurulent discharge. Fine white or greyish-white membranous films appear on 
the conjunctiva or plica semilunaris in one to three days. Oedema of the eyelids of soft 
consistency, sometimes sharply pronounced, is a frequent symptom. 
Enlargement of the cervical lymph nodes, and in infants liquid stool, sometimes 
with mucus, are not uncommon. Sometimes there is enlargement of the liver and 
spleen. The blood picture is approximately the same in all forms of adenoviral infec-
tion: a normal leucocyte count or a slight leucocytosis (less frequently-leucopenia), 
neutrophilosis; the ESR is normal or moderately increased. 
With further development of the disease the fever becomes fluctuating; it may last 
for five or six to nine or ten days (longer in some cases) and terminates by lysis. In some 
patients the pyrexia is double- or even triple-wave; the second wave follows the first in 
several days. The catarrhal phenomena, particularly cold in the nose, are usually persis-
tent and protracted. Subsidence of the conjunctivitis is relatively slow; the membranes 
persist for several days (sometimes up to the tenth or fourteenth day). 
Pneumonia is the most severe form of adenoviral infection occurring mostly in in-
fants under 1 year of age. It is often combined with a syndrome of catarrh of the respira-
tory tract or of pharyngoconjunctival fever. It may be microfocal, macrofocal, or conflu-
ent; there are marked auscultatory signs, namely copious varied rales and not infre-
quently distinct dullness of percussion sound. Dyspnoea, cyanosis, and general toxaemia 
are noted. The disease, particularly in nursing babies, has a tendency to a protracted re-
lapsing course and can terminate by death. Mortality has been high in some epidemics. 
The intestinal form of adenoviral infection occurs mostly in infants under 1; it is 
characterized by prevalence of symptoms of acute gastrointestinal disorders, viz., liq-
uid medium-frequency dyspeptic stools, sometimes containing mucus, and deranged 
appetite; some patients develop vomiting. 
Mesadenitis (inflammation of mesenteric lymph nodes) is a rare manifestation of 
adenoviral infection which develops either against the background of another syn-
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drome (e. g. pharyngoconjunctival fever) or as a prevailing syndrome, but almost al-
ways in combination with at least a slight catarrh of the upper respiratory ducts and the 
pharynx. Mesadenitis is characterized by an acute onset of fit-like abdominal pain, 
fever, nausea, and infrequent vomiting. The tongue is coated, stools are retained. The 
pain is felt predominantly in the lower part of the abdomen, often in the right iliac 
region. Appendicitis is often misdiagnosed and the patient is operated. Mesadenitis is 
sometimes complicated by intussusception. 
A pertussis-like syndrome has been described in association with adenovirus in-
fections. 
Hemorrhagic Cystitis. This syndrome has a sudden onset of bacteriologically ster-
ile hematuria, dysuria, frequency, and urgency lasting 1–2 wk. Infection with adenovi-
rus types 11 and 21 has been found in some affected children and young adults. 
Clinical diagnosis of adenoviral infection can only be made with typical pharyn-
goconjunctival fever and membranous conjunctivitis. Conjunctivitis is an informative 
sign for differentiation of this infection from other respiratory viral diseases.  
For laboratory diagnosis isolation of the virus from garglings and faeces, and sero-
logical examination during the first days and after two or three weeks, are used; a four-
fold increase of antibody titre at the minimum is considered diagnostic. 
The adenoviral nature of the disease can rapidly and conveniently be identified by 
luminescent microscopy of imprints from the nasal mucosa by which typical intranu-
clear DNA inclusions can be revealed. Fluorescent antibodies are quite valuable and 
specific for rapid diagnostic of viral etiology. 
Treatment and prophylaxis. The treatment and general prophylaxis of acute respi-
ratory viral infections is largely the same as for influenza and symptomatic. Careful hand 
washing and avoidance of manual nose and eye manipulation is the best approach to 
reducing spread. For relief of acute symptoms, a mild analgesic and saline or deconges-
tant nose drops may be used for a short time. 
Use of desoxyribonuclease by instillation into the nose or the conjunctival sac (3-4 
drops of fluid preparation, 3-4 times a day) has been suggested in adenoviral infection; 
good results were obtained in the treatment of adenoviral conjunctivitis; but this method 
has not gained wide popularity. 
Antibiotics are not effective against respiratory viral infections. They are only in-
dicated in complications of bacterial aetiology. 
Favourable results were obtained during prophylactic use of human leucocytic in-
terferon and interferonogens. Prophylactic administration of gamma-globulin to as-
thenic and especially vulnerable children in the epidemic foci is recommended. 
Measures in the infection focus. There are no official standards for hospitalization terms, 
but the patient should be isolated until the clinical signs of the disease disappear, not less than 
for 7 days from the onset. 
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PART 13  TORCH-INFECTIONS 
 
Despite immunization programs and effective antimicrobial medications 
for many infectious agents, congenital infections remain an important cause of 
birth defects among children throughout the world. Because the agents respon-
sible for these infections can damage the brain, eyes, or ears along with other 
body organs, survivors often have long-term disabilities that influence motor 
and intellectual performance. 
Relatively few infectious agents can cause congenital infections. These 
agents – viruses, spirochetes, and protozoa – tend to produce similar signs and 
symptoms and have been categorized historically as TORCH syndrome. The 
letters of the latter acronym stand for toxoplasmosis, other organisms, rubella, 
cytomegaloviral (CMV) infection and herpesviral infection. 
TORCH agents can affect the fetus by damaging the placenta (which alters 
the blood supply to the fetus) or by directly injuring the developing fetal organs. 
The extent of the damage depends upon the infectious agent and the stage of 
pregnancy at which infection occurs. Infections acquired early in pregnancy 
tend to result in more serious birth defects, whereas infections later in preg-
nancy may produce no visible signs of damage. 
Congenital infections can cause numerous long-term abnormalities. Some 
agents produce specific abnormalities, however. Congenital heart defects are 
usually associated with rubella (German measles), and scarring of the skin can 
be caused by herpes. The most serious consequences of congenital infections 
are the damaging effects on the brain, eyes and ears. As a result, infected infants 
may have shortened life spans or long-term intellectual and perceptual disabili-
ties. Although many of these children can eventually enter regular educational 
or child care environments, others are so severely affected that they require 
long-term specialized care. 
 
TOXOPLASMOSIS 
Toxoplasmosis, caused by infection with the protozoan Toxoplasma gondii, 
is the first most common human congenital infection. Rates of toxoplasmosis 
vary throughout the world and depend on age, geographic location, and dietary 
practice. 
Unlike most other organisms that cause congenital infections, Toxoplasma 
gondii is acquired from nonhuman sources. This parasite uses cats as its pri-
mary host but can infect many different species of birds and mammals. Humans 
become infected by consuming contaminated meat that is not fully cooked or by 
directly ingesting infectious particles. Cat feces may contain large quantities of 
infectious particles, making these animals an important source of infection. In 
rare, toxoplasmosis is acquired through blood transfusion. 
In most people, toxoplasmosis occurs asymptomatically or causes mild dis-
ease. In children with normal immune responses, Toxoplasma infection occa-
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sionally causes an infectious mononucleosislike illness with fever, swelling of 
lymphnodes and rash. In persons with impaired immune responses, however, 
such as persons with AIDS, toxoplasmosis can be severe, life-threatening dis-
ease. 
If nonimmune pregnant woman ingests infectious Toxoplasma gondii par-
ticles, they enter her blood stream and are carried to the placenta. Approxi-
mately one third of fetuses of infected mothers are themselves infected with 
these organisms. Whether the fetus becomes infected depends primarily on the 
stage of pregnancy at which maternal infection takes place. Most severe fetal 
infections are the result of toxoplasmosis infection during the second trimester 
of pregnancy. Approximately 5% of fetal infections with Toxoplasma gondii 
result in stillbirth or miscarriage. Most infants who survive fetal toxoplasmosis 
infection have no symptoms at birth, although some infected infants later had 
abnormalities of eyes (chorioretinitis) or hydrocephaly. 25-30% of infected 
newborns has symptoms in infancy. The spectrum of abnormalities caused by 
Toxoplasma gondii resembles that of congenital CMV infection. Both agents 
damage brain and eyes. 
Diagnosis of toxoplasmosis usually can be established by performing blood 
tests on the infant and mother. These tests measure antibodies to toxoplasma 
organisms. If the level of antibody is high or shows a fourfold or greater in-
crease soon after birth, toxoplasmosis is likely. These antibody tests detect only 
about 75% of actual toxoplasma infections. Diagnosis of Toxoplasmosis can be 
confirmed by identifying Toxoplasma organisms within human cells during 
autopsy or analysis of pathologic tissues. 
Treatment. In certain regions of the world, the diagnosis can be established 
before the infant's birth, and the mother can be treated with anti-toxoplasma 
medications. 
Table 1. 
Treatment of toxoplasmosis 
Manifestation of 
infection Medication Dosage 
Duration of 
therapy 
Pregnant women 
with acute 
toxoplasmosis 
first 18 weeks of 
gestation or until 
term if fetus not 
infected 
Spiramycin 1 g q8h without 
food 
Until fetal infec-
tion is docu-
mented or ex-
cluded at 18 
week. If excluded 
by PCR at 18 
weeks, continue 
spiramycin until 
term 
Fetal infection 
confirmed after 
17th week of ges-
Pyrimethamine Loading dose: 
100 mg/day in 2 
divided doses for 
Until term (leuko-
vorin is continued 
1 week after 
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2 days, then 50 
mg/day 
Sulfadiazine 100 mg/kg/day in 
2 divided doses 
(max, 3 g/day) 
tation or if mater-
nal infection ac-
quired in last few 
weeks of gestation 
(after amniocente-
sis and PCR to 
determine whether 
Toxoplasma is 
infecting the fe-
tus) 
Leukovorin 
(folinic acid) 
5–20 mg daily 
pyrimethamine is 
discontinued) 
Pyrimethamine Loading dose: 2 
mg/kg/day for 2 
days, then 1 
mg/kg/day for 2 
or 6 months, then 
this dose every 
Monday, 
Wednesday, and 
Friday 
Sulfadiazine 100 mg/kg/day in 
2 divided doses 
Congenital 
Toxoplasma 
infection in 
infants 
Leucovorin 5–10 mg 3 times 
weekly 
1 yr (leukovorin is 
continued 1 week 
after 
pyrimethamine is 
discontinued) 
OTHER AGENTS 
Enteroviruses. Fetal enterovirus infection is uncommonly observed, 
probably because the placenta acts as a barrier to intrauterine infection. How-
ever, a well-documented case of fatal disseminated, midgestational congenital 
enterovirus 71 infection has been published. Neonates are at risk of serious, 
sometimes fatal disease resulting from enterovirus infections acquired during 
the perinatal period. This unique susceptibility, which extends to about 10 days 
of age, may be based on immunologic immaturity and other host factors. Al-
though neonates respond to enterovirus infection with humoral neutralizing 
antibody, experimental data suggest that macrophage function, which does not 
mature sufficiently until several weeks of age in humans, is necessary to limit 
initial enteroviral replication. 
The echoviruses and group B coxsackieviruses are responsible for most 
neonatal infection. Neonates acquire enterovirus infections perinatally as a re-
sult of vertical transmission from infected mothers, and symptoms occur within 
the first week of life. During seasonal outbreaks, approximately 3% of pregnant 
women excrete enteroviruses at term. Although most transmit virus to their off-
spring, the outcome of neonatal infection is strongly influenced by the presence 
or absence of passively acquired maternal antibody specific for the infecting 
enterovirus serotype. Thus, the timing of maternal infection in relation to the 
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development of maternal IgG antibody and delivery of the infant is probably the 
most critical factor in determining the outcome of neonatal enterovirus infec-
tion. Other risk factors for severe and fatal infections include premature birth, 
maternal history of peripartum illness, and early postnatal age of onset. 
Nosocomial postnatal infection occurs less frequently than vertically ac-
quired infection. Infant-to-infant spread within nurseries occurs via the hands of 
personnel engaged in mouth care, gavage feeding, and other activities affording 
close direct contact. 
Although a wide range of clinical disease has been reported to occur in 
neonates, including nonspecific febrile illnesses, exanthems, and aseptic menin-
gitis, the most severe manifestations include myocarditis with or without en-
cephalitis, hepatitis, and pneumonia. 
Myocarditis. Neonatal myocarditis is most frequently caused by group B 
coxsackievirus serotypes 2 to 5. The onset is often abrupt, with respiratory dis-
tress, tachycardia, cyanosis, jaundice, and diarrhea. Initial examination fre-
quently reveals temperature instability, tachycardia, arrhythmia, hepatomegaly, 
and signs of poor peripheral circulation. The electrocardiogram can show low-
voltage and other electrophysiologic abnormalities, and echocardiographic stud-
ies often indicate poor left ventricular or biventricular function. Approximately 
one-third of illnesses are biphasic, with lethargy, poor feeding, or mild respira-
tory distress preceding the onset of cardiac manifestations by 2 to 5 days. 
Infants with group B coxsackievirus myocarditis often have concomitant 
meningoencephalitis, pneumonia, hepatitis, pancreatitis, or adrenalitis. Al-
though a limited number of organs can be involved pathologically, the degree of 
involvement is often severe, which has given rise to the use of terms such as 
disseminated, systemic, or overwhelming group B coxsackievirus disease in the 
neonatal period. Mortality in infants with myocarditis alone is generally re-
ported to be 30% to 50%, but it is higher when other organs are involved. 
Hepatitis. Neonatal hepatitis may be the sole manifestation of neonatal 
echovirus infection or can occur in the setting of myocarditis and other manifes-
tions of neonatal group B coxsackievirus infection. Echovirus 11 is prominent 
among the multiple echovirus serotypes reported to cause neonatal enterovirus 
hepatitis, which is often erroneously referred to as “enterovirus sepsis or sepsis 
syndrome” because of progressive hypotension, profuse bleeding, jaundice, and 
secondary multiple organ dysfunction due to fulminant liver failure. The degree 
of hepatic involvement varies, but a severe form of hepatitis unique to this age 
group is characterized by extensive necrosis of the liver and fulminant hepatic 
failure. Initial signs and symptoms of severe hepatitis resemble those of septi-
cemia, with lethargy, poor feeding, apnea, and jaundice. Within 2 to 3 days, 
evidence of hypocoagulability appears, along with ecchymoses and prolonged 
bleeding at puncture sites. Anemia, marked prolongation of the prothrombin 
time and partial thromboplastin time, and extreme elevations of serum transa-
minase levels occur. The marked hypocoagulability, more attributable to he-
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patic failure than to disseminated intravascular coagulation, causes spontaneous 
hemorrhage into the skin, lungs, gastrointestinal tract, kidneys, and brain. The 
mortality rate is high. Infants dying of hepatitis have massive hepatic necrosis 
and extensive hemorrhage into the cerebral ventricles, pericardial sac, renal 
medulla, and interstitial spaces of many solid organs. Inflammation is com-
monly limited to the liver and adrenal glands, with sparing of the heart, brain, 
meninges, and other organs. Cirrhosis and chronic hepatic insufficiency can 
develop in survivors. 
Central nervous system infection. Signs and symptoms such as extreme 
lethargy, seizures, hemiparesis, flaccid paralysis, and coma define the more 
serious form of meningoencephalitis that often accompanies myocarditis or 
hepatitis. Inflammation of the brain or spinal cord is found in approximately 
two-thirds of infants dying of myocarditis. These patients have diffuse or scat-
tered lesions consisting of perivascular infiltration with mononuclear cells and 
polymorphonuclear leukocytes in the cerebrum, cerebellum, pons, medulla, and 
spinal cord; meningoencephalitis in the absence of other organ involvement is 
rare. 
Pneumonia. Echovirus serotypes 6, 9, and 11 have been associated with a 
small number of reported cases of perinatal pneumonitis. Some cases are char-
acterized by the onset of symptoms within hours of birth, a finding suggestive 
of prenatal exposure, and these cases are associated with a high mortality rate. 
Less severe neonatal pneumonitis has been described with echovirus serotypes 
7 and 22. Pathologic evidence of pneumonitis can be seen with group B cox-
sackievirus myocarditis in newborns, but it is generally limited to focal areas of 
interstitial inflammation. 
 
Varicella-Zoster virus. The varicella-zoster virus can also cause congeni-
tal infection. Because chickenpox infections usually take place during child-
hood and seldom dining pregnancy, however, this type of congenital infection is 
uncommon. 
Congenital varicella-zoster infection of the fetus, like other congenital viral 
infections, occurs during maternal infection and results from passage of virus 
across placenta. 
Clinical manifestations of congenital varicella syndrome: 
1. skin  
 cutaneous defects 
 cicatricial scars 
 hypopigmentation 
 bullous lesions 
2. extremities  
 hypoplastic limb 
 muscular atrophy and denervation 
 joint abnormalities 
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 absent or malformed digits 
3. eye  
 chorioretinitis 
 microphthalmia 
 anisocoria 
4. central nervous system  
 intrauterine encephalitis with cortical atrophy 
 seizures 
 mental retardation 
5. urinary tract  
 hydronephrosis/hydroureter 
6. gastrointestinal tract  
 esophageal dilation/reflux 
 
If maternal chickenpox occurs within 4 or 5 days of delivery, the newborn 
infant can has widespread infection involving liver, lungs, brain and kidneys. 
As many as 30% of newborns with varicella-zoster infection died before antivi-
ral therapy. Some infants exposed to persons with chickenpox may require in-
tervention with varicella-zoster immunoglobulin. 
Infants with varicella-zoster infection can transmit disease when they have 
active skin vesicles. These infants, like older children with chickenpox, should 
be isolated from other infants or nonimmune children and adults until the skin 
lesions are crusted over. 
 
Human Parvovirus B19. Human parvovirus B19 can occasionally infect a 
nonimmune pregnant woman and damage the fetus. Human parvovirus B19 can 
cause stillbirth or severe anemia resulting in extreme edema of fetal tissues, or it 
may produce no adverse effects on fetus. Most pregnant women who become 
infected with human parvovirus B19 give birth to normal infants. 
 
RUBELLA 
Rubella (German measles) is the most common viral cause of birth defects 
in children. In children and adults rubella produces only mild systemic disease 
with fever, rash and catarrhal fenomena. If woman is infected during her first 
trimester of pregnancy, however, there is a high likelihood of damage to devel-
oping fetal organs. By contrast, the infant infrequently has signs of rubella in-
fection when maternal infection occurs after the fourth month. 
Like other congenital infections, rubella can cause miscarriage or stillbirth. 
More often, however, the infant survives and has damage to many tissues, in-
cluding eyes, brain, heart, liver, lungs, kidneys, skin, bones and hormone-
secreting organs. The tissues most commonly affected are eyes, brain and heart. 
The infant may have cataracts, microphthalmia, chorioretinitis, encephalitis, 
microcephaly and congenital heart defects (usually patent ductus arteriosus). 
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Rubella-infected infants often have skin rash, feature that reflects a reduced 
platelet count and bleeding into the skin. 
Nearly all infected infants with signs of rubella will have some degree of 
long-term neurologic impairment. Like CMV, rubella can damage the inner ear 
and produce nerve deafness. Many asymptomatic infants born to mothers who 
had rubella infection during pregnancy later develop deafness or psychomotor 
retardation. In addition, rubella-infected infants occasionally manifest thyroid 
dysfunction, growth disturbance, or diabetes mellitus. 
Table 2. 
Clinical features associated with congenital rubella syndrome 
Category Common Uncommon 
Transient 
Low birthweight Thrombocyto-
penic purpura Hepatomegaly 
Splenomegaly Bone lesions 
Cloudy corneas  
Hepatitis  
Generalized lymphade-
nopathy 
Hemolytic anemia 
Pneumonitis 
Permanent 
Sensorineural deafness Periph-
eral pulmonary stenosis Pulmo-
nary valvular stenosis Patent 
ductus arteriosus Ventricular 
septal defect Retinopathy  
Cataract  
Microphthalmia  
Psychomotor retardation Cryp-
torchidism  
Inguinal hernia, Diabetes melli-
tus 
Severe myopia  
Thyroid disorders Der-
matoglyphic abnormali-
ties Glaucoma  
Myocardial 
abnormalities 
Sensorineural deafness 
Delayed 
Peripheral pulmonary artery 
stenosis 
Mental retardation  
Central language defects 
Diabetes mellitus  
Immune complex disease 
Hypogammaglobulinemia 
Severe myopia  
Thyroiditis  
Hypothyroidism  
Growth hormone defi-
ciency Chronic rash  
Pneumonitis  
Progressive 
panencephalitis 
 
Although no effective antiviral therapy is available to treat congenital ru-
bella infection in newborns, rubella can be prevented by vaccination. The ru-
bella vaccine should be included in all childhood immunization programs. In 
addition, women of childbearing age should have their blood tested to ascertain 
whether they are immune to rubella. If they are not, they should receive the ru-
bella vaccine at time when they are not pregnant. 
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Children with congenital rubella should be excluded from center-based pro-
grams until throat and urine cultures are negative for the rubella virus. Pregnant 
women who have not had rubella or have not received rubella immunization 
should avoid contact with infants with congenital rubella. Excretion of the virus 
diminishes greatly during the first year of life. Thereafter, these children pose 
little or no risk to nonimmune pregnant women. 
 
CYTOMEGALOVIRAL INFECTION 
Human CMV infection occurs throughout the world in people of all ages. 
manifestations of CMV infection depend on the age and immune status of the 
infected individual. In healthy children and adults, including pregnant women, 
CMV infection rarely causes symptoms, although occasionally an infectious 
mononucleosis-like illness develops with fever, fatigue, and swelling of the 
lymph nodes. By contrast, people with impaired immune systems can develop 
servere complications, such as pneumonia, eye infection or encephalitis. 
The majority of congenitally infected infants have no symptoms at birth 
(the infection is recognizable by the excretion of CMV in the urine). 10-15% of 
these infected but asymptomatic infants later develop hearing loss caused by 
chronic CMV infection of inner ear and some children may also have subtle 
behavioral or developmental consequences. Approximately 5-10% of congeni-
tally infected infants have severe and sometimes fatal condition characterized 
by damage to numerous body organs, including brain, lungs, and liver. CMV 
also causes jaundice, skin rash, abnormal blood and platelet counts, en-
largement of the spleen and chorioretinitis. 
By far the most serious consequence of symptomatic CMV infection is 
damage to the developing brain. The most common abnormality in infants with 
severe CMV infection is deficient brain growth manifested by a small head size 
(microcephaly). Survivors of symptomatic CMV infection often have substan-
tial neurologic impairments, including developmental and mental retardation, 
motor abnormalities, seizures, visual deficits, and nerve deafness. 
Treatment. Currently, there is no approved agent for antiviral therapy for 
congenital CMV infection, but one study suggests a limited role for ganciclovir 
treatment of neonates with severe infection. A randomized trial compared gan-
ciclovir, 12 mg/kg/day administered intravenously in 2 divided doses daily for 6 
weeks, with no treatment in neonates with severe, symptomatic congenital 
CMV infection. Hearing thresholds declined significantly in 70% of placebo 
recipients compared with 20% of ganciclovir recipients evaluated at 1 year of 
age or older. However, treatment was not associated with statistically signifi-
cant improvement in the course of disease as indicated by laboratory abnormali-
ties (platelet count, alanine-transaminase, bilirubin) or liver and spleen size. 
Eligibility for this trial required the presence of signs of CNS disease and thus 
was limited to patients almost certain to have serious CNS sequelae. Treatment 
was associated with neutropenia that required dosage adjustment or discon-
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tinuation of ganciclovir in about half of treated patients. In addition, ganciclovir 
treatment of neonates with CMV retinitis has been associated with marked 
worsening of retinitis after discontinuation of the drug. Animal studies indicate 
the potential for reproductive toxicity and carcinogenicity at levels similar to 
those achieved in treating humans; although these two problems have not been 
recognized in humans treated with ganciclovir. Ganciclovir treatment of severe 
symptomatic congenital CMV infection may deserve consideration in some 
situations because of the evidence of modest benefit and lack of alternative 
treatments. Pharmacokinetic studies and clinical trials of oral valganciclovir for 
congenital CMV are necessary before recommendation can be considered. 
There is no evidence to support ganciclovir treatment of newborns with asymp-
tomatic or mild abnormalities in whom the potential for benefit would be low in 
relation to the risks. 
Currently, CMV infection can be neither prevented nor effectively treated. 
None of the available antiviral agents has proved to be effective against con-
genital CMV infection, although newer antiviral drugs are cur-rently being in-
vestigated. There is no vaccine that can prevent birth defects due to congenital 
CMV infection. 
CMV is present in urine, saliva, blood, cervical secretions and semen of in-
fected individuals. Urine and saliva usually contain the largest quantities of vi-
ral particles, and virus can be shed for months or even years. Transmission of 
CMV results from close, personal contact with infected individuals, often chil-
dren or sexual partners. Mothers can transmit CMV to their nursing children via 
breast milk and transfused persons can acquire CMV from infected blood prod-
ucts. 
Risk of acquiring CMV varies according to nature of contact with CMV-
infected children. Persons who work with children in hospitals have low rates of 
infection, whereas day care workers or parents of CMV-excreting young chil-
dren have relatively high rates of CMV infection.Pregnant women should avoid 
daily, hands-on contact with infants or young children with known congenital 
CMV infection. The risk may be greatest during the child's first year of life, 
when large quantities of the virus are excreted in urine or saliva. Approximately 
50% of children with congenital CMV infection continue to shed virus in their 
urine for 4 years or more. 
Any young child, especially one attending group day care, may be ex-
creting CMV. Consequently, women who have contact with young children and 
anticipate pregnancy in the future should know their CMV immune status. This 
can be determined by blood test (CMV serology), which physician can order. 
Pregnant women who are seronegative and therefore not immune to CMV 
should limit their exposure to toddler-age children (who are more likely to be 
excreting CMV) and should practice good hygiene, by washing their hands after 
contact with children or their secretions, and by avoiding oral contact with the 
children or their secretions. 
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HERPES SIMPLEX VIRUS 
HSV causes serious illness in 1 in every 10,000 live-born infants. This vi-
rus exists in two forms: HSV type 1, which causes cold sores and gingivostoma-
titis, and HSV type 2, which causes most genital herpetic lesions. Most cases of 
perinatal HSV infections are caused by HSV type 2. 
Unlike CMV and Toxoplasma gaondii, which are acquired prior to birth, 
HSV infections are usually acquired perinatally; that is, they occur during or 
shortly after birth. Although HSV can be transmitted to the fetus via the pla-
centa or amniotic fluid, most infections occur when the infant passes through 
birth canal of mother who has been infected with HSV and has HSV in her cer-
vical or vaginal secretions. Less often, the infant contracts HSV from adult who 
has active oral herpes. 
Symptoms of perinatal HSV infection usually begin during the first 5-7 
days of life and vary according to the distribution of the disease. In ap-
proximately 40% of cases, infection is localized to skin, mouth or eye, causing 
vesicles of the skin or mouth, or inflammation of cornea. In another 35% infec-
tion is restricted to the brain (herpes encephalitis) with lethargy or irritability 
and severe neurologic signs, such as seizures or coma. In as many as 25% of 
cases, the infection is disseminated throughout infant's body, causing fever, 
vomiting, jaundice, lethargy, skin vesicles and enlargement of liver or spleen. 
Table 3 
Characteristics of neonatal HSV infections 
Feature 
Skin/Eye/Mucous 
membrane infec-
tion 
Central nervous 
system infection 
Disseminated 
infection 
Usual age at onset 
(days) 7–14 14–21 5–10 
Clinical findings Vesicles on red 
base at sites of 
trauma; conjunc-
tivitis 
Lethargy, irrita-
bility, fever, sei-
zures 
Shock, hepa-
tomegaly, jaun-
dice, bleeding, 
respiratory dis-
tress 
Diagnostic testing Direct fluorescent 
antibody test and 
culture of skin 
lesions 
Direct fluorescent 
antibody test and 
culture of skin 
lesions if present; 
analysis, culture 
and PCR of CSF; 
EEG; neuroimag-
ing studies, brain 
biopsy 
 
Direct fluorescent 
antibody test and 
cultures of skin 
lesions; culture of 
nasopharynx, 
rectum, buffy 
coat, CSF 
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Mortality if treated 
(%) 
0 15 54 
Sequelae if treated 
(%) 
5 54 38 
Treatment. Antiviral therapy is beneficial for neonates with HSV infec-
tions. Vidarabine was the first agent demonstrated to benefit neonates with HSV 
infection, reducing mortality for infants with disseminated or central nervous 
system infection from 70% in placebo recipients to 40% in vidarabine recipi-
ents. Acyclovir is at least as effective as vidarabine and is the preferred agent 
because it has a more favorable safety profile. An open-label evaluation of in-
creasing dosages of intravenous acyclovir support the use of a 21-day course of 
60 mg/kg/day to treat neonatal CNS and disseminated infection. Best therapeu-
tic results are obtained when infection is localized to the skin, eyes, and mouth. 
With treatment before progression of infection, all infants survive, and > 90% 
appear to be developmentally normal, although almost half have recurrent skin 
lesions within 6 months of completion of therapy. By contrast, > 50% of infants 
with disseminated infection die, whether their disease is treated with vidarabine 
or acyclovir. About 15% of infants with central nervous system disease die de-
spite therapy, and less than half of survivors are normal at 1 year of age. Recur-
rence of central nervous system symptoms and an abnormal CSF finding are 
observed in about 8% of survivors of disseminated or central nervous system 
disease. A controlled trial is being conducted to determine if long-term suppres-
sive therapy with orally administered acyclovir will reduce recurrences of cen-
tral nervous system infection and improve long-term prognosis. 
Neonates with proven HSV infections should receive acyclovir; the role of 
empiric acyclovir therapy is not clear. Clinical settings in which empiric therapy 
should be considered include: (1) the appearance of skin lesions typical of HSV 
while awaiting results of diagnostic tests; (2) fever or other unexplained signs of 
infection in a neonate known to have been exposed to HSV at delivery; (3) pro-
gressive clinical deterioration in an infant initially suspected to have bacterial 
sepsis for whom bacterial culture results are negative; and (4) unexplained en-
cephalitis in a neonate with unremitting seizures. Whether or not antiviral ther-
apy is initiated under these circumstances, specimens obtained from the nose, 
eyes, mouth, pharynx, rectum, CSF, and buffy coat should be submitted for 
viral culture. Specimens of CSF and peripheral blood mononuclear cells also 
should be tested for HSV DNA by PCR. 
Prognosis for HSV-infected infant depends on extent of disease and prompt 
initiation of anti-HSV therapy. For example, infants with localized infection of 
skin do well with little mortality or long-term effects. By contrast, half infants 
with severe disseminated HSV infections die, and 20% to 30% of the survivors 
have long-term impairments ranging from poor growth to seizures, blindness 
and mental retardation. 
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Some instances of perinatal HSV infection can be prevented. If active geni-
tal herpes lesions are present at time of mother's labor, infant should be deliv-
ered by cesarean section, particularly if amniotic membrane has not ruptured 
(less than half the mothers who give birth to infants with HSV have either his-
tory of genital HSV infection or evidence of this condition, such as genital le-
sions). All infants younger than 2 months should be isolated from adults who 
have active oral herpes lesions. Any adult with active oral herpes should wear 
protective mask when caring for infants younger than 1 month. 
 
GENERAL RECOMMENDATIONS  
FOR ALL CONGENITAL INFECTIONS 
Children who survive congenital infections often have multiple long-term 
complications that require multidisciplinary approach to treatment guided by 
developmental pediatrician or pediatric neurologist. Many medical services may 
be required, including those of ophthalmologist, orthopedist and audiologist. 
Children with developmental delay require early intervention programs. In-
telligence testing with age-appropriate instruments should be performed as early 
as reliable results can be obtained. Because visual abnormalities are common 
complications of congenital infections, affected children should be examined by 
pediatric ophthalmologist. 
Because many congenital infections are associated with nerve deafness 
(sensorineural deafness), periodic audiologic testing is important. Some chil-
dren, particularly those infected with CMV or rubella virus, can develop pro-
gressive or new-onset hearing loss. Conservative approach is to perform audio-
metric testing at birth, at 6 months, at 1 year, and annually thereafter until child 
reaches school age. Many children will benefit from hearing aids. Deafness is 
sometimes so severe, however, that the child requires special supportive ser-
vices throughout school years and beyond. 
As with nearly all infections, the risk of transmitting infection from certain 
congenitally infected infants can be greatly diminished by good hygiene. Dia-
pers should be promptly discarded in appropriate containers. Also, personnel 
should wash their hands well after contact with infected infants. Gloves need 
not be worn except when one is handling infants with active HSV or varicella 
zoster skin lesions or changing diapers of infants with CMV infection. 
 
PART 14   PROPHYLACTIC IMMUNIZATION 
 
The widespread use of vaccines led to the global eradication of smallpox, the 
elimination of poliomyelitis from the Americas, and the virtual elimination of polio-
myelitis from the Western Pacific. In the United States, immunization has almost 
eliminated congenital rubella syndrome, tetanus, and diphtheria and reduced the inci-
dence of pertussis, rubella, measles, mumps, and Haemophilus influenzae type b men-
ingitis dramatically. 
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Definitions and mechanisms. Vaccination means the administration of any vac-
cine or toxoid. Immunization describes the process of inducing immunity artificially 
by administering antigenic substances, such as an immunobiologic agent. Administra-
tion of an immunobiologic agent cannot be equated automatically with the develop-
ment of adequate immunity. 
Active immunization consists of inducing the body to develop defenses against 
disease by the administration of vaccines or toxoids that stimulate the immune system 
to produce antibodies and cellular immune responses that protect against the infectious 
agent. Passive immunization consists of providing temporary protection through the 
administration of exogenously produced antibody. Passive immunization occurs 
through the transplacental transmission of antibodies to the fetus, which provides pro-
tection against several diseases for the first 3–6 mo of life, and the injection of im-
mune globulin for specific preventive purposes. 
Immunizing agents include vaccines, toxoids, and antibodies containing prepara-
tions from human or animal donors. Most of these agents contain preservatives, stabi-
lizers, antibiotics, adjuvants, and a suspending fluid. 
The principal approaches to active immunization are the use of live, usually at-
tenuated, infectious agents and the use of inactivated or detoxified agents or their ex-
tracts or specific products of recombination (hepatitis B). Both approaches have been 
employed for many diseases (influenza, poliomyelitis). Live, attenuated vaccines are 
thought to induce an immunologic response more like that elicited by natural infection 
than killed vaccines. Inactivated or killed vaccines consist of inactivated whole organ-
isms (pertussis vaccine), detoxified exotoxins alone (tetanus toxoid), or endotoxins 
linked to carrier proteins, soluble capsular material (pneumococcal polysaccharide) or 
conjugated capsular material (Hib conjugate vaccine), or extracts of some component 
(hepatitis B) or components of the organism (subunit influenza). 
The most important protective antibodies include those that inactivate soluble 
toxic protein products of bacteria (antitoxins), facilitate phagocytosis and intracellular 
digestion of bacteria (opsonins), interact with components of serum complement to 
damage the bacterial membrane with resultant bacteriolysis (lysins), prevent prolifera-
tion of infectious virus (neutralizing antibodies), or interact with components of the 
bacterial surface to prevent adhesion to mucosal surfaces (anti-adhesions). Many of 
the structural constituents of microorganisms and exotoxins are antigenic. Most anti-
gens require the interaction of B cells (thymus independent) and T cells (thymus de-
pendent) to generate an immune response (measles), but some initiate B-cell prolifera-
tion and antibody production without the help of T cells (pneumococcal type III poly-
saccharide.). 
The first step in the induction of a thymus-dependent antibody response is the ac-
tivation of T helper cells by presentation of an antigen to mononuclear phagocytes or 
dendritic cells, a step that may be facilitated by the use of an adjuvant. Presentation of 
an antigen triggers the secretion of a cascade of mediators, called cytokines, which are 
made by or act on elements of the immune system to stimulate the maturation of naive 
T helper cells and to communicate between leukocytes, using interleukins (IL) to 
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regulate the immune response. Depending on the stimulus, T lymphocytes are stimu-
lated to differentiate into one of two subsets: T helper 1 cells (TH1), which mediate 
cell-mediated immune responses, or T helper 2 cells (TH2), which enhance antibody 
production. TH1 cells produce IL-2 and interferon-g, and TH2 cells produce IL-4, IL-
5, and IL-10. 
Antibodies formed to vaccine constituents may be of any immunoglobulin class. 
Antibodies function alone or in conjunction with other components of the immune 
system (complement, opsonin) by participating directly in the neutralization of a toxin 
(diphtheria); by opsonization of virus (poliovirus); by initiating or combining with 
complement and promoting phagocytosis (pneumococcus, cholera); by reacting with 
nonsensitized lymphocytes to stimulate phagocytosis; or by sensitizing macrophages 
to stimulate phagocytosis. The primary response to a vaccine antigen requires a latent 
period of several days before humoral and cell-mediated immunity can be detected. 
Circulating antibodies do not appear for 7–10 days. The immunoglobulin class of the 
response changes over time. Early-appearing antibodies are usually IgM; later-
appearing antibodies are usually IgG. When the antigen is thymus-dependent, IgM 
and IgG antibodies are secreted initially by B cells, with IgM appearing first. IgM 
antibodies fix complement, making lysis and phagocytosis possible. The IgM titer 
falls as the titer of IgG rises during the 2nd wk (or later) after immunogenic stimula-
tion. The switch from IgM synthesis to predominately IgG synthesis in B cells re-
quires T-cell cooperation. IgG antibodies are produced in high concentrations and 
function in the neutralization, precipitation, and fixation of complement. IgG titers 
reach a peak within 2–6 wk. 
Heightened humoral or cell-mediated responses are elicited by a second exposure 
to the same antigen. Secondary responses occur rapidly, usually within 4–5 days. The 
secondary response depends on immunologic memory mediated by T and B cells and 
is characterized by a marked proliferation of antibody-producing cells or effector T 
cells. 
Because the organisms in live vaccines multiply in the recipient, antigen produc-
tion increases until it is checked by the onset of the immune response it is intended to 
induce. In recipients who develop a response, the live, attenuated viruses (measles, 
rubella, mumps) are thought to confer lifelong protection with one dose. In contrast, 
killed vaccines, except for purified polysaccharide antigens, do not induce permanent 
immunity with one dose. Repeated vaccination and boosters are needed to develop 
and maintain high levels of antibody (diphtheria, rabies). Although more antigen is 
introduced initially in inactivated vaccines, the multiplication of organisms in the host 
results in a greater antigenic stimulus by live vaccines. 
The oral poliovirus vaccine is an exception to this general principle because oral 
feeding does not consistently result in infection ('take') with the vaccine virus. Therefore, 
multiple doses are necessary. 
The major advantage of non-replicating vaccines is the relative stability of the an-
tigens. Fluctuations in temperature of storage and transportation reduce the potency of 
live vaccines more rapidly than that of killed and toxoid vaccines. 
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Vaccine-preventable diseases. Diseases against which vaccines are currently avail-
able. 
1) Diseases preventable by environmental improvement or by immunization - 
Japanese encephalitis, tuberculosis, yellow fever, typhoid fever, rabies, cholera and 
hepatitis B (horizontal transmission). 
2) Diseases preventable only by immunization - Poliomyelitis, diphtheria, measles, 
tetanus, rubella, pertussis, mumps, meningococcal meningitis (A and C serotypes), influ-
enza, H.influenzae meningitis, chicken pox, hepatitis B (vertical transmission). 
Passive Immunization. Passive immunization is used to provide temporary immu-
nity in an unimmunized person exposed to an infectious disease when active immuni-
zation is unavailable (e.g., hepatitis A) or has not been given before exposure (e.g., 
rabies). Passive immunization is used in the treatment of certain disorders associated 
with toxins (e.g., diphtheria), in certain bites (e.g., snake and spider bites), and as a 
specific (e.g., immune globulin) or nonspecific (e.g., antilymphocyte globulin) immu-
nosuppressant. 
Three types of preparations are used in passive immunization: standard human 
immune serum globulin (e.g., intravenous or intramuscular gamma globulin), special 
immune serum globulins with a known antibody content for specific agents (e.g., 
hepatitis B or varicella-zoster immune globulin), and animal serums and antitoxins. 
In pediatric practice, routine immunization is given to individual children for their 
personal protection. In public health practice (primary health care) individual as well 
as community protection is desired. For the latter, the transmission chain of the infec-
tious agent must be broken by protecting an adequate proportion of susceptible indi-
viduals. Thus, the risk of disease in the unimmunized children is also reduced. This 
phenomenon is generally referred to as the herd effect of immunization. 
Vaccines which protect against infections as well as disease have better herd effect 
than those which protect only against disease. Measles and oral poliovirus vaccines have 
excellent herd effect. Diphtheria vaccine is directed against the toxin, not against the 
infecting organism. Vaccine-induced protection is incomplete in the case of pertussis and 
typhoid fever. For these reasons, herd effect is not very prominent with diphtheria, per-
tussis and typhoid vaccines. For tetanus, there is no herd effect since transmission is not 
man-to-man. Recent evidence suggests little or no herd effect for BCG vaccine. The herd 
effect can be maximized by immunizing large numbers of susceptible children in a short span 
of time. Thus, measles and oral poliovirus vaccines may be used in discontinuous immuniza-
tion campaigns to achieve rapid and effective control of disease. This strategy is called annual 
pulse immunization. 
Immunization in primary health care. Ideally all susceptible children should be im-
munized. Therefore, the opportunity of a sick visit should also be utilized to promote im-
munization. Minor illnesses such as upper respiratory infection or diarrhea are not contra-
indications for administering any vaccine. 
Some practical aspects: 
- There is no contraindication to concurrent administration of multiple vaccines such as DPT, 
OPV or MMR. 
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- A lapse in the schedule of immunization does not necessitate reinstitution of the 
total course. If the second or third dose of DPT or OPV was missed or delayed, there 
is no need of giving all the three doses of primary vaccination schedule. 
- If immunization status of a child is unknown, there is no harm in giving appropriate 
vaccines again. 
- It is desirable not to reduce the dose of the vaccine as it may cause inappropriate 
immunological response. Dose should not be exceeded to avoid side effects. 
- Measles, mumps and rubella vaccines should not be given to children, who were 
given immune globulin within the previous three months, since this may hinder ade-
quate response to active immunization. But concurrent administration of hepatitis B, 
tetanus or rabies immune globulin and the corresponding vaccine or toxoid is not con-
traindicated. Likewise immune globulins do not interfere with immune response to 
OPV and yellow fever vaccine. 
- Live-virus vaccines of all types and BCG should not be given to patients with 
congenital disorders of immune functions. These should also not be used in children 
treated with large doses of steroids or during illnesses, which are known to suppress 
immune response. Short-term (less than two weeks) low-dose steroid therapy is not a 
contraindication to live-virus vaccines.  
-Children suffering from neurologic disorders or with previous history of convul-
sions is at a higher risk of adverse reactions following pertussis vaccine.  
- Active immuno-prophylaxis after exposure to disease is recommended for rabies, 
measles (within three days of exposure), hepatitis and tetanus. 
Immunogenic and protective efficacy. Immunogenic efficacy of a vaccine refers 
to its ability to induce an immune response; protective efficacy refers to actual protec-
tion against disease. In the case of live viral and toxoid vaccines, antibody response 
almost always results in protection. In the case of killed bacterial vaccines and BCG, 
antibody response or CMI may not necessarily be protective. The breakthrough dis-
ease after immunization is indicative of vaccine-failure. When the administration of 
recommended doses of vaccine does not result in immune response sufficient to pro-
tect against disease, the vaccine-failure is primary. When disease occurs in spite of 
immune response, it is referred to as secondary vaccine-failure. Primary vaccine fail-
ure occasionally occurs after three doses of oral poliovirus vaccine; secondary vaccine 
failure occurs not infrequently after pertussis, typhoid and BCG immunization. Vac-
cine failure is very rare after measles, diphtheria, and tetanus immunizations. 
Immunological adjuvants are substances given along with antigens in order to en-
hance their immunogenic efficacy. Aluminium salts are used as adjuvants in diphtheria - 
pertussis -tetanus vaccines. 
Diphtheria. Maternal antibodies protect the infant against diphtheria for several 
weeks to months after birth. The toxoid vaccine, absorbed with aluminium hydroxide 
is usually combined with pertussis and tetanus toxoid vaccines as a triple antigen 
(DPT vaccine) or with tetanus toxoid (DT vaccine). Primary immunization requires 
three doses, at intervals of 4,6 or 8 weeks; the first booster is recommended during the 
second year of life (18 months) and a second booster at five years. Subsequent boost-
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ers are not necessary in countries such as India where C. diphtheriae infection is 
common. In case primary immunization is to be carried out in an older child or an 
adult, the adult type of toxoid (Td) containing less quantities of antigen should be em-
ployed. 
Immunization does not eliminate C. diphtheriae in skin or nasopharynx. Clinically 
obvious diphtheric infection may not always confer immunity. 
Pertussis. The pertussis vaccine is usually given in the form of the DPT vaccine. 
Each dose contains a required number of killed organisms of B. pertussis. Since pro-
tective antibodies against this disease do not cross the placenta, early immunization is 
desired. Three doses are recommended at 4-8 weeks of interval, commencing at 1-3 
months of age so that primary immunization is completed by 4-6 months of age. The 
protective efficacy is approximately 75 percent. Occasional vaccine failure may be 
expected. 
Common adverse reactions include local pain, swelling, mild to moderate fever 
and irritability. Prolonged screaming by the infant is an uncommon reaction, the sig-
nificance of which is not clear. Rarely convulsions may occur either due to the fever 
or due to an encephalopathy syndrome. An infant who develops prolonged screaming 
or convulsions following a dose of DPT should not be given any further pertussis vac-
cine; further doses should be DT vaccine or tetanus toxoid alone. An infant with pro-
gressive neurological disease also should not be given pertussis vaccine. However, a 
static neurological disease (cerebral palsy) and febrile convulsions are not contraindi-
cations. The administration of a few doses of an antipyretic (acetaminophen) is a 
common practice, which may help reduce fever and pain. 
Tetanus. Neonatal tetanus is an important cause of mortality in many developing 
countries. Since there is no natural immunity to C. tetani toxin, unimmunized mothers 
do not transfer antibodies to the infants. Therefore, immunizing pregnant women or 
women of child-bearing age against tetanus using tetanus toxoid (TT) is an important 
public health strategy to reduce the incidence of neonatal tetanus in high risk coun-
tries. If children are fully protected with DPT vaccine and TT booster doses are given 
at 5-10 year intervals, immunization during pregnancy will eventually become unnec-
essary. This is a better approach since tetanus may occur at any age. It is particularly 
important in India with its agrarian society and love for cattle, the two factors contrib-
uting to the risk of infection with C. tetani. 
BCG vaccination. Bacillus Calmette Guerin (BCG) is an attenuated strain of Myco-
bacterium tuberculosis var. bovis, used as a live vaccine against tuberculosis. In order to 
maintain its potency, the vaccine is supplied in freeze-dried (lyophilized) form. At 4°C its 
potency remains satisfactory for several months. 
BCG is administered intradermally over the deltoid muscle. The dosage is 0.05 ml 
(newboms) or 0.1 ml (all other ages). After 2-3 weeks a papule develops at the site (indicat-
ing the multiplication of BCG) which gradually heals leaving a scar. Neonates of mothers 
with bacillary tuberculosis may be given special isoniazid-resistant BCG along with the 
drug itself to protect from primary tuberculosis. Four to 12 weeks after immunization the 
tuberculin (PPD) test becomes positive in the majority of infants. 
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BCG may be given any time from birth since mother's immunity is not transferred 
to the fetus. In the neonate and young infant, tuberculin testing is unnecessary before 
giving BCG.  
Poliomyelitis. Two types of polio vaccine are licensed in the United States: OPV, 
a live, attenuated trivalent poliovirus vaccine (Sabin), and IPV, an inactivated (killed) 
trivalent poliovirus vaccine (Salk). A full course of either vaccine protects the recipi-
ent against paralytic poliomyelitis almost without exception. Because rare cases of 
paralytic poliomyelitis occur in recipients of OPV or in their close contacts, some have 
advocated returning to IPV for routine immunization of children. However, immuni-
zation advisory groups in the United States have continued to recommend OPV for 
routine immunization of children because of the virtual eradication of poliomyelitis 
from the United States by OPV and because of the belief that the circulation of wild 
virus in the community is controlled better by the greater intestinal immunity afforded 
by OPV. 
Primary immunization by IPV requires 3 doses, given intramuscular or subcutaneous, 
at 4-8 weeks interval. In countries where poliovirus circulation is slow on account of excel-
lent hygiene, periodic booster doses of IPV are necessary to maintain high antibody levels. 
Where virus circulation is intensive, it is believed that infection will reinforce immunity and 
booster doses may not be needed. 
Immunization should be completed by about six months of age. For individual 
protection five doses of OPV are recommended for primary immunization. Three 
doses may be given simultaneously with DPT, two doses either before or after, at in-
tervals of at least four weeks. At subsequent visits for measles immunization and DPT 
booster, two additional doses of OPV may be given to ensure near 100 percent protec-
tion rate.  
OPV should not be given to individuals proven or suspected to be immunocom-
promised, including those with congenital and acquired immunodeficiencies and those 
whose immune mechanisms are impaired by therapy. OPV should not be given to 
household contacts of immunocompromised individuals or to subsequent siblings of a 
child with congenital immunodeficiency until the younger child is shown to be nor-
mal. 
Both KPV and OPV are very safe vaccines without adverse reactions. Transient 
diarrhea following OPV has been noted, but no etiologic association has been proven. 
One in a few million vaccinees in some Western countries develops paralytic polio-
myelitis due to vaccine virus infection itself. In India, the risk of paralytic poliomyeli-
tis is 1 in 100 to 300 unimmunized children.  
Where an outbreak of poliomyelitis occurs, the rapid administration of OPV to 
preschool children irrespective of their previous history of immunization will arrest 
the epidemic. This is due to the displacement of natural, (wild) poliovirus in the com-
munity by vaccine viruses.  
Although breast milk contains antibodies against polioviruses, they do not appear 
to inhibit vaccine-virus 'take' and subsequent immune response. However, it is prudent 
to withhold breast-feeding for 30 minutes before and after giving OPV.  
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The potency of OPV is stable for 3-4 months at 4-8°C and for 1-2 years at -20°C. 
Temperature fluctuations, particularly those above 8°C rapidly reduce the potency. 
KPV should be used in immune-compromised children, those with AIDS, family 
members of immunodeficient individual, partially immunized or unimmunized adults 
and in some tropical countries with poor facilities for cold chain. 
Measles. Live attenuated measles virus is used as the vaccine. The minimum recom-
mended potency is 1000 median cell culture infectious doses of virus. It may be given sub-
cutaneous or intramuscular. 
Residual maternal antibody in the infant's serum neutralizes the immunogenic property 
of the vaccine and it should be offered at an age when most infants would have lost this 
effect. Therefore, in developing countries the recommended minimum age is nine months. 
Depending upon the strain of vaccine virus, between 10 and 20 percent of vaccinees may 
develop mild to moderate fever about 6-8 days after receiving measles vaccine. It lasts 1-3 
days and is not associated with malaise. Between 1 and 5 percent of children may develop 
a few red spots on the trunk at this time. Malignancies associated with immunosuppression 
and therapy with antimetabolites, alkylating agents and corticosteroids are contraindica-
tions for measles vaccine. Treatment for primary tuberculosis is not a contraindication. 
The Edmonston-Zagreb strain of vaccine grown in human diploid cells has been suc-
cessfully administered as an aerosol to immunize infants against measles. By utilizing the 
respiratory route it is hoped to avoid neutralization by any maternal. 
Rubella. As the vaccine consists of live attenuated virus, it should be given only after 
maternal antibodies have disappeared: the recommended minimum age is 12 months. 
Three attenuated virus strains are available, namely HPV-77, Cendehill and RA 27/3. 
All of them induce antibody response in over 95 percent of recipients. Vaccine is often 
combined with measles and mumps vaccine. Adverse reactions to rubella vaccine include 
lymphadenopathy, arthralgia and transient skin rash, all of which are self-limiting. Preg-
nancy and immunosuppression are contraindications.  
Mumps. In developing countries, the priority for mumps prophylaxis is low on ac-
count of many other more pressing priorities. The vaccine consists of live attenuated 
mumps virus (Jeryl Lynn strain). It is usually combined with measles and rubella vaccines 
into one trivalent vaccine (MMR). Mumps vaccine of MMR may be given after 12-15 
months of age. Since orchitis and oophritis are occasional complications of mumps in 
adults, some experts recommend mumps vaccine to all young adults who have not had the 
disease earlier. Clinical efficacy is 75 to 90 percent. 
Rabies. Since transmission of rabies virus is almost exclusively through the bite of an 
infected animal and since the incubation period is relatively long, post-exposure prophy-
laxis is possible. Two types of vaccines are available in India and other developing coun-
tries. These are the animal (sheep, goat, rabbit or monkey) brain-grown and inactivated 
rabies virus vaccine (modified Semple's vaccine) and the cell-culture-grown, inactivated 
and purified vaccine. Both are killed virus vaccines. 
As an animal bites virus if present in saliva, is inoculated into the wound. Immediate 
washing with soap and liberal amounts of water does eliminate a large part of virus parti-
cles. The wound should not be stitched or cauterized. The vaccine should be administered 
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subcutaneously, preferably in the anterior abdominal wall, daily for 7-14 days: some 
schedules require booster doses. 
The modern rabies vaccines may be prepared in cell cultures of human, simian or 
avian origin. Currently the vaccines prepared from rabies virus grown in human dip-
loid cell strain (HDCS rabies vaccine) or in chick embryo cells (CEC rabies vaccine) 
are used widely. The two advantages of the vaccines over the conventional vaccine are 
the absence of neurological complications and better protective efficacy. The main 
disadvantage is the high cost. A course consists of six doses given intramuscularly or 
subcutaneously on days 0,3, 7,14, 30 and 90. When using the vaccines, animal contact 
incidents are not categorized. However, when the bite of an infected animal is on 
head, neck, hands or genitalia, irrespective of the type of vaccine given, equine an-
tirabies serum must also be given in doses of 40 iu/kg body weight, with due precau-
tions. When available, human anti-rabies immunoglobulin is preferred but is very 
expensive. The dose is 20 iu/kg given on day 0, half the dose being given by deep 
intragluteal injection and half of the dose is infiltrated in the wound. 
Cell culture rabies vaccine is suitable for pre-exposure prophylaxis. The schedule 
is 1 ml of vaccine IM or SC or 0.1 ml ID on days 0, 28 and 56 or on days 0, 7 and 28, 
respectively. Purified chicken cell cultures vaccine is now easily available and is much 
less expensive. 
Typhoid fever. The currently available vaccine consists of a standard suspension 
of acetone-killed Salmonella typhi. The addition of S. paratyphi A or B does not seem 
to offer any advantage; therefore monovalent typhoid vaccine is preferred to TAB or 
TA vaccines. Primary immunization requires two subcutaneous doses given four 
weeks apart; during an outbreak the interval can be reduced up to 1 week. The dose is 
0.5 ml for children 10 years of age and for younger children the dose is 0.25 ml. 
Booster doses once in three years are recommended in typhoid endemic areas.  
Influenza. The conventional vaccine consists of formalin-killed influenza virus. 
Two doses are given 4-8 weeks apart for primary immunization. Newer vaccines such 
as subunit (hemagglutinin) vaccine and a live (recombinant) virus vaccine are used. 
The objective' of immunization is to prevent mortality in individuals at high risk. 
Japane encephalitis (JE). A killed virus vaccine prepared from the Nakayama strain of 
JE virus grown in suckling-mouse-brain has been used widely in Japan, Korea and some SE 
Asian countries. Three doses are recommended at four weeks or more intervals. The protec-
tive efficacy is moderately high. 
ChicKenpox (Varicella). A live attenuated virus (Oka strain) vaccine has been de-
veloped in Japan and field-tested in many countries. It is safe and effective; it protects 
against varicella but not against herpes zoster. Its greatest usefulness is in children with 
malignancies who are at high risk of life-threatening infections with varicella virus. The 
vaccine is likely to be released for routine use in a year. 
Yellow fever. Yellow fever immunization is required only for those living in en-
demic zones or those who travel to such areas. Two live virus vaccines are available, 
namely 17D and Dakar; the former is preferred. The virus is grown in chick embryos 
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and lyophilized before distribution. The vaccine can only be obtained and adminis-
tered at a Yellow fever vaccination center. 
Being a live vaccine, only one dose is sufficient for protection for at least 10 years. 
Infants below 6 months and pregnant women should not be given the vaccine due to 
increased risk of neurological side-effects for the immature brain. 
Meningococcal, Pneumococcal and Hemophilus mfluenzae infections. The 
capsular polysaccharide of N. meningitidis (Groups A and C) has been successfully 
used to immunize against meningococcal menigitis. Monovalent (group A or C) and 
bivalent vaccines are available. Similarly, capsular polysaccharides of several sero-
types of S. pneumoniae have been combined into a polyvalent vaccine. H. mfluenzae 
type B vaccine consists of its capsular polysaccharide. 
As a rule, infants and very young children respond poorly to polysaccharide anti-
gens. Therefore, these vaccines are offered to children above one year (meningococcal 
vaccine) or above two years (pneumococcal and H. influenzae vaccines). Ordinarily a 
single dose of these vaccines is sufficient. 
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The schedule of immunization 
VACCINE DISEASE 
1 day of life  VHepВ    
3 day of life Tuber-
culosis 
    
1 mo   VHep В    
3 mo   Diptheria 
Pertusis 
Tetanus 
(DPT) 
Poliomyelitis 
Hib 
 
4 mo   DPT Poliomyelitis 
Hib 
 
5 mo   DPT Poliomyelitis 
Hib 
 
6 mo  VHepВ    
12-15 mo     Measles, 
Mumps, 
Rubella,  
(MMR) 
18 mo   DPT Poliomyelitis 
Hib 
 
3 year    Poliomyelitis  
6 year   Diphtheria 
Tetanus 
Poliomyelitis MMR 
7year Tuber-
culosis 
    
11 year   Diphthe-
ria, Teta-
nus 
 MMR 
(if it were 
missed at 6 
year) 
14 year Tuber-
culosis 
 Diphtheria 
Tetanus 
Poliomyelitis  
15 year     Rubella (for 
girls), 
Mumps (for 
boys) 
18 year   Diphtheria 
Tetanus 
  
Adults  VHepВ Diphtheria 
Tetanus 
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